Evidence-based guidelines and secondary meta-analysis for the use of transcranial direct current stimulation (tDCS) in neurological and psychiatric disorders

Felipe Fregni, MD, PhD[1*], Mirret M. El-Hagrassy, MD[1*], Kevin Pacheco-Barrios, MD, MSc[1,2], Sandra Carvalho, PhD[1,3], Jorge Leite, PhD[1,3], Marcel Simis, MD, PhD[4], Jerome Brunelin, PhD[5], Ester Miyuki Nakamura-Palacios, MD, PhD[6], Paola Marangolo, PhD[7], Ganesan Venkatasubramanian, MD, PhD[8], Daniel San-Juan, MD, PhD[9], Wolnei Caumo, MD, PhD[10], Marom Bikson, PhD[11], André R. Brunoni, MD, PhD[12], and Neuromodulation Center Working Group[1 #]

[#] **Neuromodulation Center Working Group:**

Alejandra Cardenas-Rojas, MD, Stefano Giannoni-Luza, MD, Judah Leao, MD(c), Douglas Teixeira Leffa, MD, Piero F. Mejia-Pando, MD, Maria Alejandra Luna-Cuadros, MD, Marina Gnoatto-Medeiros, MD(c), Ana Balbuena-Pareja, MD, Roberto M. Machado, MD(c), Mayumi Toyama, MD, Anna C. Gianlorenco, PhD, Huiyan Zeng, MD, PhD.

* Equally contributing authors

[1]Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Boston, Massachusetts, USA.

[2]Universidad San Ignacio de Loyola, Vicerrectorado de Investigación, Unidad de Investigación para la Generación y Síntesis de Evidencias en Salud. Lima, Peru.

[3] Psychological Neuroscience Laboratory–CIPsi, School of Psychology, University of Minho, Campus de Gualtar, Braga, Portugal.

[4]Physical and Rehabilitation Medicine Institute of the University of Sao Paulo Medical School General Hospital, Brazil.

[5]CH Le Vinatier, PSYR2 team, Lyon Neuroscience Research Center, UCB Lyon 1, 95 boulevard Pinel, Bron, France.

[6]Laboratory of Cognitive Sciences and Neuropsychopharmacology, Department of Physiological Sciences, Federal University of Espírito Santo, ES, Brasil.

[7]Dipartimento di Studi Umanistici, Università Federico II, Naples, Italia and IRCCS Fondazione Santa Lucia, Rome, Italy.

[8]Translational Psychiatry Laboratory, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, India.

[9]Neurophysiology Department. National Institute of Neurology and Neurosurgery Manuel Velasco Suárez, México.

[10]Post-Graduate Program in Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS); Surgery Department, School of Medicine, UFRGS; Pharmacology Department, Instituto de Ciências Básicas da Saúde, UFRGS; Pain and Palliative Care Service at Hospital de Clínicas de Porto Alegre (HCPA); Laboratory of Pain and Neuromodulation at HCPA, Porto Alegre, Brazil.

[11]Department of Biomedical Engineering, The City College of New York of CUNY, New York, NY, USA.

[12] Service of Interdisciplinary Neuromodulation, Laboratory of Neurosciences (LIM-27), Department and Institute of Psychiatry & Department of Internal Medicine, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.

Corresponding Author:
Felipe Fregni, MD, PhD, MPH, MMSc
Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
96 13th Street, Charlestown MA 02129
Phone: 617-952-6153
Email: felipe.fregni@mgh.harvard.edu

Abstract

Background: Transcranial direct current stimulation (tDCS) has shown promising clinical results, leading to increased demand for an evidence-based review on its clinical effects.

Objective: We convened a team of tDCS experts to conduct a systematic review of clinical trials with more than one session of stimulation testing: Pain, Parkinson's Disease Motor Function and Cognition, Stroke Motor Function and Language, Epilepsy, Major Depressive Disorder, Obsessive-Compulsive Disorder, Tourette Syndrome, Schizophrenia and Drug Addiction.

Methods: Experts were asked to conduct this systematic review according to the search methodology from PRISMA guidelines. Recommendations on efficacy were categorized into: Levels A (definitely effective), B (probably effective), C (possibly effective) or no recommendation. We assessed risk of bias for all included studies to confirm whether results were driven by potentially biased studies.

Results: Although most of the clinical trials have been designed as proof-of-concept trials, some of the indications analyzed in this review can be considered as definitely effective (Level A) such as depression, probably effective (Level B) such as neuropathic pain, fibromyalgia, migraine, post-operative patient-controlled analgesia and pain, Parkinson´s disease (motor and cognition), stroke (motor), epilepsy, schizophrenia and alcohol addiction. Assessment of bias showed that most of the studies had low risk of biases and sensitivity analysis for bias did not change these results. Effect sizes vary from 0.01 to 0.70 and were significant in about 8 conditions, with largest effect size being in postoperative acute pain, and smaller in stroke motor recovery (nonsignificant when combined with robotic therapy).

Conclusion: All recommendations listed here are based on current published Pubmed-indexed data. Despite high level of evidence in some conditions, it needs to be underscored that effect

sizes and duration of effects are often limited; thus, real clinical impact needs to be further determined with different study designs.

Keywords: tDCS, clinical evidence, evidence-based medicine, neurological disorders, psychiatric disorders

Abbreviations

4-CRT	4-choice reaction time
6MWT	Six-minute walk test
9HPT	9-hole peg test or 9-pin pegboard test
10MWT	10 Meter Walk Test
AAAQ	Alcohol Approach and Avoidance Questionnaire
ABM	Attentional Bias Modification
ACT3D	Arm Coordination Training 3D
AED	Antiepileptic drug
AH	Auditory Hallucinations
AHRS	Auditory Hallucination Rating Scale
ARAT	Action Research Arm Test
AUQ	Alcohol Urge Questionnaire
AVH	Auditory verbal hallucinations
BBS	Berg Balance Scale
BBT	Box and Block Test
BCI	Brain–computer interface training
BDI	Beck Depression Inventory
BPI	Brief Pain Inventory
BWSTT	Body weight-supported treadmill training
C1	Left central (10-10 International EEG system), corresponding to left leg area
C2	Right central (10-10 International EEG system), corresponding to right leg area
C1h	Left central (10-10 International EEG system), corresponding to left knee motor area
C2h	Right central (10-10 International EEG system), corresponding to right knee motor area
C3	left central (10-20 International EEG system) corresponding to left M1
C4	right central (10-20 International EEG system), corresponding to right M1
CBM	Cognitive Bias Modification
CBT	Cognitive behavioral therapy
CCT	Cognitive control training/therapy
CGI	Clinician Global Impression
CI	Confidence interval
CICT	Computerized cue-induced craving assessment task
CIMT	Constraint-induced movement therapy
CNS	Canadian Neurological Scale
CP3	left S1
CP4	right S1
Cz	Vertex location (10-20 International EEG system)
DDD	Drinks per drinking day
DGI	Dynamic Gait Index
DS	Digit Span
DVPRS	Defense and Veterans Pain Rating Scale
ED	Epileptiform discharges
EEG	Electroencephalography
ES	Effect size
F3	Left frontocentral (10-20 International EEG system), corresponding to left DLPFC
F4	Right frontocentral (10-20 International EEG system), corresponding to right

	DLPFC
FAC	Functional Ambulation Categories, Motricity Index leg sub score
FES-I	Falls Efficacy Scale – International
FM UE	Fugl-Meyer Upper Extremity Score
FM LE	Fugl-Meyer Lower Extremity Score
FMA LL	Fugl-Meyer Assessment, lower limb
FOG	Freezing of gait
FOG-Q	Freezing of Gait Questionnaire
FR (%)	Functional reach (distance reached during FR expressed as a percentage of the person's height
FSST	Four Square Step Test
FTSST	Five-Times-Sit-To-Stand Test
HADS	Hospital Anxiety and Depression Scale
HDRS	Hamilton Depression Rating Scale
HD-tDCS	High-density transcranial direct current stimulation
HTLV-1	Human T-lymphotropic virus type I
I^2	I squared statistic
IDS	Inventory of Depressive Symptomatology
IAAA	Implicit Alcohol Approach Association
Iz	Inion
JTHFT	Jebsen-Taylor Hand Function Test
LANSS	Leeds Assessment of Neuropathic Symptoms and Signs Pain Scale
LL	Lower limbs
LNSWAIS	Letter Number Sequencing Task of the Wechsler Adult Intelligence Scale
LT-RGO	Locomotor training with a robotic gait orthosis
M1	Primary motor cortex
MADRS	Montgomery–Åsberg Depression Rating Scale
MAS	Modified Ashworth Scale
MBC	Modified Brunsstrom Classification
mCIMT	Modified constraint-induced movement therapy
MD(c)	Medical student
MDS-UPDRS	Movement Disorder Society revision of the Unified Parkinson's Disease Rating Scale
MFT	Manual Function Test
MI	Motricity Index
MI LL	Motricity Index leg subscore
MMT	Manual Muscle Test
MPS	Myofascial Pain Syndrome
MRC	Medical Research Council (muscle power)
MMSE	Mini-Mental State Exam
MVC	Maximum voluntary contraction
NNT	Number needed to treat
NPS	Neuropathic Pain Scale
NRS	Numerical Rating Scale
OCDS	Obsessive Compulsive Drinking Scale
OCD-VAS	OCD Visual Analog Scale
OMCASS	Orgogozo MCA Scale
OSI	Overall Stability Index of Biodex Balance System
OT	Occupational therapy
Oz	Occipital area

PACS	Pennsylvania Alcohol Craving Scale
PANAS	Positive and negative affect scale
PANSS	Positive and Negative Syndrome Scale or Positive and Negative Symptom Scale
PCA	Patient-controlled analgesia
PD-CRS	Parkinson's Disease-Cognitive Rating Scale
PHDD	Percent heavy drinking days
POMA	Performance Oriented Mobility Assessment
PPT	Purdue Pegboard Test
PT	Physical therapy/training
PT + OT	Physical and occupational therapy
QIDS-C	Quick Inventory of Depressive Symptomatology (Clinician-rated)
RMA	Rivermead Motor Assessment
ROM	Range of motion
RNS	responsive neurostimulation
rPNS	repetitive peripheral nerve stimulation
rs-FC	resting state functional connectivity
rSO	right supraorbital region
RT	Reaction/response time
RWT	Regensburg Word Fluency Test
SF-36	36-Item Short Form Health Survey
SF-MPQ2	Short-Form McGill Pain Questionnaire 2
SMD	Standardized mean difference
SO	supraorbital region
SS180 (steps)	Number of steps taken during the standing start 180 degrees turning test
SRT	Sit and Reach Test
SST	Standing Stork Test
STS	Sit to Stand Test
SUMD	Scale to assess Unawareness in Mental Disorders
SWS	Stand Walk Sit
TCT	Trunk Control Test
tDCS	transcranial direct current stimulation
TENS	Transcutaneous electrical nerve stimulation
TMS	transcranial magnetic stimulation
TMT B	Trail making test B
TT	Turn time of a modified Standing-start 180 turn test
TUG	Timed Up and Go Test
UL-MT	Upper limb motor task
UPDRS	Unified Parkinson Disease Rating Scale (has parts I, II and III)
VAS	Visual Analog Scale
VAS craving	Visual Analog Scale for Craving
VLMT	Verbal Learning Memory Test
VNS	Vagal nerve stimulation
VNS	Visual Numerical Scale
VR	Virtual Reality
WMFT	Wolf motor function test
WMFT-FAS	Wolf motor function test-Functional Ability Scale
WMFT-TIME	WMFT performance time
YBOCS	Yale Brown Obsessive Compulsive Scale
YGTSS	Yale Global Tic Severity Scale

INTRODUCTION

Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulatory technique (Woods AJ et al., 2016) that may help treat various neurological and psychiatric disorders, even when medically refractory, e.g., intractable chronic pain (Moreno-Duarte et al., 2014; Brietzke et al., 2016; Mendonca et al., 2016). TDCS trials carry a "nonsignificant risk" designation; typical side effects are transient and minor, e.g., skin irritation, itching, tingling and erythema (Andre Russowsky Brunoni et al., 2011a; Bikson et al., 2018). As it is low-risk, well-tolerated (Aparício et al., 2016; Bikson et al., 2016), easy to use, portable (Charvet et al., 2015; Dobbs et al., 2018; Im et al., 2019) and low-cost, clinicians should consider if and how to make tDCS treatment available, particularly in patients with limited options (Bikson et al., 2016).

TDCS' official regulatory status is in development in many countries (F Fregni et al., 2015; Antal et al., 2017), with early EU clearances for Depression and Pain, and many centers worldwide use tDCS as an investigational or off-label therapy (Fregni et al., 2015). Despite hundreds of published human trials led by independent researchers free of proprietary incentives, tDCS' non-linear development path challenges its advancement as a clinical tool. In drug trials, a single company validates a proprietary compound using an organized stepwise strategy, beginning with preclinical testing and progressing through phase I, phase II, and then phase III trials if results are confirmed. Clear Go/No-Go criteria in phase I/II randomized controlled trials (RCTs) and "success" milestones in phase III drug trials (typically developed in consultation with regulatory agencies) facilitate clinical benefit assessments. Conversely, no single corporation leads tDCS development and studies are so diverse that clinicians might struggle to assess its potential benefits or decide on therapeutic approaches.

We therefore convened an expert panel to perform an evidence-based review of tDCS' therapeutic efficacy. We emphasize that the trials are heterogeneous, utilizing varying doses,

montages, adjunct treatments, and inclusion/exclusion criteria (Brunoni et al., 2012; Bikson et al., 2018; Wood et al., 2016; Ekhtiari et al., 2019). Clinicians should always refer to the original publications as any claims, limitations, lacking or mixed evidence must be interpreted in the context of different protocols. We explain how that might work below.

TDCS CLINICAL APPLICATION AND MECHANISMS OF ACTION

Neuromodulation by tDCS is thought to follow Hebbian Theory, ("neurons that fire together, wire together") (Anon, 1950). If presynaptic and postsynaptic neurons are both active, the result is synaptic strengthening; if one or both are inactive, either no change occurs (co-occurrence rule), or conversely, synaptic weakening occurs if one is active while the other is inactive ("neurons out of sync delink") but no change occurs if both are inactive (correlation rule, anti-Hebbian) (Földiák, 1990; Artola and Singer, 1993; Pulvermüller, 2018). Neural network excitation/inhibition exists in a finely tuned balance; any abnormalities can lead to pathology (Ziemann et al., 2015). Neuroplasticity involves long-term potentiation (LTP) and long-term depression (LTD), which depend on post-synaptic calcium levels, with the involvement of *N*-methyl-D-aspartate (NMDA) (Bliss and Gardner-Medwin, 1973; Rioult-Pedotti et al., 1998, 2000) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (Bashir et al., 1991; Beattie et al., 2000; Malinow and Malenka, 2002), metabotropic glutamate receptors, as well as GABA-A and GABA-B receptors (Wigström and Gustafsson, 1983; Davies et al., 1991).

TDCS occurs via a constant electric current produced by a battery-operated current generator connected to at least two electrodes (anode and cathode) applied to specific head locations (or extracephalic regions in case of the return electrodes). Most of the electric current is shunted through scalp, skull and CSF, but the remainder alters neuronal resting membrane potentials, increasing the likelihood of depolarization or hyperpolarization without inducing action potentials (M. El-Hagrassy et al., 2018). Polarization directionality depends on

axonal/dendritic orientations within the electric field. While some literature has questioned tDCS efficacy and placebo effects given the weak current (Schambra et al., 2014), and while its exact mechanisms are unclear, the abundance of adequately blinded positive sham-control RCTs speak to tDCS' therapeutic effects.

Multiple factors can alter tDCS after-effects, including the polarity, duration and frequency of stimulation, current density (i.e. current intensity/electrode surface area), stimulation/return electrode locations, neuroanatomy, underlying pathology/state, and co-administered drugs/treatments (Nitsche et al., 2003). Traditionally, anodal stimulation increases cortical excitability and cathodal stimulation decreases it, but the net effects depend on alterations in the overall network balance, e.g., longer durations and more frequent stimulation often lead to prolonged after-effects (Nitsche and Paulus, 2001) up to a limit, after which excitation may switch to inhibition or after-effects may be shorter (Monte-Silva et al., 2010, 2013). Additionally, although tDCS' effects are maximal under the electrodes, they do influence distant neural networks directly or indirectly (Marshall et al., 2004; Ardolino et al., 2005; Lang et al., 2005; Boros et al., 2008; Kwon et al., 2008; Vines et al., 2008). To ensure maximal effectiveness (and for safety) it is important to avoid factors increasing resistance (e.g., certain hair or skin products) or leading to shunting across the scalp. For example, we would recommend careful preparation of the scalp and hair and keeping a distance of at least 7 cm between the electrodes to avoid shunting; however, most people do not have 7 cm in distance between their motor cortices or between their dorsolateral prefrontal cortices, adding an extra challenge to bilateral montages. We recommend moving the electrodes further apart - even if that moves the electrode center away from the exact target so long as it still covers the desired region; this will likely prevent shunting and overall improve current delivery. However, studies do not typically report on the distances between electrodes, and those that do sometimes allow for as little as 1 cm in between electrodes.

Thus, it is critical to carefully select subjects and montage/stimulation parameters considering the various possibilities influencing tDCS outcomes in clinical trials.

METHODOLOGY

Review Criteria

Our team consists of international experts on tDCS trials in specific neurological, rehabilitation and psychiatric conditions. We followed PRISMA guidelines (Liberati et al., 2009) in conducting a systematic review on interventional human tDCS studies (See Table S1). In summary, for each of the selected conditions, inclusion criteria were: Pubmed-indexed English-language Class I-III (Table 1) tDCS adult randomized clinical trials (RCTs) with a sham control up to July 5th, 2019. Obsessive-compulsive disorder (OCD) and Tourette syndrome (TS) were exceptions - we allowed Class IV studies due to its intractability and limited evidence; additionally, we did not exclude studies on pediatric patients in epilepsy, OCD and Tourette Syndrome due to the limited adult data. We only addressed major clinical outcomes and did not include neurophysiologic outcomes such as motor evoked potentials or EEG.

We did not search databases other than Pubmed, however, we included a few additional papers identified by our authors which had not shown up in search results, but which fit the above criteria (including the July deadline); these papers are detailed in each section.

Search terms and main criteria for each condition:

Pain: "tDCS AND <the name of each pain condition>" which were neuropathic, fibromyalgia, migraine, post-operative, myofascial and low back pain respectively. We included only spontaneous pain outcomes.

Parkinson's disease (PD): "transcranial direct current stimulation" and "Parkinson Disease". We included only motor and cognitive functions. In studies with motor outcomes

(PD and stroke) we did not include scores primarily on activities of daily living due to the difficulty of associating changes with a specific montage.

Stroke: "tDCS and Stroke". Briefly, stroke studies were classified as chronic (> 6 months) or subacute (24 hours to 6 months), using 3 montages (ipsilesional anodal M1 tDCS, contralesional cathodal M1 tDCS, and bilateral M2 tDCS). We included motor outcomes in chronic and subacute stroke, and aphasia in chronic stroke only. Hemorrhagic strokes were also included.

Epilepsy: 'transcranial direct current stimulation' OR 'tDCS' OR 'brain polarization' OR 'galvanic stimulation' AND 'epilepsy'. We included seizure frequency.

Major depressive disorder: "transcranial direct current stimulation" and "major depressive disorder". We included depression scores.

Obsessive Compulsive Disorder and Tourette's Syndrome: "tDCS" and "OCD"; "tDCS" and "Gilles de la Tourette syndrome".

Schizophrenia: "tDCS AND schizophrenia". We included auditory hallucinations/positive or negative symptoms in schizophrenia (schizoaffective disorder mixes were also allowed).

Addiction: "alcohol AND tDCS", "cocaine AND tDCS" and "methamphetamine AND tDCS". Addiction in each disorder was assessed separately, assessing relapses and cravings.

(Please insert Table 1 about here)

Qualitative Analysis

We used the same methodology of a recent evidence-based review on transcranial magnetic stimulation (TMS) (Brainin et al., 2004; Lefaucheur et al., 2014a). Each study was classified based on population, sample size, randomization, placebo-control, allocation concealment, outcomes, inclusion/exclusion criteria, withdrawals/dropouts, and baseline characteristics. Class I, II, III and IV studies have low, moderate, moderately high and high

risk of bias respectively. See Table 1 for our classification criteria and how these classes were used for evidence level assessments and recommendations.

Please note that Lefaucheur and colleagues published an evidence-based review on tDCS in 2017 (Lefaucheur et al., 2017), employing somewhat different search terms than ours but using a classification system derived from the same source (Brainin et al., 2004). An important difference is that they classified Class II studies as having at least 10 patients in the active group receiving "active" tDCS (Lefaucheur et al., 2017). Also, their search period was up to 2015, although some of the studies included in their review were published in 2016. While we excluded case series/case reports (except in OCD/TS), we did include RCTs with smaller samples in the active group as: 1) we have no evidence that a strict but arbitrary cutoff of active n=10 will better estimate true effects; 2) this cutoff is not in the original criteria (Brainin et al., 2004; Lefaucheur et al., 2014a); 3) pilot and especially device trials in emerging fields (particularly non-proprietary devices as tDCS) often have smaller samples, so excluding RCTs with smaller samples would likely exclude a large number of existing RCTs and bias the results; 4) power is a function of both the sample size and the effect size, thus even small RCTs might be adequately powered and show significant changes if the treatment is optimized and has a large effect (conversely, larger trials with weak effects might not show significant changes); 5) given the same intervention with the same effect size, a small sample may increase the risk of false negatives (type II error) – but would reduce the risk of false positives (type I error) - for this reason we prioritize positive results as they are less likely to be spurious.

Therefore, while our primary recommendations (the ones described in the tables) did not restrict by sample size, in conditions that included studies with n<10 we performed a "sensitivity" analysis and described any changes in recommendations if those studies were removed.

Also, we included single-session studies in our descriptive data (tables shaded in dark gray) and discussions as they are important to understand the literature. However, we only used studies with repeated tDCS sessions as well as comparable protocols to determine levels of evidence and recommendations (similar to Lefaucheur et al., 2017), as most therapeutic uses require multiple sessions. We would like to highlight that most repeated-session studies do not measure outcomes after the first tDCS session, making it harder to distinguish between acute and cumulative within-study effects - although some did take repeated measures at later points in the study, e.g., weekly for 4 weeks.

Another important difference from Lefaucheur and colleagues' work (Lefaucheur et al., 2017) is that we performed a risk of bias assessment, which we describe further under *Risk of Bias* below. We also summarize the pooled effect sizes of the included disorders and performed meta-analyses to better showcase existing data (see *Quantitative Analysis* section).

We use conventional nomenclature as applied across modern tDCS publications (Bikson et al., 2019). "Anodal" and "cathodal" tDCS indicate if a specific electrode (polarity) is hypothesized to drive the outcome of interest, and is thus near the intended target region (e.g. anodal M1), even while computational models suggest more nuanced brain current flow patterns (Datta et al., 2009; Bikson et al., 2010). Similarly, "return" electrode indicates an electrode not necessarily implicated in the outcome of interest. "Bilateral" indicates that both electrodes are hypothesized to be active for the outcome of interest.

Outcomes

We classified relevant clinical outcomes as positive (significant improvement from baseline in active vs. sham tDCS) or negative (no significant improvement compared to sham). For instance, if a motor outcome was significantly improved from baseline in the active tDCS group compared to sham, we considered the trial to be positive for motor function (i.e. tDCS improved efficacy), irrespective of whether this outcome was the primary endpoint of the trial

or an exploratory outcome, and irrespective of whether there were statistical corrections for multiple outcome measurements. This was necessary as many papers do not clearly state the primary outcomes.

We also listed related negative outcomes within the same trial but did not consider them to invalidate positive results as many "negative" outcomes were simply underpowered for efficacy (e.g., both active and sham groups improved from baseline, or the active group improved more but without significant differences between groups). Therefore, if a study was positive for one motor outcome but negative for several, we considered the trial positive and made recommendations accordingly. We did not include scales on activities of daily living in or other outcomes we considered too vague, nonspecific or where the score included unrelated categories.

Study Classification

Class I or II studies require concurrent controls; crossover studies are considered Class III as participants are used as their own controls. This is central for Level B and C recommendations. Second, sample size per active arm (with a cutoff n of 25) is used to classify studies as Class I vs. all other classes (Table 1). Therefore, while we allowed for small samples, we did consider their representativeness of the target population and their potential influences on systematic error (i.e. bias).

A study's systematic error must first be assessed in order classify it, and there should be a clear strategy to account for conflicting evidence. An uncontrolled Class IV study is considered to be more prone to bias than Class I-III studies; therefore, only Class I-III studies are used to determine level of evidence. After that, the studies selected for the recommendation are assessed to see if they have conflicting results. Higher quality studies with less bias and random error are prioritized; e.g., if a particular outcome such as motor function has a positive

Class I study but a negative Class II and negative Class III study, the results of the Class I study would supersede the other 2 studies and the determination would be Level B rather than Level A. Therefore, by providing the best level of available evidence, a Class I study is enough to recommend a Level B of evidence (i.e., probable effect).

Risk of Bias

We also assessed for risk of bias using the Jadad Scale (Jadad et al., 1996), which is scored from 0-5 with questions relating to adequacy of randomization and blinding, and the description of withdrawals and dropouts. We conducted this bias risk assessment for all repeated-sessions trials, then a sensitivity analysis was conducted by excluding papers with a high-risk of bias, defined as having less than 3 points in the Jadad Scale.

In each section, studies were divided differently according to tDCS mechanisms and available data, e.g., chronic pain was divided by the main pain syndrome (i.e. neuropathic pain, fibromyalgia, etc.). Only epilepsy and OCD/Tourette's Syndrome included pediatric patients due to limited adult studies.

Panel Recommendations

Based on the qualitative review, the panel reached an agreement on the recommendations for each clinical indication. In the first step, each expert assessed studies published in his/her own field, summarizing the studies in a table and then discussing recommendations with the entire group. On the next step, M.M.E. read and assessed all papers in this review for comprehensiveness and discussed with F.F. as to maintain consistency with our methodology across different sections in tables and text. In summary, we have 4 categories of recommendations: Level A (definitely effective or ineffective); Level B (probably effective or ineffective); Level C (possibly effective or ineffective); or no recommendation. All panelists approved the final recommendations of the manuscript.

Table Display

We prioritized ease of recognizing stimulation parameters such as montage, current density, duration, number of sessions, concomitant therapies/tasks, and the main outcomes that we would use to make recommendations for those sections. For this reason, we displayed studies with multiple montages (whether parallel or crossover) more than once in the tables; we did not add extra rows for sham groups/conditions, irrespective of montage, but did add extra rows for active control groups to better display their montages. Crossover studies are marked with a "+" followed by the conditions, e.g., "+as" indicates crossover with anodal and sham tDCS conditions.

The sample size (*n*) column describes the total sample analyzed in both parallel and crossover studies. For example, if 130 patients were randomized but only 120 analyzed, we listed an *n* of 120, irrespective of how many groups this sample was divided into – if a parallel RCT on stroke with an *n* of 120 has 2 table entries, one in the ipsilesional and one in the contralesional sections, that means 120 patients were analyzed for the whole study - including both montages as well the sham group. For crossover studies, number of sessions describes the number *for each condition*, e.g. 10 would mean they received 10 sessions for each of the active and sham conditions. Washout periods were variable, and we commented on them in the discussions only when strictly necessary. If anode and cathode electrode sizes were different (which usually meant the study had used a large reference electrode to reduce its biological activity) current densities for anodal conditions/groups were displayed, unless the stimulation was specifically intended to be cathodal. All sessions were consecutive unless stated otherwise.

We aimed to standardize the montage description as much as possible by using 10-20 or 10-10 International EEG system nomenclatures to describe active electrode positions (as they were often described in this way, even when researchers used other measurement methods such as TMS or neuronavigation). We typically described reference electrodes as supraorbital

(SO) as that may be more intuitive for readers compared to "FP1/FP2" (right and left frontopolar, the same location as supraorbital or anterior prefrontal). However, in some cases the supraorbital cathode was active, and for consistency we kept the same nomenclature (i.e. left SO instead of FP1). We used the descriptions we thought most representative of where the electrodes had actually been placed, but papers sometimes described different locations for the same cortical regions. The most commonly used locations were C3/C4 for left/right primary motor cortex (M1) respectively, F3/F4 for left/right dorsolateral prefrontal cortex (DLPFC) respectively, and SO; see Abbreviations for further descriptions.

As mentioned above, single-session studies were shaded, and our levels of evidence or recommendations included only studies with repeated tDCS sessions. When useful, we subdivided tables by the studies we used for recommendations and those studies that we did not use for recommendations (e.g., because the protocol was too different to interpret them together).

In summary, we aimed to organize the tables in a way that would help provide a "recipe" for designing tDCS clinical trials. However, it is important to consider the variability between studies, and how it might change sample size calculations or therapeutic plans in a target population.

Quantitative Analysis

To provide additional quantitative data, we extracted baseline and post-intervention values on each outcome of interest from each study/montage used for EBM classification using a structured form. We used WebPlotDigitizer v.3.11 to extract data from relevant graphs. The extracted data were tabulated, coded, and then imported into a dataset for analysis. We selected only studies with n of 10 or more subjects.

We performed an exploratory meta-analysis on our prioritized outcomes per condition, i.e., the ones used for classification in Tables 2-11. We decided to do an exploratory synthesis

to compare across the spectrum of available tDCS approaches in each condition, despite the variability of those parameters. We did this because homogenizing would result in a small sample of studies to perform a valid meta-analysis per disorder; additionally, pooled effect sizes are expected to account for some variability, and clinicians can best make their decisions when able to view the nuances of the existing literature in both the qualitative tables and the pooled quantitative data. Where possible, we used pre- and post-tDCS scores to calculate the mean difference between groups; this difference was then converted to an effect size (ES). Given that Cohen's d_s has a slight bias to overestimate in small sample sizes ($n<20$ (Lakens et al., 2013) or $n<50$ (Higgins JPT et al., 2011)), we adjusted Cohen's d_s to Hedge's g_s by applying a correction factor (Lakens et al., 2013). We assessed publication bias visually by funnel plot, and also using Egger and Begg testing for meta-analyses with at least 10 included studies (Higgins JPT et al., 2011).

In addition, we assessed heterogeneity using I^2 statistic considering low heterogeneity when I^2 <40%. We consider the random-effects models appropriate for use due to the overall heterogeneity in populations and interventions. The data was processed using Stata v15.0 software (StataCorp LLC).

Where pooled results were available and significant, they were listed under the qualitative recommendations for each disorder. Otherwise, pooled results available for each disorder are listed in Table 13; please note that they are often from a smaller study sample than those used for the qualitative recommendations. Additionally, we restricted the outcomes of interest to that were in multiple studies and could thus be pooled. We pooled both positive and negative outcomes in the quantitative analysis but highlight that as many of these outcomes were exploratory (as opposed to primary outcomes) many of the negative results are likely underpowered and do not affect our qualitative recommendations. In fact, some of the positive results in the qualitative tables were positive only on adjusted analysis or modeling, and so

their pooled effects may have been nonsignificant for the purposes of our quantitative analysis. The qualitative and quantitative analyses should thus be viewed as separate but complementary methods to understand the data.

TDCS IN NEUROLOGICAL DISORDERS

Pain

Chronic pain is a prevalent, disabling syndrome with few evidence-based treatments, particularly in severe cases. Recurrent pain leads to maladaptive neuroplasticity (M. El-Hagrassy et al., 2018), perpetuating the sensation of chronic pain in the presence of central sensitization; neuromodulating maladaptive networks by tDCS is thus appealing (Naro et al., 2016). A recent Cochrane review on chronic pain (O'Connell et al., 2018) found a difference for pain intensity between active and sham groups (0.82 points of control group outcome), but the evidence was very low quality and clinically nonsignificant, with heterogeneity and small study bias and it is unclear whether experimental pain was included. While we cannot control for study size and heterogeneity due to the nature of the field, we evaluated spontaneous pain ratings and not experimental pain, as the former is more clinically informative.

Aiming to understand the effects of different prevalent pain conditions separately, we conducted a PubMed search using the keywords "tDCS AND <the name of each pain condition>" which yielded 12, 8, 2, 5, 2 and 3 results that fit our criteria for neuropathic, fibromyalgia, migraine, post-operative, myofascial and low back pain respectively (Table 2).

(Please insert Table 2 about here)

tDCS in neuropathic pain

Regarding studies with repeated tDCS sessions, all but one of the Class II studies showed significant pain improvements following anodal tDCS of M1 on the side opposite to pain. The one negative trial (Lewis et al., 2018) was on neuropathic upper limb pain and used

half the current intensity (1 mA) of the others; the crossover studies were negative. We describe single and repeated session studies below.

The first tDCS human pain study was on pain due to spinal cord injury (Fregni, et al., 2006f) and showed that anodal M1 tDCS improved pain cumulatively from the 2nd to 5th sessions, though the effect was no longer significant at follow-up. Spinal cord injury trials that followed had mixed results but were overall consistent with cumulative analgesic effects (Jensen et al., 2013; Wrigley et al., 2013; Thibaut et al., 2017). Meanwhile, tDCS combined with a visual illusion encouraging subjects to "see" themselves walking reduced overall pain intensity as well as continuous and paroxysmal pain (Soler et al., 2010); the combined group had a shorter pain duration compared to the others. One study found benefits for breathing-controlled electrical stimulation (BreEStim), but the single session was insufficient in long-standing pain patients.

Meanwhile, home-based tDCS had no pain benefits in patients with unilateral drug-resistant central/peripheral neuropathic pain who previously received rTMS (O'Neill et al., 2018); they did not reach the minimal clinically important difference (MCID) despite an adequate sample size and placing the anode over the previous TMS-mapped M1 hotspot. Notably, there was no relationship between previous rTMS responders and tDCS responders, potentially highlighting mechanistic differences between the two techniques. Similarly, one RCT on radiculopathic pain found that 10Hz rTMS improved pain significantly more than tDCS, which was no different than sham (Attal et al., 2016); tDCS duration was 10 minutes longer than usual, raising the question of altered after-effects.

Finally, tDCS reduced post-stroke pain (Bae et al., 2014), and a single session RCT found that subjects with neurogenic arm pain had over twice the pain reduction (36.5% vs. 15.5%) following one session of tDCS and transcutaneous electrical nerve stimulation (TENS) compared to tDCS alone (Boggio et al., 2009).

Recommendation: anodal M1 tDCS is probably effective in reducing neuropathic pain (Level B) (Table 2).

On excluding the one study (Class II) with n <10, the recommendation does not change.

tDCS in fibromyalgia

Anodal M1 tDCS reduced pain in all Class II repeated-session RCTs; other montages had mixed effects. Five consecutive M1 tDCS sessions caused minor but significant pain reduction in the first fibromyalgia study (Fregni et al., 2006e), and a larger one where benefits lasted 30 days (Fagerlund et al., 2015); meanwhile, 10 sessions at higher current density reduced pain by 40-49% over 2 weeks (Khedr et al., 2017a). Later trials found benefits to combining M1 tDCS with rehabilitation or aerobic exercise (Riberto, 2011; Mendonca et al., 2016).

Computer modeling shows the importance of stimulation parameters and current flow: one single-session RCT using a higher current density and cervicothoracic junction return electrode found that M1 tDCS (temporoparietal current flow) was ineffective, but pain significantly decreased following both anodal and cathodal stimulation of the right prefrontal cortex (anterior prefrontal current flow) (Mendonca et al., 2011). Meanwhile, a single session of high-definition tDCS (HD-tDCS) using a 4x1 ring configuration led to better pain relief (effect size 0.36 vs. 0.30) with anode center stimulation (inward current) compared to cathode center stimulation (outward current), but the latter had more immediate effects (Villamar et al., 2013). Finally, twice weekly bi-occipital tDCS significantly improved pain but not fatigue (unlike invasive occipital nerve stimulation), while DLPFC tDCS improved pain and fatigue, perhaps providing top-down regulation to midbrain-thalamic-cingulate pathways (To et al., 2017).

Recommendation: anodal M1 tDCS is probably effective in reducing fibromyalgia pain (Level B) (Table 2).

Quantitative analysis of 5 studies shows a barely significant ES of -0.62 (95% CI -1.23, -0.01) in favor of tDCS, primarily influenced by the favorable results of one study (Khedr et al., 2017); there is significant and substantial heterogeneity (I^2 = 68.2%, p=0.013) (Table 13, Supplemental Figure 1a).

tDCS in migraine

Anodal M1 tDCS reduced pain intensity in 2 Class II trials using nonconsecutive sessions (Andrade et al., 2017; daSilva et al., 2013), although the pain reduction was not significant until the fourth week of follow-up in one of them; this same study also showed shortened migraine attacks (daSilva et al., 2013). Using different parameters, pain reduction was greater following left DLPFC than M1 tDCS in the other study (Andrade et al., 2017).

Recommendation: Anodal M1 tDCS is probably effective in reducing migraine pain (Level B) (Table 2).

tDCS in myofascial pain syndrome (MPS)

Anodal M1 tDCS Class II studies had mixed results and used different concomitant therapies. Combining standard MPS therapy with anodal M1 tDCS accelerated pain reduction (1st week effect), but MPS therapy led to a ceiling effect on weeks 2-4 (Sakrajai et al., 2014). Trigger point injections (Choi et al., 2014) resulted in reduced pre-post session pain on days 2-5 in the left DLPFC tDCS group had, but after the last session the DLPFC, M1 and sham groups had similar improvements.

Recommendation: none (Table 2).

tDCS in postoperative acute pain after chronic pain-related surgery

M1 anodal tDCS reduced patient-controlled analgesia (PCA) in all Class II and one Class I repeated-session studies; pain was reduced in 2 Class II and one Class I study. M1 electrode location varied by type of surgery, and only one study gave tDCS pre- rather than post-operatively (Ribeiro et al., 2017). This novel RCT found a decrease in post-hallux valgus surgery PCA use (72.3%) and pain (Ribeiro et al., 2017).

Two studies on total knee arthroplasty (Borckardt et al., 2013; Khedr et al., 2017b) were reduced PCA use at higher current densities. In one (Borckardt et al., 2013). the active group used 46% less hydromorphone and found pain less unpleasant. The same group found 23% less hydromorphone use and a 31% decrease in "pain-at-its-least ratings" by discharge following lumbar spine surgery (Glaser et al., 2016). In both cases they concluded that tDCS activation at the anode (motor cortex intended to represent the knee or lower back/trunk) and deactivation at the cathode (right DLPFC) might have reduced pain perception. However, single-session anodal/cathodal left DLPFC tDCS had no benefits. Due to the varying study parameters, we cannot give a "definitely effective" recommendation.

Recommendation: postoperative anodal M1 tDCS is probably effective in reducing patient-controlled analgesia and pain (Level B) (Table 2).

Quantitative analysis of 3 studies shows a significant ES of -0.70 (95% CI -1.09, -0.30) in favor of tDCS effects on pain due to favorable results in 2/3 studies (Borckardt et al., 2013; Ribeiro et al., 2017) (Table 13, Supplemental Figure 1a).

tDCS in low back pain

Single Class I and Class II M1 anodal tDCS study results were mixed. M1 anodal tDCS plus offline cognitive behavioral therapy (CBT) showed no significant pain reduction at 2 primary endpoints measured after one week of tDCS and 4 weeks of CBT respectively (Luedtke et al., 2015); however, the RCT design was based on their negative single-session crossover pilot on experimental pain (Luedtke et al., 2012) Additionally, if tDCS' maximum effect occurred during the 4 weeks of CBT it would go unmeasured; following CBT both groups improved to similar levels. In another study 10 group exercise sessions followed a week of tDCS, and pain significantly improved up to the one-month follow-up; exercise plus sham tDCS led to no improvements at any timepoint (Straudi et al., 2018).

Meanwhile, cathodal frontocentral tDCS targeting the left dorsal anterior cingulate cortex may have improved affective dimensions but not pain intensity (Mariano et al., 2019)

Recommendation: none (Table 2).

Summary and Literature Synthesis

Anodal M1 tDCS probably improves neuropathic, fibromyalgia, migraine and post-operative pain, as well as reducing PCA post-operatively. Quantitative analysis of 18 studies in neuropathic, fibromyalgia, migraine and post-operative pain shows a significant and moderate ES of -0.47 (95% CI -0.71, -0.23) favoring tDCS effects on pain (Table 13, Supplemental Figure 1a) with significant but low heterogeneity (I^2=39.7%, p=0.043). No publication bias was found (symmetrical funnel plot and non-significant Egger and Begg tests, Supplemental Figure 1b).

Consistent with the 2018 Cochrane review, studies often used heterogeneous therapeutic strategies, and there is a clear need for RCTs with larger samples and clinically meaningful long-term outcomes. Careful outcome selection is critical as different stimulation

parameters can lead to changes in onset of pain relief (or pain threshold), pain intensity, duration, location, and may have different effects on clinical vs. experimental pain. One tool to utilize is the IMMPACT consensus statement, which classifies a decrease in pain of < 15% as no important change, ≥ 15% as a minimally important change, ≥ 30% as a moderately important change, and ≥ 50% as a substantially important change (Dworkin et al., 2008; O'Connell et al., 2014). It is important to carefully select the time period of pain measurement (e.g., average of previous 24 hours, previous week) and to include this consideration in the design and reporting of clinical trials. Mobile apps may help avoid the problem of pain recall accuracy if designed for clinical trial use, as opposed to unvalidated commercial apps (Salazar et al., 2018; Zhao et al., 2019).

On comparing our results with other qualitative/quantitative studies, Lefaucheur et al., 2017 (Lefaucheur et al., 2017), gave a similar recommendation (Level B) in fibromyalgia for anodal left M1 tDCS, although we had only 3 overlapping studies. Meanwhile, similar to our results, the most recent meta-analysis on tDCS in fibromyalgia (Lloyd et al., 2020) found active tDCS to be beneficial, but barely so (SMD of -0.50 with 95% CI -0.87, -0.14) with statistically significant but weak clinical relevance (17% pain improvement) and high heterogeneity; when only anodal M1 tDCS was considered the effect size remained the same. Their results were also driven by Khedr et al., 2017 (Khedr et al., 2020), and they plausibly suggested that the extra-cephalic reference may have better influenced pain processing in deep brain and midbrain structures.

As to migraines, a meta-analysis (Feng & Zhang et al., 2019)found that excitatory M1 NIBS (tDCS and rTMS studies pooled together) had a large effect size in reducing migraine headache intensity (5 studies: Hedges' g of -0.94, 95% CI -1.28, -0.59) and frequency (4 studies: Hedges' g of -0.88, 95% CI -1.38, -0.38). Meanwhile, our pooled effects of 2 studies were null; however, we did not include TMS, did not have their positive anodal tDCS studies

(Feng & Zhang et al., 2019), they did not have one of ours, and the one study we had in common was null at that timepoint (the effects of DaSilva et al., 2012, were positive only on follow-up. As to Lefaucheur et al., 2017 (Lefaucheur et al., 2017), they made no recommendations.

A recent integrative review and meta-analysis on tDCS in chronic non-cancer pain (Zortea et al., 2019) found that active tDCS compared to sham improved pain with a pooled standardized mean difference of -0.66 (95% CI -0.91, -0.41), and that results appeared better for M1 anodal tDCS (0.68, 95% CI -1.00, -0.35) rather than anodal DLPFC (-0.54, 95% CI -0.91, -0.16), although there were less than a handful of studies for DLPFC. Both measures are greater than the pooled effects for our pooled analysis on neuropathic pain, which had an effect size of -0.47, though the confidence limits overlap (CI 95%: -0.71, -0.23). The literature seems consistent that active tDCS can reduce pain, typically with a moderate effect size, and particularly with M1 anodal tDCS. However, optimal strategies for each pain disorder require further investigation.

Parkinson's Disease

Parkinson's Disease (PD) is a chronic progressive neurodegenerative disorder affecting 315/100,000 people aged 40 years and above (Pringsheim et al., 2014). Dopaminergic cell degeneration leads to dopamine depletion (Dauer and Przedborski, 2003) and downstream changes in basal ganglia circuitry (Niethammer and Eidelberg, 2012) with motor cortico-striato-pallido-thalamocortical (CSPT) circuit abnormalities (DeLong and Wichmann, 2007). Evidence suggests that contralateral M1 and bilateral cerebellar hemispheres are hyperactive in PD, and that the supplementary motor area (SMA), pre-SMA and putamen are hypoactive (Yu et al., 2007).

PD is characterized by resting tremor, bradykinesia, rigidity, asymmetric onset, postural instability and responsiveness to dopaminergic agents (Gelb et al., 1999) although

these medications can lead to serious side effects (Ray Chaudhuri et al., 2018). Patients often also have cognitive symptoms relating to executive functioning (Kehagia et al., 2010; Santangelo et al., 2015). While deep brain stimulation (DBS) has long been used for PD motor symptoms, it is associated with serious adverse events (Buhmann et al., 2017) including cognitive deterioration (Gruber et al., 2019). Therefore, we aimed to see if tDCS could non-invasively improve motor and cognitive functions.

A PubMed search using the keywords "transcranial direct current stimulation" and "Parkinson Disease" yielded 23 results for motor and cognitive function respectively that fit our criteria (Table 3).

tDCS for PD motor symptoms

Regarding motor improvement in studies with repeated-sessions, one Class III and 2/4 Class II studies on anodal motor/premotor/supplementary motor area (SMA) tDCS were positive; regarding DLPFC tDCS, 3/4 Class II studies - one repeated twice (Doruk et al., 2014) - were negative, but the montage was largely intended for comparison or cognitive functions.

Motor/premotor/SMA tDCS

Most motor studies aimed to target premotor and SMA regions, while others used M1 (the electrodes likely overlapped with premotor regions in either case). Bradykinesia, gait and other motor functions were addressed using tDCS on typically alternating days, and in all cases motor function in the tDCS group improved beyond baseline; negative results meant sham tDCS improved similarly.

Two negative RCTs combined tDCS with physical therapy (PT) (Yotnuengnit et al., 2018) or gait training with visual cues (Costa-Ribeiro et al., 2017), yet the cued gait-training study used similar interventions to the group's earlier RCT (Costa-Ribeiro et al., 2016, 2017) where the active tDCS group improved more quickly and maintained the benefit a month later.

Meanwhile, one RCT combining thrice-weekly M1 tDCS with dual task gait training found significant cognitive – not motor - improvements during motor testing (Schabrun et al., 2016).

Two trials of tDCS without concomitant motor therapy were positive: One RCT alternated anode positions between premotor and anterior prefrontal (SO) areas while likely inhibiting the posterior quadrant bilaterally (Benninger et al., 2010); multiple outcomes were positive but the trial was terminated early. One crossover RCT targeted the leg initiating movement after freezing of gait (FOG) with 5 consecutive sessions and found persistent benefits for 4 weeks (Valentino et al., 2014).

As to single-session crossover RCTs, protocols and results were quite mixed, although they give mechanistic insight. One ran 3 experiments (OFF state), and found that anodal M1 but not cathodal M1 (Experiments 1a and 1b) nor anodal DLPFC tDCS (as a control) (Fregni, et al., 2006d) significantly improved motor outcomes. Importantly, motor evoked potentials (MEPs) significantly increased and decreased following anodal and cathodal M1 tDCS respectively, highlighting tDCS neurophysiologic effects. Conversely, one trial (ON) found a significant decline in walking (Verheyden et al., 2013), and anodal M1 tDCS with treadmill training led to ceiling effects (Fernández-Lago et al., 2017). Meanwhile, HD-tDCS significantly improved freezing and other gait parameters compared to "active" sham (Dagan et al., 2018); the multi-target approach may have enhanced dopaminergic circuitry, executive effects on motor control, or improved communication between DLPFC, M1 and subcortical regions (highlighting functional decoupling between the cognitive control network and basal ganglia in PD patients with freezing (Shine et al., 2013). Yet a neuronavigated crossover RCT on FOG (OFF state) found no improvement in self-initiated anticipatory postural adjustments (APA) and execution despite substantial cue-induced improvements in gait initiation prior to baseline (Lu et al., 2018). This may have been due to having greater current densities anterior to SMA leg regions, or due to the lack of dopaminergic activity (OFF). Finally, a nested trial

with a posterior current direction (small cathode at inion) showed significant improvements in gait and stability only with combined physical training plus tDCS (Kaski et al., 2014), perhaps by modulating cortico-cerebellar and cortico-striatal circuits involved in motor learning (Duchesne et al., 2016) and internal regulation of movement.

DLPFC tDCS

Both active/sham group patients with mild cognitive impairment (PD-MCI) (Manenti et al., 2016) improved significantly in static and dynamic balance for up to 3 months and had a less lasting improvement of trunk flexibility. In a dual NIBS study, patients with FOG (ON) safely received left DLPFC anodal tDCS combined with excitatory M1 rTMS (Chang et al., 2017); rTMS led to motor (and MEP) ceiling effects, except on post-5th session timed up-and go test (TUG). Finally, targeting cognition with repeated DLPFC stimulation had no motor benefits (Doruk et al., 2014).

Single-session RCT results were mixed (Fregni et al., 2006d; Lattari et al., 2017), though one negative trial suggested less dual task cost with active tDCS (Swank et al., 2016).

Overall, motor/premotor/SMA tDCS shows promise despite varying parameters and outcomes, while prefrontal tDCS is largely noneffective.

Recommendation: Anodal motor/premotor/SMA tDCS is possibly effective for motor function in PD (Level C); anodal prefrontal tDCS is probably not effective for motor function in PD (Level B) (Table 3).

Quantitative analysis of motor function in the ON state (UPDRS III: 4 studies/montages, motor velocity: 4 studies/montages) irrespective of location of stimulation shows a significant ES of -0.38 (95% CI -0.68, -0.09) in favor of tDCS despite none of the studies' effect sizes reaching statistical significance (Table 13, Supplemental Figure 2a).

(Please insert Table 3 about here)

tDCS for PD cognitive symptoms

All Class II repeated-session DLPFC tDCS studies were positive for improved cognition, and the one M1 tDCS study found more accurate responses on word lists and counting during TUG, as described above (Schabrun et al., 2016).

One sham-control RCT with parallel anodal tDCS groups (left DLPFC, right DLPFC, and either right/left DLPFC) (Doruk et al., 2014) found that only the active tDCS groups maintained improvements in Trail-Making Test B (TMT B); no other cognitive measures were significant. Similarly, dual left DLPFC tDCS and excitatory rTMS of lower limb M1 led to improvements in TMT-B beyond rTMS effects alone (Chang et al., 2017), and using DLPFC/frontotemporal tDCS with PT improved PD-MCI to the point that patients had normal scores after active treatment (Manenti et al., 2016). Meanwhile, left DLPFC tDCS with online computerized cognitive control training focused on executive function (Manenti et al., 2018) significantly improved phonemic fluency in the active group (independent of decreased depression); other cognitive measures improved over time in both groups but PD-CRS reached MCID in the active group only.

Regarding single-session crossover RCTs, Boggio and colleagues' Experiments 1 and 2 found improved cognition (working memory) only following 2 mA anodal left DLPFC tDCS, while 1 mA and M1 tDCS had no benefits (Boggio et al., 2006). Multi-target left DLPFC and M1 tDCS – but not M1 tDCS alone - significantly improved the correct number of words on the Stroop test.

Recommendation: anodal DLPFC tDCS is probably effective for cognitive function in PD (Level B) (Table 3).

Summary and Literature Synthesis

Most studies were good quality RCTs on idiopathic PD. While anodal motor/premotor/SMA tDCS may benefit motor function and while DLPFC tDCS likely improves cognition, there does seem to be a feedback loop between motor and cognitive function. The quantitative analyses measures grouped by motor Unified Parkinson's Disease Rating Scale (UPDRS) and velocity (for bradykinesia) in ON periods were each nonsignificant, as were the cognitive measures grouped by TMT B; meanwhile, there were significant pooled motor (but not cognitive) effects. These were the most commonly measured quantifiable outcomes across studies. Meanwhile, Lefaucheur et al., 2017 (Lefaucheur et al., 2017), gave no recommendations for either motor or nonmotor/cognitive benefits of tDCS in PD due to the variability of outcome measures and targets, although they thought that combining tDCS with rehabilitation or priming may improve efficacy.

As to quantitative analyses in other studies, a recent meta-analysis on PD locomotion (Lee et al., 2019) found that short-term benefits were significant with an effect size of 0.36 ($p=0.001$), but not long-term benefits, and that multiregional targets improved outcomes compared to single brain targets. A meta-analysis (Kim et al., 2019) on freezing of gait combining both rTMS and tDCS studies found better results in the PD subset than in parkinsonism overall; the FOG-Q effect size in PD was moderate with an SMD of 0.57 (95% CI 0.15, 0.98), and UPDRS III also improved by SMD of 0.43 (95% CI 0.01, 0.86). As to cognition, another pooled analysis (Goodwill et al., 2017) of 3 studies found no significant benefit to tDCS, although they had combined many more cognitive outcomes together.

Outcome selection is still challenging for motor and cognitive function. Clinical scales used often combine multiple aspects of motor function, e.g., UPDRS part III rates speech, facial expression, tremor, rigidity, various movements of the hands and legs, bradykinesia, posture/stability and gait. Varying stimulation targets and parameters (and whether patients

were in OFF/ON states) could affect those motor subcomponents in different ways. Outcome measurements and study protocols varied for cognition as well. Larger PD motor/cognitive RCTs are necessary to identify best practices, different outcome MCIDs, and duration of effects.

Stroke

Stroke is the top cause of disability in the US, with 3% prevalence and high morbidity and mortality rates (Ovbiagele and Nguyen-Huynh, 2011). There is tremendous need for effective therapies to help stroke survivors recover motor, language, and other functions. Rehabilitation typically follows recruitment of intact nearby tissues and reorganization of the brain to compensate for the damaged area, but despite high-quality rehabilitation patients often still have still have mild to severe residual deficits. We aimed to evaluate the efficacy of tDCS as a tool for stroke motor and language rehabilitation due to their impact on disability and caregiver burden.

tDCS effects on motor function in stroke

Strokes can lead to unilateral weakness in the face, arm, and leg, as well as other symptoms relating to impaired sensation, visual and balance problems, all of which may exacerbate motor disability. It may be easier to enhance the magnitude of plasticity with tDCS in acute/subacute vs. chronic stroke due to the major plastic changes in this phase, although those changes can make it difficult to distinguish spontaneous recovery and therapeutic effects (thus necessitating sham control, where recovery is likely to be of similar magnitude). Spontaneous recovery is minimal in chronic stroke, thus methods promoting adaptive neuroplasticity are desirable.

A PubMed search using the keywords "tDCS and Stroke" yielded 63 results that fit our review criteria. We then selected the categories we believe most critical to tDCS effects on motor function and excluded the few studies that did not fit those categories, as we discuss below. We were unable to categorize for other relevant criteria such as patient characteristics (e.g., side, volume of stroke, cortical vs. subcortical stroke, anterior vs. posterior circulation, ischemic vs. hemorrhagic stroke, severity of impairment, age of patient, dominant side, concomitant treatments) and specific tDCS parameters (e.g., active/reference electrode sizes/presumed current distribution, stimulation duration, interval, and number of sessions) due to the scope of this paper and as the above information was not always available. Nor were we able to categorize for outcome measures, although we list measured motor outcomes in Tables 4 and 5. However, the type of outcome is important for the research question, e.g. the Jebsen Taylor Hand Function Test (JTHFT) is considered appropriate for mild-to-moderate stroke due to a lack of ceiling effects, while the Fugl Meyer Test (FM) may reach both ceiling and floor effects (Lin et al., 2009; Thompson-Butel et al., 2015; Santisteban et al., 2016).

Classification of studies

The first major category was time since stroke: "subacute" (24 hours to 6 months) or "chronic" (greater than 6 months). It is important to note that some trials used different cutoffs for "acute" vs. "subacute" designations, and while most strokes were infarcts, hemorrhagic "strokes" were also included.

The second major category was side and polarity of stimulation; patients received either: 1) Ipsilesional anodal M1 tDCS (anode over M1 on same side as stroke); 2) Contralesional cathodal M1 tDCS (cathode over M1 on opposite side of stroke); and 3) Bilateral M1 tDCS (ipsilesional M1 anode, contralesional M1 cathode). Therefore, we created

6 subcategories (see Tables 4-5). In the chronic stroke category, we also subdivided by repeated-session studies using tDCS to enhance robotic training and studies without it.

Some trials enrolled both subacute and chronic stroke patients. The few papers with 1-2 subacute stroke patients among many chronic patients were included in the chronic stroke table (Lindenberg et al., 2010, 2012; Tanaka et al., 2011). Meanwhile, papers with a larger mix of subacute and chronic patients were marked (#) and added to both tables (Tables 4-5); one showed no significant effect of time since stroke (Fleming et al., 2017), mean time since stroke was 4.9 +/- 3 months in another (Wu et al., 2013), and the third (Triccas et al., 2015) had a near even mix of subacute and chronic patients.

Chronic Stroke

All repeated-session Class II and III studies using ipsilesional anodal M1 tDCS were positive for motor improvement; however, when tDCS was used to enhance motor effects of robotic therapy/training, only 2/5 Class II studies showed tDCS benefits. As to contralesional cathodal M1 tDCS, 1/2 Class II and both Class III studies were positive; 4/6 Class II and one Class III study on bilateral tDCS were also positive. These studies had comparable montages, and thus the recommendation is that tDCS is probably effective in all 3 categories (Table 4), although ipsilesional anodal tDCS has no benefits over robotic training. Single session studies were also mostly positive in all but bilateral tDCS.

Most studies trained subjects in motor tasks to reach asymptotic levels prior to testing - except when the intended outcome related to skill acquisition; e.g. (Zimerman et al., 2012). All but one of the ipsilesional repeat-sessions studies without robotics used additional training, including constraint-induced movement therapy (CIMT), virtual reality, etc., yet tDCS benefits went beyond those therapies. Conversely, robotic training was more prone toward a ceiling effect, including the largest study (n=77 ischemic stroke), which used intensive robotic therapy

after each of 36 tDCS sessions (Edwards et al., 2019); improvements in Fugl Myer (by 5 points) and Wolf Motor Function Tests (WMFT) were not significantly different between groups. Most other tDCS montages were also combined with other therapies, again with mostly positive results, although there was great heterogeneity in tDCS protocols and concomitant therapies (descriptions of which are beyond the scope of this review).

An important question is whether one montage is superior to another in a particular population, or whether it could lead to deleterious results. One single-session trial showed impaired motor function after contralesional anodal tDCS (i.e. facilitation of the intact hemisphere) and improved function with ipsilesional anodal tDCS (Madhavan et al., 2011). The above results may have related to the severity of corticospinal tract damage, which we discuss further below. One single-session study using robotics found a detrimental effect to cathodal contralesional M1 tDCS (Yao et al., 2015), showcasing the possibility that concomitant training/treatments may change or even reverse expected tDCS effects.

Recommendations: anodal ipsilesional, cathodal contralesional and bilateral tDCS of M1 montages are probably effective for motor rehabilitation in chronic stroke (Level B). Anodal ipsilesional M1 tDCS to enhance robotic therapy is probably not effective in chronic stroke (Level B) (Table 4).

On excluding studies with n <10: in anodal ipsilesional tDCS the exclusion of two studies - one without (Class III) and one with robotics (Class II) - does not change recommendations; in cathodal contralesional tDCS the exclusion of one study (Class II) changes the recommendation from Level B to Level C (possibly effective).

For motor function in chronic stroke without robotics, quantitative analysis of 7 ipsilesional, 2 contralesional and 5 bilateral tDCS studies shows a significant ES of 0.44 (95% CI 0.10, 0.79) in favor of bilateral tDCS effects, and the 3 montages pooled together have a significant effect of 0.51 (95% CI 0.19, 0.84) in favor of tDCS effects overall on chronic stroke,

although there is also significant and high heterogeneity (I^2=62.8%, P=0.001) (Table 13, Supplemental Figure 3.1.1).

(Please insert Table 4 about here)

Acute/Subacute Stroke

Regarding repeated-session tDCS studies, 4/6 Class II studies showed benefits to anodal ipsilesional M1 tDCS; however, when used to enhance motor effects of robotic therapy/training, the 3 Class II and one Class I study showed no tDCS benefits. As to contralesional cathodal M1 tDCS, 4/6 Class II studies were positive, but the same Class I robotics study was negative. Finally, in bilateral tDCS, the largest Class II study and a Class III study were positive, while 2 Class II studies (with fewer sessions) were negative. Therefore, tDCS may be effective in all 3 categories (Table 4), although it has no benefits over robotic training. Almost all single session studies were also positive.

Similar to chronic stroke, intensive robotic-therapy improved clinical and sometimes kinematic (Triccas et al., 2015; Mazzoleni et al., 2017) outcomes in both active and sham groups comparably. Almost all non-robotic studies combined tDCS with other therapies, but active tDCS tended to enhance the effects of those therapies. We also highlight a single-session exploratory crossover RCT in subacute subcortical stroke showing that dual anodal tDCS of ipsilesional M1 and DLPFC significantly improved continuous time-based outcomes (RT and 9HPT) compared to both sham and anodal M1 tDCS (Achacheluee et al., 2018). Dual tDCS benefits may have related to high current density and distribution with sensorimotor-cognitive integration.

Recommendations: anodal ipsilesional and cathodal contralesional M1 tDCS montages are probably effective for motor rehabilitation in subacute stroke (Level B). Bilateral M1 tDCS is possibly effective for motor rehabilitation in subacute stroke (Level C). Anodal

ipsilesional and cathodal contralesional M1 tDCS to enhance robotic therapy are probably not effective for motor rehabilitation in subacute stroke (Level B) (Table 5).

For motor function in subacute stroke without robotics, quantitative analysis of 8 ipsilesional, 5 contralesional and 3 bilateral tDCS studies shows a significant ES of 0.47 (95% CI 0.10, 0.84) in favor of contralesional tDCS effects, and the 3 montages pooled together have a significant ES of 0.45 (95% CI 0.18, 0.72) in favor of tDCS effects overall on subacute stroke, although there is also significant and high heterogeneity (I^2 64.8%, P<0.001) (Table 13, Supplemental Figure 3.2.1.).

(Please insert Table 5 about here)

Other relevant parameters and summary of motor function in stroke

As previously mentioned, we will focus on modifiable factors we think are most important to treatment; we are unable to categorize for several non-modifiable factors that may affect tDCS efficacy, e.g., age, area of stroke, degree of impairment, etc. (Marquez et al., 2015). The most critical parameters appear to be montage, current density, number of sessions, duration of stimulation, and concomitant treatments. Higher current density, more frequent and longer sessions tend to cause improved and more durable clinical effects; however, a change in any of these factors can change outcomes, and we do not have a systematic measurement of how these factors interact.

Meanwhile, when planning the montage (electrode positions), it is important to consider stroke severity and whether the M1/corticospinal tracts are damaged beyond the point of effective neuroplasticity. In such cases, anodal stimulation of ipsilesional M1 may be ineffective and cathodal stimulation of contralesional M1 may be detrimental due to the need for intact corticospinal tracts from the intact hemisphere to take over some motor functions of

the lesioned hemisphere. We may speculate that studies using reversed polarity (e.g. anodal stimulation of contralesional M1 or reversed bilateral stimulation) could produce better results in some such cases; however, this must be formally studied as the outcome measure and other factors will likely have an effect. For example, online anodal stimulation (with somewhat unusual parameters) of ipsilesional leg M1 in mostly subcortical strokes improved an ankle-tracking task, while anodal contralesional leg M1 stimulation had a detrimental effect on learning (Madhavan et al., 2011). In a negative trial on contralesional cathodal stimulation within a month of stroke, half the subjects' corticospinal tracts may have been too damaged to modulate, and using a right shoulder reference may have reduced current flow to the left M1 that was damaged in half the patients (Fusco et al., 2014).

Computational models show that electrode positions (including "reference" electrodes) could dramatically change current flow directions (Brunoni et al., 2012). Standard tDCS is non-focal and electrodes can overlap with and stimulate contiguous regions responsible for different functions. Cha and colleagues (Cha et al., 2014) showed improved upper and lower limb FM scores with an upper limb montage. Also, cortical anatomy changes post-injury and target areas are measured in variable ways, including tape measurements, TMS and neuronavigation.

Most stroke studies included infarcts (predominantly) and hemorrhages; however, Mortensen et al. (Mortensen et al., 2016) included only intracranial hemorrhages, mainly in the basal ganglia. One may speculate if this affected the positive results for handgrip strength (benefiting from intact M1) and negative results for Jebsen Taylor Hand Function Test (JTHFT – as basal ganglia dysfunction can impair speed). Functional recovery may vary between ischemic and hemorrhagic strokes (Schepers et al., 2008), thus an an imbalance may be important, especially in acute/subacute stroke, and with longer treatment durations potentially confounding recovery.

Regarding trial duration, washout periods in crossovers are important to avoid carryover effects. As placebo effects tend to drop during follow-ups, parallel arm RCTs with longer follow-ups may help identify whether tDCS alone is beneficial or whether it prolongs the benefits of concomitant therapies, especially acutely effective therapies such as robotics.

Most trials were performed with concomitant treatments or motor tasks that were online, offline, or both (sometimes depending on treatment duration and feasibility). In some studies, these associated therapies seemed to lead to improved outcomes in tDCS groups, while in others they caused a ceiling effect. The temporal relationship of concomitant treatments might enhance, counteract or cancel out tDCS effects, depending on networks activated and desired outcomes, e.g., Giacobbe and colleagues (Giacobbe et al., 2013), showed that tDCS applied prior to robotic training led to improvement, but tDCS during or after training worsened outcomes. A careful evaluation of the literature with power/sample size calculations and strategies to optimize neuroplasticity is thus particularly important for combined therapies. This is especially important for tDCS to enhance robotic therapy, since the negative results might be related to type II error. It is relevant to note that the pooled effects of robotic therapy (with anodal ipsilesional tDCS) on motor function were non-significant in each of chronic and subacute stroke; however, the pooled effects of 3 tDCS montages without robotics were significantly favorable in both chronic and subacute stroke despite high heterogeneity.

Therefore, more high-quality RCTs are needed to better understand the effect of many parameters that can have major impact on motor function in different stroke populations.

Summary and Literature Synthesis

TDCS improves motor rehabilitation in chronic and subacute stroke, except when used to enhance robotic therapy. The overall moderate effect size of active tDCS does not seem to enhance the benefits of robotic therapy on any motor outcome using the study protocols tested in our sample, with the exception of two studies in chronic stroke. The quantitative analysis is

consistent with these findings, although it is important to note that pooling multiple motor outcomes – and the occasional alternative montage - for each study may have affected the results. For example, while anodal ipsilesional tDCS is probably effective in chronic and subacute stroke in the qualitative assessment, the pooled motor results miss significance for ipsilesional tDCS (mostly anodal). Contalesional tDCS is probably effective in chronic stroke (possibly effective on excluding a smaller study) and in subacute stroke, and although its limited pooled sample missed significance in chronic stroke, the larger pooled sample is significant in subacute stroke. Bilateral tDCS is effective in chronic stroke by quantitative and qualitative measures. Overall, in acute and chronic stroke the pooled results of all montages consistently show that tDCS is beneficial, and there is substantial overlap of confidence intervals in favor of tDCS. Additionally, while there is significantly high heterogeneity among studies, there is no evidence of publication bias (Table 13, Supplemental Figures 3.1 to 3.2).

Lefaucheur et al., 2017 (Lefaucheur et al., 2017), also noted the heterogeneity between studies, giving no recommendations for tDCS in motor stroke recovery/rehabilitation (with a much more limited sample than ours) although they too suggested that tDCS seemed to trend toward synergistic effects when combined with other therapies. Meanwhile, a meta-analysis by Bai and Guo et al., 2019 (Bai and Guo et al., 2019), analyzed tDCS effects on patients with limb dysfunction following a first unilateral stroke by various factors that are worth mentioning. They found that tDCS significantly improved post-stroke motor function in the upper limbs (SMD 0.26, 95% CI 0.09, 0.42) and lower limbs (SMD 0.47, 95% CI 0.17, 0.77). In case of upper limb dysfunction, tDCS showed significant effects only in chronic stroke, but not subacute or acute stroke, and even then the effects were modest (SMD 0.25, 95% CI 0.04, 0.39); the pooled effects of acute through chronic were also modest but significant (SMD 0.22, 95% CI 0.04, 0.39). Furthermore, anodal (SMD 0.25, 95% CI 0.66, 0.43) and especially cathodal (SMD 0.41, 95% CI 0.15, 0.67) but not bilateral tDCS significantly improved upper

limb function. Interestingly, more tDCS sessions were not necessarily better – significant upper limb improvements were found following 10 or fewer sessions of anodal (SMD 0.40, 95% CI 0.16, 0.65) and cathodal (0.79, 95% CI 0.43, 1.16) tDCS at a current density greater than 0.29 A/m^2, but no improvements followed more than 10 tDCS sessions (in 4 anodal and one cathodal study). Our qualitative review also showed no clear benefit to more than 10 tDCS sessions, although this is confounded by the concomitant treatments. Bai and Guo et al., 2019 (Bai and Guo et al., 2019), also reported in a smaller sample of lower limb dysfunction that tDCS had a significant moderate effect on subacute stroke (SMD 0.56, 95% CI 0.22, 0.90), as well as subacute plus chronic stroke pooled together (SMD 0.47, 95% CI 0.17, 0.77), but not chronic stroke alone (only 2 studies). Furthermore, bilateral tDCS (3 pooled studies) had a moderate effect size on subacute stroke lower limb dysfunction (SMD 0.59, 95% CI 0.14, 1.03). It is worth noting that this meta-analysis used only one motor outcome for each study, and that their selected studies overlapped with ours but included other studies as well, perhaps as they had searched more databases than Pubmed. They concluded that the optimal parameters and their timing for upper and lower limb post-stroke dysfunction were different.

Other meta-analyses addressed other aspects of tDCS for post-stroke motor function, e.g., one found that rTMS but not tDCS improved postural control and functional balance (Kang et al., 2020); one found that tDCS improved fine motor function with a moderate effect size of 0.31 (95% CI 0.08, 0.55) and had a large effect size of 1.25 (95% CI 0.09, 2.41) upon function of the non-dominant hand when applied to the contralesional non-dominant hemisphere (O'Brien et al., 2018); one found that paretic limb force production (grip force, pinch force, knee extension torque, etc.) benefited from tDCS and rTMS in acute to chronic stroke (Kang et al., 2016). Yet, despite multiple studies and meta-analyses, there is a great need for larger RCT samples and careful optimization of tDCS parameters.

tDCS effects on language function in stroke

A third of strokes, particularly left-sided strokes involving language networks, lead to aphasia (Franzén-Dahlin et al., 2010; Basso et al., 2013; Rohde et al., 2013), an acquired language expression and/or comprehension disorder. Aphasia is one of the most socially disabling post-stroke deficits; symptoms often persist after therapy (Lazar et al., 2010), so new rehabilitation techniques are needed, particularly low-risk therapies such as tDCS. Generally, tDCS treatment aims to address interhemispheric competition between residual language areas in the damaged left hemisphere and the intact right hemisphere (Kiran, 2012). Thus, similar to stroke motor function parameters, tDCS strategies often aim to excite and thus enhance perilesional left hemispheric output or inhibit the intact right hemisphere and counteract its inhibitory effect on the ipsilesional hemisphere.

A PubMed search on "tDCS and aphasia" resulted in 25 studies on chronic aphasia that fulfilled our criteria, excluding the few variable publications on acute/subacute aphasia.

tDCS in chronic aphasia

Our results were divided into anodal (predominantly left-sided), cathodal (predominantly right-sided), and bilateral stimulation groups. We mostly classified aphasia into nonfluent (expressive) and fluent (receptive), giving more detail when relevant as this broad categorization does not distinguish between different forms of nonfluent (e.g., Broca's aphasia, transcortical motor aphasia), fluent aphasia (e.g., Wernicke's aphasia, transcortical sensory aphasia), and so on. For example, repetition is impaired in perisylvian aphasias including Broca's, Wernicke's, conduction and global (expressive and receptive) aphasias, but relatively preserved in transcortical aphasias. Broca's aphasia is typically thought to follow damage to the inferior frontal gyrus (posterior aspect of the operculum), while Wernicke's aphasia follows damage to the posterior superior temporal gyrus. However, the exact areas can

vary, subcortical regions may be involved, and injuries to other areas may lead to similar or overlapping deficits (Naeser et al., 1987; Alexander et al., 1990; Kreisler et al., 2000; Hillis et al., 2008).

We included aphasia types in the sample size column (Table 6). As areas targeted and their descriptions varied, sometimes guided by imaging, we mostly avoided EEG nomenclature (which was variable and less intuitive than with motor areas) and used what we thought was the clearest description of the target region.

Anodal tDCS

Regarding repeated-session RCTs, one Class I study was positive for non-futility, 2 Class II studies had different parameters and results, and 15/18 Class III studies/montages were positive (Table 6).

In line with approximate estimations of language regions, the studies in this review mostly targeted anodal tDCS at left inferior frontal regions for nonfluent aphasias and left posterior/temporal regions for fluent aphasias. However, this was not always consistent, and studies often included a mix of different types of aphasia. The vast majority were crossover RCTs, and all included study-specific language training or treatment (ranging from anomia treatment, to repetition tasks, melodic intonation therapy, conversational therapy, speech therapy, etc.) except for one crossover RCT where inpatients were undergoing speech therapy that was not intended as a concomitant treatment for tDCS (Volpato et al., 2013a). This RCT found no effect on object and action naming, perhaps because the inpatient logopedic therapy was separated from tDCS by 90 minutes (to avoid interaction), or perhaps because 6/8 patients had fluent aphasia but they targeted Broca's area (Volpato et al., 2013a). Nevertheless, patients reported subjective everyday language improvement. Likewise, 2 other studies were negative on providing anodal tDCS to the left superior temporal gyrus but in patients with nonfluent

(including global) aphasia (You et al., 2011; Marangolo et al., 2014a).

All other studies were positive for anodal tDCS, although one Class I study used a nonfutility design and was not powered for efficacy (Fridriksson et al., 2018). Most crossover studies showed significant improvements compared to sham, predominantly in naming (for nouns and/or verbs), as well as reaction times, response accuracy, repetition and also production of (conversational) content units. Multiple crossover studies (Fiori et al., 2013; Marangolo et al., 2013a) showed improvements in noun naming accuracy after left temporal anodal tDCS, and in verb naming accuracy after left frontal anodal tDCS, highlighting the different functions of those regions. Anodal tDCS with conversational therapy only led to significant improvements when targeting left inferior frontal areas (Marangolo et al., 2014a; Marangolo et al., 2014b).

Meanwhile, a study tested anodal stimulation over Broca's homologue at the right inferior frontal gyrus (Cipollari et al., 2015; Keser et al., 2017) in patients with nonfluent aphasia. It combined tDCS (enhancing the unaffected hemisphere) with melodic intonation therapy and found improvements in word and sentence repetition (Cipollari et al., 2015); additionally, while cortical modulation occurred on TMS-EEG in active and sham conditions, cortical excitability was maximized by anodal tDCS. A smaller study which found improved verb fluency also combined melodic intonation therapy with anodal right inferior frontal tDCS, but more posteriorly and with only 3 (vs. 15) tDCS sessions at higher current density (Vines et al., 2011). Another study that combined right temporoparietal cortex anodal tDCS with online anomia training found improved picture naming for trained objects (Flöel et al., 2011).

One trial gave twice daily anodal left M1 tDCS with computer-assisted naming therapy, and yet this unusual montage improved aphasia (Meinzer et al., 2016).

The single-session crossover RCTs had unusual designs. One targeted the left DLPFC and found improvements in phonemic verbal fluency and in picture naming RT, but only for

very high frequency words (Pestalozzi et al., 2018). The other was a small crossover RCT within a nested parallel study design (patients in the anodal left and cathodal right frontotemporal groups were randomized to active and sham tDCS conditions) (Monti et al., 2008); only cathodal tDCS right frontotemporal region led to positive results (in picture naming accuracy but not response time), but there were errors in polarity applications.

Recommendation: anodal tDCS of Broca's area, its homologue, or Wernicke's area is possibly effective (Level C) in chronic post-stroke aphasia (Table 6).

On excluding 13 studies/montages with n<10 (all Class III), the recommendation changes to anodal tDCS of Broca's area is possibly effective (Level C) in chronic post-stroke aphasia.

Quantitative analysis of 4 studies on ipsilesional anodal tDCS over Broca's area in aphasia (naming accuracy, production of correct content, object and naming accuracy) shows a significant ES of 0.65 (95% CI 0.29, 1.01) in favor of tDCS (Table 13, Supplemental Figure 3.3.).

Cathodal tDCS

Two Class II and two Class III repeated-session RCTs were positive. In the Class II study mentioned above, cathodal tDCS of the right superior temporal gyrus led to significant improvements (in auditory verbal comprehension), while anodal tDCS of the left superior temporal gyrus did not – perhaps because of the left infarcts (You et al., 2011). This may be consistent with the interhemispheric competition theory mentioned previously. Right temporoparietal cathodal (and anodal, as mentioned above) tDCS conditions improved trained picture naming (Flöel et al., 2011). The Class II and III studies on cathodal tDCS of Broca's homologue are both positive.

As to single-session studies, Monti and colleagues' Experiment 1 was positive as

mentioned above (Monti et al., 2008) for cathodal tDCS of the left frontotemporal region, but Experiment 2 was unsurprisingly negative for occipital tDCS (Monti et al., 2008). Another crossover study shows the importance of tDCS target relating to lesion location as it was positive for patients with Broca's area lesions and also correlated with arcuate fasciculus integrity (Rosso et al., 2014).

Recommendation: cathodal right frontotemporal tDCS is possibly effective (Level C) in chronic post-stroke aphasia recovery (Table 6).

Bilateral tDCS

Four Class III studies repeatedly targeting the left inferior frontal gyrus with anodal tDCS and its homologue with cathodal tDCS in combination with language or speech therapy were positive (Marangolo et al., 2013c; 2014b; 2016). The single-session study was also positive (Santos et al., 2017).

Recommendation: bilateral tDCS with anodal stimulation of Broca's area and cathodal stimulation of its homologue is possibly effective (Level C) in chronic post-stroke aphasia recovery (Table 6).

All 3 studies (Class III) had n<10, so excluding them changed the recommendation to none.

(Please insert Table 6 about here)

Summary and Literature Synthesis

The research on tDCS in chronic post-stroke aphasia appears promising, though still its early stages. While there were many more trials in the anodal group than the others, they did not quite fulfill criteria for probable effectiveness. However, limited quantitative analysis of the only 4 studies we could extract showed that ipsilesional anodal tDCS significantly improves aphasia, and all studies had good overlap of their 95% confidence limits.

Conversely, Lefaucheur et al., 2017 (Lefaucheur et al., 2017), gave no recommendation

on anodal left Broca's area tDCS in post-stroke nonfluent aphasia. However, a previous meta-analysis (Bucur et al., 2019) found that tDCS moderately improved post-stroke naming with an effect size of 0.33 (95% CI 0.03, 0.62), noting that effects were greater at follow-up (ES 0.54, 95% CI 0.21, 0.86) than immediately after tDCS treatment (ES 0.34, 95% CI 0.02, 0.65); benefits were in chronic stroke (there were only 2 subacute studies). Meanwhile, an individual patient data meta-analysis (Rosso et al., 2018) on repeated tDCS sessions in chronic post-stroke aphasia found a much higher improvement in naming (SMD 0.80, 95% CI 0.27, 1.33); furthermore, a dose-dependent relationship was found (more than 5 tDCS sessions), and naming improved irrespective of aphasia severity, disorders of comprehension, or time between stroke occurrence and tDCS application.

The literature is therefore encouraging of further investigation into different tDCS protocols and language outcomes; we recommend that methods of localization (by MRI as in much of our sample) and aphasia subtypes should guide eligibility criteria. We also recommend that future studies report primary language outcomes in a way that can be calculated for future meta-analyses.

Epilepsy

Epilepsy, a serious and prevalent chronic neurological disorder affecting nearly 70 million people (Ngugi et al., 2010) is "a disorder of the brain characterized by an enduring predisposition to generate epileptic seizures, and by the neurobiological, cognitive, psychological and social consequences of this condition...." (Theodore et al., 2006; Fisher et al., 2014). About 25-30% of epilepsy patients do not reach the treatment goal of "no seizures and no side-effects" even on 2 appropriate antiepileptic drugs (AEDs); these patients often require surgical evaluation (Kwan et al., 2010; Brodie et al., 2012). However, surgery is not always possible, so various adjunctive neuromodulation techniques have been used,

predominantly vagal nerve stimulation (VNS), and to a lesser extent more invasive techniques such as cortical stimulation, responsive neurostimulation (RNS) and DBS (Theodore and Fisher, 2004, 2007; Groves and Brown, 2005; Boon et al., 2007; Löscher et al., 2009; Salanova et al., 2015; Thomas and Jobst, 2015) and noninvasive techniques such as such as rTMS and tDCS. The underlying principle is that extrinsic stimulation can reduce hyperexcitability, suppress seizures and interfere with epileptiform discharges (EDs) seen on EEG (Löscher et al., 2009; San-Juan et al., 2015). We therefore evaluated the literature for safety and efficacy of tDCS in epilepsy regarding seizure frequency.

A PubMed search using the keywords: 'transcranial direct current stimulation' OR 'tDCS' OR 'brain polarization' OR 'galvanic stimulation' AND 'epilepsy' yielded 7 results that fit our criteria, and we added two more papers identified by our authors (Auvichayapat et al., 2016; Assenza et al., 2017). As mentioned previously, this disorder was one of the exceptions where we included trials with pediatric and/or adult patients.

tDCS in epilepsy

Of repeated-sessions RCTs, 3/4 Class II and the one Class III trial were positive for decreased seizure frequency. One Class II trial showed safety but not efficacy. All trials were well-tolerated.

A recent trial randomized patients with refractory mesial temporal lobe epilepsy with hippocampal sclerosis (mTLE-HS) into 3 groups: 2 cathodal (3 vs. 5 daily sessions) and one sham tDCS over the epileptic focus (San-Juan et al., 2017). Despite a prominent placebo effect with all groups improving, the 3- and 5-day active groups each did significantly better than sham at the two-month follow-up (seizure frequency decreased respectively by 43.4%, 54.6% and 6.25%). Response was achieved by 50%, 62.5% and 25% of those groups respectively. The two active groups had no significant differences in efficacy, and active tDCS did not

impact EDs. Meanwhile, a crossover RCT gave patients with refractory mTLE-HS modulated cathodal tDCS to decrease excitability and also modulate the cortex with its natural rhythm (using 12Hz frequency based on EEG-neurofeedback studies). Three sessions significantly reduced seizure frequency up to a month later. About 83% of the active group (mostly male) achieved response (Tekturk et al., 2016). Another trial on TLE, this time well-controlled, gave left DLPFC anodal tDCS aiming to improve depression and working memory; indeed, depression improved, with no change in seizure frequency or EDs, thereby suggesting safety of even anodal tDCS in well-controlled epilepsy (Liu et al., 2016).

The last repeated-sessions RCT targeted children with Lennox-Gastaut Syndrome (LGS), a severe childhood epilepsy with highly frequent and different types of seizures, most with motor components. This study (Auvichayapat et al., 2016) found that cathodal left M1 tDCS significantly reduced seizure frequency compared to sham on each of the 5 days of tDCS, plus immediately and at 1, 2, 3 and 4 week follow-ups. In fact, the baseline mean seizure frequency (nearly 81 seizures/day) of the active group dropped 99.84% by Day 5, and 55.96% by 4 weeks later. The active group had significantly decreased frequency of tonic, atonic and absence seizures (not myoclonic or partial seizures) compared to sham. Epileptiform discharges also decreased significantly up to 3 weeks later. Both groups tolerated the treatment well with no differences in vital signs or oxygen saturation during and after treatment.

As to single-session studies, the first aimed to investigate safety (Fregni et al., 2006c) due to concerns about increasing excitability under the (reference) anode. Patients with malformations of cortical development (MCD) had a trend towards seizure reduction (by 56% a month later), and marginally significant ED reduction following cathodal tDCS (Fregni et al., 2006f). In pediatric patients with severely intractable focal epilepsy (Auvichayapat et al., 2013), one tDCS session led to a minor but significant drop in clinical seizure frequency, and a significant decrease of EDs up to 57.6% by 48 hours later (Auvichayapat et al., 2013).

Intractable TLE also had improved seizures after one session (Assenza et al., 2017).

Recommendation: cathodal tDCS is probably safe (no increase in seizures) and effective (decreased seizures) in epilepsy (Level B) (Table 7).

Quantitative analysis of 4 studies/montages shows a significant ES of -0.70 (95% CI -1.38, -0.02) in favor of cathodal tDCS effects on seizure frequency in epilepsy (Table 13, Supplemental Figure 4).

(Please insert Table 7 about here)

Summary and Literature Synthesis

While Lefaucheur et al., 2017 (Lefaucheur et al., 2017) gave no recommendations for tDCS in epilepsy, in our review all cathodal tDCS studies/montages showed statistically significant, clinically relevant and long-lasting reductions in seizure frequency in patients with intractable epilepsy with as few as 3-5 sessions. This was confirmed on quantitative analysis of pooled effects despite the small sample, and there was overlap of confidence limits in all studies included. Additionally, anodal tDCS to treat comorbid neuropsychiatric symptoms may be safe in well-controlled epilepsy. However, larger RCTs are needed to investigate different stimulation parameters and forms of tDCS on seizure control, EEG findings, long-term effects and mechanisms of action. AED use should also be considered in epilepsy trials. While anodal tDCS might be inhibited by sodium-channel blockers such as carbamazepine, they may not influence cathodal tDCS. This is important as many AEDs are sodium-channel blockers, and thus cathodal tDCS is a promising adjunctive treatment - even in women on lamotrigine who are pregnant or of child-bearing age. TDCS also theoretically poses no risk to the fetus (Vigod et al., 2014), and early results from a trial on depressed pregnant women show tolerability (Palm et al., 2017a).

tDCS in Psychiatric Disorders

Major depressive disorder

Major depressive disorder (MDD) is a disabling chronic condition affecting 4.4% of the global population in 2015 and severely impairing millions (Murray and Lopez, 1997; Hedden et al., 2016; Anon, 2017). MDD symptoms include persistent low mood, anhedonia (diminished pleasure in previously enjoyable activities), negative thoughts, sleep impairments and psychomotor retardation. Depression has an estimated all-cause mortality risk of 1.6 and suicide risk of 19.7 (Chesney et al., 2014). Additionally, nearly 30% of patients have refractory depression despite receiving appropriate psychological and pharmaceutical therapy (Rush et al., 2006), and thus need other treatment options.

Such options include electroconvulsive therapy (ECT) and NIBS techniques, e.g., rTMS, which is now FDA-approved for MDD even in refractory depression (Burt et al., 2002; Horvath et al., 2014), and deep-TMS (Yip et al., 2017). TDCS is safer than both techniques and has had positive results on multiple meta-analyses (Kalu et al., 2012; Berlim et al., 2013; Shiozawa et al., 2014). We therefore aimed to investigate the effects of tDCS on depression in MDD.

Lefaucheur and colleagues gave a Level B recommendation (probable efficacy) for left DLPFC anodal/right DLPFC cathodal tDCS in non-resistant major depressive episodes (Lefaucheur et al., 2017). Electrode placement and polarity are important for network modulation in different populations, and MDD brains have structural and functional alterations, e.g. in fronto-cingulo-striato-pallido-thalamic circuits (Bora et al., 2012a, 2012b) and other areas relating to emotional and cognitive regulation. These differences can relate to the severity, chronicity and treatment-responsiveness of the disease (Chen et al., 2007; Sacher et al., 2012; Fu et al., 2013; Sämann et al., 2013; Chi et al., 2015; Dichter et al., 2015). For example, patients with more gray matter in the pregenual anterior cingulate cortex (ACC) had

faster and longer lasting improvement with fluoxetine (Chen et al., 2007). Additionally, resting-state hyperconnectivity in the default mode network and hypoconnectivity in the cognitive control network (which includes DLPFC and ACC) is greater in treatment-resistant MDD compared to treatment-sensitive MDD; the latter occurs with higher fronto-limbic connectivity (Dichter et al., 2015). When designing NIBS protocols such as TMS or tDCS, it is important to consider the specific cortical and subcortical imbalances in MDD pathophysiology, the efficacy of modulating chosen targets and the likely downstream effects of this modulation.

A PubMed search using the keywords "transcranial direct current stimulation" and "major depressive disorder" yielded 15 results that fit our criteria. It is relevant to note that while most papers excluded bipolar disorder, 2 studies included unipolar depression (primarily) and bipolar disorder patients (Palm et al., 2012; Loo et al., 2018). We did not restrict our recommendations to response and remission, influenced by a meta-analysis (Shiozawa et al., 2014) that showed efficacy with continuous outcomes (i.e. depression improvement) but not categorical outcomes (response or remission); most trials had small samples (Table 8), so we consider them underpowered for categorical/binary outcomes.

tDCS in MDD

All studies had at least 5 tDCS sessions and the overwhelming majority placed the anode over the left DLPFC (F3), or just anterior to the left DLPFC ("pF3"). Seven studies placed the cathode over the right DLPFC (F4), while the rest placed the cathode over the right supraorbital area (frontopolar/orbitofrontal stimulation) or more laterally at F8 (frontotemporal), except for one RCT using an extracephalic reference. Due to evidence of hypofunction in the left DLPFC and hyperfunction in the right DLPFC in MDD (Mayberg et

al., 2000), multiple recent studies targeted those sites for excitation and inhibition respectively (Table 8).

Left DLPFC anode, right DLPFC cathode

Two Class I and 1/4 Class II studies were positive for this montage (a study on pregnancy was analyzed separately).

The negative studies included one on treatment-resistant MDD patients (many resistant to ECT) where both active and sham tDCS groups improved after 15 sessions (Blumberger et al., 2012); one combined active/sham tDCS with online cognitive control therapy (CCT) – again, both groups improved but with no differences between them, suggesting that CCT had a ceiling effect (Brunoni et al., 2014) despite the higher current density and longer tDCS session (Table 8). Meanwhile, a pilot trial on severely depressed inpatients provided right unilateral ultrabrief ECT following bilateral DLPFC active/sham tDCS. Again, depression improved in the active tDCS group by the end of the second week but it was not significant, perhaps overshadowed by stronger ECT effects (Mayur et al., 2018). Aside from demonstrating safety and feasibility of the combined intervention, it is interesting to note that the active tDCS group required a significantly higher stimulus dose at 6 times seizure threshold (from the second to the sixth and last ECT session) compared to the sham tDCS group. It suggests that either the right cathodal DLPFC tDCS or the combination or left anodal and right cathodal tDCS raised the seizure threshold significantly, which might have implications for how to combine the 2 treatments in the future, and also for patients at risk of seizures outside of ECT.

Of the positive studies, one found improved depression (and cognitive tasks including attention and working memory) in antidepressant-free patients with moderate to severe depression; there was an association between cognitive control and depression improvement

(Salehinejad et al., 2017). The other positive studies were Class I RCTs comparing tDCS to selective serotonin reuptake inhibitors (SSRIs).

SELECT-TDCS (n=120), a 2x2 factorial trial on sertraline vs. tDCS (Brunoni et al., 2013), found significant and clinically relevant additive sertraline and tDCS effects; additionally, the combined tDCS+sertraline group and tDCS alone had significantly improved response (63.3% and 43.3%) and remission rates (46.7% and 40%). Driven initially by tDCS, only the combined group improved significantly at 2 weeks.

ELECT-TDCS (n=245) compared tDCS to escitalopram in moderately to severely depressed but antidepressant-free patients. While they did not find tDCS to be noninferior to escitalopram (escitalopram had better results though this cannot be confirmed with a noninferiority design), tDCS was better than placebo and the difference was clinically relevant though delayed (by Week 10 but not Week 3); previous trials also showed delayed tDCS effects (Brunoni et al., 2017). By Week 10, response (not remission) rates were significantly improved in each of the tDCS and escitalopram groups. Despite using 22 tDCS sessions, clinical improvements were similar to prior studies.

It is important to note that the combined group in SELECT-tDCS and tDCS group in ELECT-tDCS had more treatment-emergent mania/hypomania; however, patients had been antidepressant-free prior to enrollment.

Finally, a pilot study on pregnant women who declined antidepressants to avoid fetal effects showed nonsignificant improvements after active/sham treatment; nevertheless, the 4 point change on Montgomery–Åsberg Depression Rating Scale (MADRS) was greater than the MCID of 1.6-1.9 (Vigod et al., 2019). Significantly, 75% vs. 15% of active vs. sham tDCS patients were in remission one month postpartum. Safety outcomes for mother and child were similar between groups, showing that tDCS may be a good option for pregnancy, although larger studies are needed in this vulnerable population.

Left DLPFC anode, right frontotemporal cathode

For this montage, 1/2 Class I and 1/2 Class II studies were positive; all included moderately to severely depressed patients who were not necessarily antidepressant-free.

One RCT combined active/sham CCT with active/sham tDCS (Segrave et al., 2014), and found significantly improved depression (and 44% response rates) in the tDCS+CCT group 3 weeks later, but not right after the 5 sessions (the half-sham groups had the opposite effect). This montage may have better targeted the ACC (including the pregenual area) compared to the bilateral DLPFC montage used with CCT above, perhaps explaining the significant but delayed improvement in the combined group here, which correlated with improved working memory.

Meanwhile, Loo and colleagues (Loo et al., 2010) gave moderately treatment-resistant patients 5 active/sham tDCS sessions followed by 5 active tDCS sessions for both groups; both groups had similarly improved (and clinically relevant) depression, response and remission rates. In Loo and colleagues' later study patients (n=64) received double the current density over 15 sessions, and tDCS significantly improved MADRS with an effect size of 0.49 (Loo et al., 2012). The patients then entered into an open-label phase, with better results; 27 patients became responders from both groups, though the active group had a longer duration of response. But then Loo and colleagues' largest study on stable patients using greater current density, stimulation duration and frequency showed only modest improvement in the sample (n=120) in both unipolar (n=84), bipolar (n=36) depression (Loo et al., 2018), and it was negative for differences between active/sham groups. That said, the authors later found that their sham technique (giving 0.034 mA throughout) was biologically active. This suggests that 20 sessions of "sham" current density 0.010 A/m^2 led to MADRS results similar to a current

density of 0.714 A/m^2, and that perhaps the higher current intensity of 2.5 mA was not optimal – in fact, in unipolar depression the "sham" group had higher remission than the active group.

Left DLPFC anode, right frontopolar cathode

Class II studies (3/4) were mostly positive, and the one Class III study was negative for this montage.

The first 2 MDD studies successfully used this montage on 5 alternate days (Fregni et al., 2006a). Another early study found that this montage improved depression, response and remission compared to sham and active control groups – which did not differ (Boggio et al., 2008a); the effects persisted a month later in the DLPFC group. The purpose of the active control (with occipital anode) was to investigate right supraorbital cathodal effects, but it was the left DLPFC anode that improved depression. It is worth noting that while occipital bending is more common among MDD patients than healthy controls (Maller et al., 2014), any impact on occipital stimulation is unclear.

Patients were off antidepressants in the early studies above. However, combining twice-daily tDCS sessions with escitalopram in treatment-resistant MDD found no benefits for tDCS beyond those of the drug (Bennabi et al., 2015). Meanwhile, the one crossover study (Palm et al., 2012) evaluated treatment-resistant depression (including 2 bipolar patients) and found that tDCS improved depression minimally better than placebo, and also improved positive emotions. They initially used 1 mA (for safety) and then 2 mA, but these changes did not affect the results, although notably they had no washout period.

Finally, an RCT on moderate-to-severe depression combined a working memory task with tDCS followed by CBT, and found nonsignificantly greater improvements in depression scores (and response and remission) following active tDCS compared to sham (Nord et al., 2019). This may be as they used 7-8 weekly sessions at low current density, as well as a left

DLPFC anode with left deltoid reference. However, functional MRI (fMRI) did find that greater left DLPFC activation at baseline was associated with greater improvements in depression only in the active tDCS group, thereby demonstrating a potential biomarker.

Recommendation: anodal left DLPFC tDCS is definitely effective in improving depression in MDD (Level A) (Table 8).

Quantitative analysis of 13 studies on left DLPFC anodal tDCS effects on depression (HDRS, BDI, MADRS) shows a significant ES of -0.36 (95% CI -0.66, -0.06) in favor of tDCS effects but with significant and moderately high heterogeneity (I^2=44.7%, P=0.041) (Table 13, Supplemental Figure 5).

Summary and Literature Synthesis

Left DLPFC tDCS is effective in treating depression in MDD according to the qualitative review and quantitative analysis, with significant heterogeneity between different studies but no sign of publication bias (Supplemental Figure 5b). Lefaucheur et al., 2017 (Lefaucheur et al., 2017), reported that anodal left DLPFC tDCS with right orbitofrontal (defined as FP2 or F8) cathode is probably effective (Level B) in depression without drug-resistant major depressive episodes, but probably ineffective (Level B) in those with such episodes. They gave no recommendation for bilateral DLPFC tDCS (left anode, right cathode). For our purposes the study protocols using bilateral DLPFC tDCS tended to be different from those using a right supraorbital (FP2) or frontotemporal (F8) cathode, so we do not make that distinction.

A number of meta-analyses took different approaches assessing tDCS effects in depression. A 2018 systematic meta-review of previous-decade meta-analyses (McGirr et al., 2018) reported that active tDCS as well as rTMS in major depression have shown small to moderate effect sizes. One study compared various non-surgical brain stimulation techniques

in a network meta-analysis: Mutz et al, 2019 (Mutz et al., 2019), found that, compared to sham, the summary OR of improving MDD or bipolar depression response rose across the following techniques: tDCS showing the least improvement (OR 2.65, 95% CI 1.55, 4.55) followed by high frequency left rTMS, intermittent theta burst stimulation, low frequency right rTMS, bilateral theta burst stimulation, bilateral rTMS, magnetic seizure therapy, priming TMS, high dose right unilateral ECT, and finally the greatest improvement was in bitemporal ECT (OR 8.91, 95% CI 2.57, 30.91). That is, although tDCS was not as effective as bitemporal ECT, it was still quite effective and showed much a much tighter 95% confidence interval; furthermore, tDCS is much safer.

Meanwhile, an individual patient data (rather than aggregate data) meta-analysis (Moffa et al., 2019) showed that compared to sham, active tDCS significantly improved depression (effect size: B of 0.31, 95% CI 0.15, 0.47), as well as response (OR 1.96, 95% CI 1.30, 2.95; NNT: 9) and remission (OR 1.94, 95% CI 1.19, 3.16; NNT: 13). Finally, the most recent meta-analysis on depressive episodes (Razz et al., 2020) had similar findings for active tDCS vs. sham: improved depression scores (effect size g: 0.46, 95% CI 0.22, 0.70), response (OR 2.28, 95% CI 1.52, 3.42; NNT: 6), and remission (OR 2.12, 95% CI 1.42, 3.16; NNR: 10.7).

Therefore, both the qualitative and quantitative literature shows efficacy of active tDCS in depression; however, there is much room to enhance tDCS parameters and strengthen its benefits. We suggest giving more than 10 sessions of anodal left DLPFC tDCS lasting 20-30 minutes at a current density of at least 0.571 A/m^2. Whether to place the cathode over the right DLPFC to improve the imbalance, or over the right supraorbital or frontotemporal regions to better target the ACC and subcortical regions is less clear and may depend on the severity and treatment-resistance of the population. CCT and pharmaceuticals such as sertraline and escitalopram may improve tDCS effects on depressive symptoms, but future studies should be

carefully powered, and adverse events such as treatment-onset mania/hypomania should be carefully monitored (particularly in populations with low treatment-resistance).

(Please insert Table 8 about here)

Obsessive-compulsive disorder and Tourette Syndrome

Obsessive-compulsive disorder (OCD) and Gilles de la Tourette Syndrome (TS) are disabling neuropsychiatric disorders; OCD is characterized by the presence of obsessions and/or compulsions, and TS by rapid, stereotyped movements and vocalizations (i.e. motor and vocal tics). Neuroimaging studies suggest that cortico-striato-thalamo-cortical loop alterations are implicated in the pathophysiology of OCD (Gonçalves et al., 2011, 2015) and TS (Wang et al., 2011), with the SMAs and pre-SMAS showing deficient response inhibition (Maltby et al., 2005; Nachev et al., 2008; Hsu et al., 2011; de Wit et al., 2012). Both conditions are often resistant to drugs and CBT, but early rTMS and tDCS studies show some promising effects (Mantovani et al., 2006; Kwon et al., 2011; Saba et al., 2015) in targeting dysfunctional circuits.

PubMed searches on "tDCS" and "OCD", and on "tDCS" and "Gilles de la Tourette syndrome" yielded 8 and 3 results respectively that fulfilled our criteria. As mentioned previously, we allowed for uncontrolled trials due to the limited literature. All OCD and TS results were Class IV studies except for 2 OCD Class III crossover RCTs; we identified additional Pubmed-indexed papers through our authors, including a case study (Carvalho et al., 2015) and a recent Class II study (Gowda et al., 2019). All were on treatment-resistant patients receiving tDCS as an add-on to pharmacological treatment (Table 9).

OCD

Based on a Class II, a Class III and multiple Class IV studies, pre-SMA/SMA tDCS shows potential though polarity impact (vs. individual variability) is unclear. The one Class II study (Gowda et al., 2019) gave anodal tDCS over the pre-SMA and found significant improvement; furthermore, active group participants who did not achieve response during the RCT were enrolled in the open-label extension and their scores improved significantly, although they still did not achieve response. A case series aimed to target the pre-SMA and SMA via an Fz anode (with right supraorbital cathode), based on the hypothesis that striatal hyperactivity in OCD results from deficient pre-SMA inhibition (Narayanaswamy et al., 2015). Yale Brown Obsessive Compulsive Scale (YBOCS) scores (40% and 46.7%) as well as well as depression and anxiety improved, and clinical results were sustained for 1-2 months; one patient had an fMRI confirming increased left SMA activity. Conversely, SMA cathodal tDCS in 2 cases led to a minor and delayed response in one while the other improved by 20 sessions and had 45% improvement 6 months later (da Silva et al., 2016). One case from another group had worsening of YBOCS with 10 sessions of anodal pre-SMA tDCS, so she was switched over to 10 sessions of cathodal tDCS, and YBOCS improved (D'Urso et al., 2016a). This was followed by a partial crossover study (D'Urso et al., 2016b) that placed the active anode/cathode anterior to Cz (closer to Fz) with a right deltoid reference (to better target the hyperactive pre-SMAs based on their computational model). The found that only cathodal stimulation led to significant improvements, and 2 patients worsened with anodal tDCS, improving after being crossed over to cathodal tDCS.

An early case report used active/sham monopolar cathodal tDCS and low frequency (inhibitory) rTMS over the left DLPFC, as fMRI had shown baseline hyperactivation and hypoactivation of the left and right anterior circuits respectively (Volpato et al., 2013b). However, none of the conditions improved YBOCS (Volpato et al., 2013b). Meanwhile, another patient received left orbitofrontal cortex cathodal tDCS (Mondino et al., 2015a) - with

a large right occipital reference – and YBOCS decreased by 26% only a month later. Likewise, an open label study aimed modulate the orbitofronto-striato-pallido-thalamic loop by inhibiting the hyperactive left orbitofrontal cortex and increasing excitability in the right hypoactive cerebellum (Bation et al., 2016), and found significant improvements on YBOC (26.4% decrease) and on OCD-VAS (45.6% decrease) lasting 3 months. Finally, one case improved following bilateral DLPFC tDCS combined with sertraline (Palm et al., 2017b).

Our recommendation is based on one convincing Class II study and its open-label extension. Individual variability and expectations may have impacted the other cases.

Recommendation: Anodal pre-SMA tDCS is possibly effective in improving OCD (Level C) (Table 9).

On excluding 8 studies/montages with n<10 (all Class IV), the recommendation does not change.

TS

All cases used variable parameters. Cathodal tDCS over the left motor-premotor areas of 2 TS patients decreased their motor and vocal tics compared to sham, and dramatically increased their feelings of general wellbeing (Mrakic-Sposta et al., 2008). A severely refractory 16-year old received pre-SMA cathodal tDCS as compassionate treatment and had drops of 41% and 46% in tic severity and global score respectively (verbal tics improving before motor tics) by the end of 10 sessions; the benefits lasted at least 6 months (Carvalho et al., 2015). Additionally, fMRI showed decreased left precentral sensorimotor resting state network and cerebellar activity after cathodal tDCS (Carvalho et al., 2015). However, twice daily sessions over a week using a different montage led to worsened tic counts in 3/3 other cases, despite decreased tic severity and YGTSS in one patient (who had TS onset during childhood) (Behler et al., 2018).

Recommendation: no recommendation for TS (Table 9).

All 3 studies (Class IV) had n<10, so excluding them did not change the recommendation.

(Please insert Table 9 about here)

Summary and Literature Synthesis

Overall, the studies showed promising but very preliminary results for tDCS in OCD and TS. Anodal pre-SMA tDCS was positive in a convincing Class II OCD study, but the cases showed variable results. It seems the bilateral pre/SMAs, left DLPFC and orbitofrontal regions might be the most targets to study in future RCTs. Lefaucheur et al., 2017 (Lefaucheur et al., 2017), adds no recommendations and there are no meta-analyses on these topics; our own limited quantitative analysis showed no significant results (Table 13, Supplemental Figure 6). However, considering that DBS was FDA-approved in severely intractable OCD under a humanitarian exemption (Anon, n.d.), a systematic investigation of non-invasive measures is important, and off-label tDCS is an option for compassionate care.

Schizophrenia

Schizophrenia is a debilitating chronic neuropsychiatric disorder characterized by delusions, (typically verbal auditory) hallucinations, disorganized speech/behavior and decreased emotional expression. It might be the "most disabling" disease globally (Salomon et al., 2012). About 20% of patients are treatment-resistant, but may respond to ECT (Kennedy et al., 2014), so NIBS techniques including rTMS and tDCS have been investigated to treat resistant symptoms (Agarwal et al., 2013; Kubera et al., 2015; Mondino et al., 2015a). The typical tDCS montage is based on neuroimaging findings: cathodal stimulation of the hyperactive left temporoparietal region targeting auditory hallucinations (Jardri et al., 2011), and anodal stimulation of the hypoactive frontal areas (mainly left DLPFC and ACC) targeting

negative symptoms (Molina Rodríguez et al., 1997; Sanfilipo et al., 2000; Brunelin et al., 2012).

A PubMed search on "tDCS AND schizophrenia" yielded 11 results that fit our criteria, including auditory hallucinations/positive or negative symptoms in schizophrenia (we also allowed studies that included schizoaffective disorder). We also added another paper identified by an author that fit our criteria (Bose et al., 2018).

tDCS effects on auditory hallucinations, negative and positive symptoms in schizophrenia

Almost all montages placed the anode on the left DLPFC (F3) or midway between it and frontopolar/supraorbital region (FP1 in Table 10, left SO in other tables), that at a more anterior and mesial prefrontal location; cathode was typically on the left temporoparietal region (between midtemporal T7 and parietocentral P3), although some montage variations were used.

Left prefrontal anode, left temporoparietal cathode

All were Class II RCTs using twice daily tDCS at similar parameters, and 6/7 studies showed improvements in auditory hallucinations, Auditory Hallucinations Rating Scale scores (AHRS).

In the first RCT (Brunelin et al., 2012), after a week of twice-daily tDCS the active group had a significant 31% drop in Auditory Hallucinations Rating Scale scores (AHRS) and a 38% improvement 3 months later. Two other studies (most of whose patients had been in the one above (Brunelin et al., 2012)) also found significant auditory verbal hallucination (AVH) improvements (Mondino et al., 2015b; Mondino et al., 2016). After active tDCS, patients had fewer misattributions of covert and overt speech, which correlated with a (46%) drop in AVH frequency, supporting the hypothesis that hallucinations related to internal events were wrongly perceived as occurring in external space (Mondino et al., 2015b). The third study also showed

decreased auditory hallucination severity following active tDCS, which correlated with decreased left temporoparietal junction resting state functional connectivity (rs-FC) with the left anterior insula; additionally, tDCS significantly reduced left temporoparietal rs-FC with the right inferior frontal gyrus (which is active during AVHs), but increased this rs-FC with the left DLPFC, left angular gyrus and precuneus (Mondino et al., 2016).

Conversely, a study on patients with medication resistant AVHs showed no difference in AHRS between active and sham tDCS groups despite being adequately powered and controlling for confounders; nor was it significant for positive/negative symptoms (Chang et al., 2018). However, the study had unclear eligibility criteria and included schizoaffective disorder (n=9/60) with schizophrenia, and they were on low doses of medications relative to the group's pilot study. Yet, the active tDCS group demonstrated significantly improved insight into their symptoms, particularly positive symptoms.

In a larger multicenter RCT (Kantrowitz et al., 2019) using similar stimulation parameters, AHRS improved in active vs. sham groups only when chlorpromazine equivalents (which correlated with higher baseline AHRS) was added as a covariate. The authors suggested covariation for baseline medication doses when analyzing future AVH studies, and that participants with putative high cognitive symptoms were less responsive. There were no differences between schizophrenic and schizoaffective (n=17/53) patients, nor among sites, but outpatients receiving active tDCS had significantly improved remission and hallucination scores; conversely, inpatients on active tDCS had significantly less improvement than both active outpatients and sham inpatients.

In another study on inpatients with treatment resistant schizophrenia or schizoaffective disorder (n=9/28) that was also clozapine-resistant, increased number of sessions (40 vs. 10) was possibly helpful, as AHRS total scores decreased significantly by 21.9% with active tDCS and the decrease at Week 4 was greater than Week 2. Subscores on hallucination frequency,

length and number of voices also decreased. While clinical significance is preliminary, the results are encouraging in this "ultra-treatment-resistant" inpatient sample (Lindenmayer et al., 2019). However, another 10-session study (Bose et al., 2018) found significant AHRS improvement with an effect size of 1.98 (higher than 1.58 in the study they were replicating (Brunelin et al., 2012)); furthermore, the sham tDCS patients improved significantly more in the open-label phase than during the RCT.

Left DLPFC anode, right DLPFC cathode

Both Class II studies were nonsignificant for positive/negative symptom changes with this bilateral DLPFC montage. Ten sessions of active bilateral tDCS did not improve these symptoms whether at a higher current density and duration (with daily sessions) in clinically stable multicenter schizophrenia patients (Jeon et al., 2018), or at the typical twice daily dose combined with cognitive training (Shiozawa et al., 2016).

Other montages

Only 1/3 of the remaining Class II trials showed apparent improvement in positive and negative symptoms. In this proof-of concept RCT on severe paranoid/disorganized schizophrenia left DLPFC anodal-right orbitofrontal cathodal tDCS (both electrodes considered active) improved the Positive and Negative Symptom Scale (PANSS) total and negative subscales, and the Scale for Assessment of Negative Symptoms (SANS). Functional connectivity MRI data showed significant tDCS effects in the bilateral DLPFC and subgenual regions, but relationship to symptoms was unclear (Palm et al., 2016).

Meanwhile, Fitzgerald and colleagues conducted 2 pilot studies comparing left unilateral and bilateral tDCS (DLPFC anode, temporoparietal cathode) over 15 daily sessions, but found so significant improvements in auditory hallucinations, positive or negative

symptoms for unilateral or bilateral tDCS, nor for the whole sample (schizoaffective disorder n=7/24) (Fitzgerald et al., 2014).

Therefore, while there are clear benefits to tDCS in auditory hallucinations, effects on positive and negative symptoms are harder to determine. However, we did not include a Class I RCT (n=100) by Valiengo and colleagues (Valiengo et al., 2019) that was published after our search date limits; this study showed significant and clinically relative benefits of anodal left prefrontal and cathodal left temporoparietal tDCS to negative symptoms, which would change our classification to probably effective (Level B) for negative symptoms in schizophrenia.

Recommendation: anodal left prefrontal with cathodal left temporoparietal tDCS is probably effective for reducing auditory hallucinations in schizophrenia (Level B) (Table 10).

On excluding the one study (Class II) with n<10, the recommendation does not change.

Quantitative analysis of 7 studies/montages on auditory hallucinations (AHRS) shows a significant ES of -0.52 (95% CI -0.86, -0.17) in favor of tDCS. Quantitative analysis of 6 studies/montages on positive and negative symptoms (PANSS) shows a significant ES of -0.45 (95% CI -0.84, -0.06) in favor of tDCS, albeit with significantly high heterogeneity (I^2 57.4%, P=0.029). Pooled analysis shows a significant ES of -0.47 (95% CI -0.72, -0.22) favoring tDCS effects on AHRS and PANSS combined, although again with significant and high heterogeneity (I^2=50.2%, P=0.020) (Table 13, Supplemental Figure 7a).

Summary and Literature Synthesis

Our findings are overall consistent with and promising for twice daily (3 hours apart) left prefrontal anodal and left temporoparietal cathodal tDCS modulation of the network producing and monitoring internal speech, thereby improving auditory verbal hallucinations. Our quantitative analysis shows that tDCS (all montages pooled) significantly improves AHRS and PANSS to a moderate degree, but with high heterogeneity and some evidence of

publication bias (Supplemental Figures 2a and 2b). Lefaucheur et al., 2017 (Lefaucheur et al., 2017), gave no recommendations for tDCS in schizophrenia based on fewer studies.

Meanwhile, a prior meta-analysis (Yang et al., 2019) showed that active left DLPFC-left temporo-parietal tDCS significantly improved auditory hallucinations compared to sham with a standardized mean difference of -4.59 (95% CI -7.91, -1.27); the results were nonsignificant when pooled with a study using a left DLPFC-right supraorbital tDCS montage (Smith et al., 2015) in a population of smokers with schizophrenia or schizoaffective disorder. Additionally, another meta-analysis (Kim et al., 2019) showed that while tDCS did not improve auditory hallucinations, positive or negative symptoms on the main analyses, there were more specific benefits on subgroup analyses that confirm our own results and add direction for stimulation protocols. Specifically, based on 3-7 pooled studies, there were significant improvements in auditory hallucination severity following twice daily tDCS (SMD 1.04, P=0.02), while 10 or more stimulation sessions improved auditory hallucinations (SMD 0.86, 95% CI 0.22, 1.51) as well as severity of negative symptoms (SMD 0.41, 95% CI 0.01, 0.81). Upon meta-regression, mean age was negatively associated with auditory hallucinations (slope -0.15, 95% CI -0.22, -0.09) and negative symptoms (slope -0.08, 95% CI -0.16, -0.02); also, studies with greater severity of negative symptoms at baseline seemed to respond better to tDCS (Kim et al., 2019). These are all factors to consider in future RCT design.

(Please insert Table 10 about here)

Drug Addiction

Drug addiction or dependence is a chronic disease leading to severe medical, psychiatric, psychological, and social consequences (Healey et al., 1998; Daley, et al. 2013). Alcoholism is an important risk factor for disease (Navarro et al., 2011), disability and death

(Suokas et al., 2005). Yet, medical treatments for alcohol dependence are often underutilized and have limiting contraindications or side effects (Goh and Morgan, 2017). Meanwhile, psychoactive stimulant crack-cocaine (Fischer et al., 2015) establishes a rapid and severe dependence with powerful withdrawal effects and a poor prognosis (Hatsukami and Fischman, 1996; Moura et al., 2014). Methamphetamine or "crystal meth" is also a potent psychoactive stimulant with numerous healthcare consequences, including psychosis; dependent patients have few effective medical options (Härtel-Petri et al., 2017). Bio-psychosocial and pharmacological therapeutics often focus on managing acute or protracted abstinence (Siegal et al., 2002; McKay et al., 2005), but seldom focus on craving (the uncontrolled urge to use drugs) (Robinson and Berridge, 1993; Hormes et al., 2012) and/or relapses (resuming previous patterns of heavy drug use) (Wesson et al., 1986; Iruzubieta et al., 2013); they tend to have only modest efficacy (Assanangkornchai and Srisurapanont, 2007; Miller et al., 2011; Fischer et al., 2015).

Addiction results from progressive maladaptive neuroplasticity, beginning with an initial impulsive action; (Koob and Volkow, 2016); later environmental cues can lead to cravings and trigger relapses. Addicted patients have impaired executive functions, likely due to decreased volume and disrupted activity in relevant areas such as the DLPFC, cingulate and orbitofrontal cortices (Moselhy et al., 2001; Di Sclafani et al., 2002; Duka et al., 2011; Koob and Volkow, 2016). The DLPFC is involved in "top-down" regulation of attention (Cummings, 1993; Arnsten and Rubia, 2012) and the ability to control drug intake (Duka et al., 2011). As such, modulating excitability in the DLPFC and other regions by tDCS may help improve success in abstinence from drugs.

Pubmed searches on "alcohol AND tDCS", "cocaine AND tDCS" and "methamphetamine AND tDCS" yielded 9, 2 and 1 studies that fit our criteria. We focused on cravings and relapses.

Alcohol Dependence

Of repeated-session RCTs, 2/2 Class II studies on right DLPFC anode and left DLPFC cathode were positive, 2 Class II studies with reversed polarity and bias modification training were negative, and other montages were mixed.

Klaus and colleagues had 2 RCTs using right/left DLPFC anodal/cathodal tDCS. One study using twice daily tDCS for a week found 3 times less relapse in the active group at 6 months compared to sham even though both groups had similarly improved cravings (Klauss et al., 2014). Their next study (using alternating days) found that craving scores significantly decreased in a linear fashion over the weeks from baseline to a week after tDCS with a large effect size (1.1 Cohen's d), a 3-fold drop in alcohol cravings, and a number needed to treat (NNT) of 3.5 patients (Klauss et al., 2018b). Additionally, 72.7% of the active group (vs. 27.8% of sham) maintained alcohol abstinence over 3 months post-treatment. Our recommendations are thus based on these results.

Meanwhile, den Uyl and colleagues used left/right DLPFC anode/cathode tDCS for 4 sessions. The first combined tDCS with cognitive bias modification (CBM)/its control but found no significant improvements in alcohol craving or relapse (den Uyl et al., 2017) with either online or offline CBM. This study listed a number of limitations such as missing data, change in primary outcome, and some baseline differences. Their next study on alcohol-dependent but abstinent patients combined the above tDCS montage with active/control attentional bias modification (ABM) with active/sham tDCS (den Uyl et al., 2018) but tDCS did not help craving (which was very low at baseline), automatic biases or relapse; however, the study was limited by the large number of dropouts in follow-up, and there was still 16% less relapse with active tDCS (similar magnitude to the previous study). The limitations of those studies led to them being Class II rather than Class I RCTs despite larger samples.

As to other tDCS montages, one RCT aimed to modulate the right inferior frontal gyrus with anodal tDCS while combining it with mindfulness-based relapse prevention to reduce drinking in alcohol use disorder but found no benefit to tDCS (Witkiewitz et al., 2019). Weekly left DLPFC tDCS in Lesch IV alcoholics improved depression and craving on one scale but unfortunately led a trend toward more relapses and less abstinence in the anodal group (which drank twice as much at baseline) compared to sham (da Silva et al., 2013).

As to single-session RCTs, all DLPFC tDCS irrespective of polarity improved outcomes but left inferior frontal gyrus tDCS did not help (Table 11).

Recommendation: right DLPFC anodal with left DLPFC cathodal tDCS is probably effective in decreasing relapses or craving in alcohol addiction (Level B) (Table 11).

Crack-cocaine

Two Class II RCTs using right/left DLPFC anodal/cathodal tDCS had mixed results. TDCS for 5 alternate days significantly decreased craving and had other neuropsychological benefits in crack-cocaine addicts admitted to an addiction clinic (abstinent for 35 days) (Batista et al., 2015). This is consistent with the efficacy of the right/left DLPFC montage in addiction. In a second study on more severe crack-cocaine use, baseline craving scores were greater and the effect size after treatment was also larger (Hedge's g 0.97 vs. 0.54) - however, there were no significant differences between groups in cravings or relapse 30 and 60 days later (Klauss et al., 2018a).

Recommendation: none (Table 11).

Methamphetamine Dependence

A single-session crossover RCT on abstinent methamphetamine users found that one session of right DLPFC anodal tDCS with an online computerized cue-induced craving task

(CICT) reduced immediate craving at rest, but worsened craving on exposure to meth-related cues (Shahbabaie et al., 2014). This was possibly due to DLPFC effects on drug cue saliency and craving.

Recommendation: none (Table 11).

(Please insert Table 11 about here)

Summary and Literature Synthesis

While available evidence for tDCS use in drug addiction is somewhat promising, there is a need for larger studies. Lefaucheur et al., 2017 (Lefaucheur et al., 2017), recommended that combined right DLPFC anodal with left DLPFC cathodal tDCS is probably effective (Level B) in addiction/craving reduction (of alcohol, crack-cocaine and smoking combined). We found that montage to be probably effective for alcoholic cravings or relapses (Level B) although our limited quantitative analysis combining Pennsylvania Alcohol Craving Scale (PACS), Obsessive Compulsive Drinking Scale (OCDS) and relapse missed significance (Table 13, Supplemental Figure 8). We can give no recommendation for crack-cocaine or methamphetamine users.

Risk of bias assessment and sensitivity analysis

Mean Jadad scores for each condition in this review can be found in Table 12. We conducted a sensitivity analysis by excluding papers with high-risk of bias. There were no changes in the recommendations for all clinical conditions.

Additionally, for the secondary meta-analyses we included funnel plots, Egger and Begg tests to evaluate publication bias in disorders with 10 or more pooled studies (Supplement); in each disorder we mentioned when there was evidence of publication bias.

(Please insert Table 12 about here)

Discussion

TDCS is a flexible, low-cost and relatively benign tool. In this review a panel of tDCS experts gave evidence-based recommendations on tDCS use in 9 neurological and psychiatric conditions: Pain, Parkinson's Disease (Motor Function and Cognition), Stroke (Motor Function and Language), Epilepsy, Major Depressive Disorder, Obsessive Compulsive Disorder, Tourette Syndrome, Schizophrenia and Drug Addiction (Table 13). Although many tDCS studies appear promising, the heterogeneity in populations, outcomes, tDCS parameters and concomitant therapies necessitate further research before its clinical benefits can be fully demonstrated. This review is therefore important to provide initial guidance to assess tDCS' potential clinical benefits.

Most clinical trials primarily aimed to investigate efficacy, and safety profiles typically come from secondary analyses (Brunoni et al., 2011a; Poreisz et al., 2007), although no moderate or severe adverse events have been reported thus far. That said, clinicians should exert caution when using tDCS off-label before more conclusive reports are published, as long-term effects have not been established, nor is it clear in what conditions tDCS can reach at least minimal clinically important differences. It is also important to note that electrode locations were measured in different ways while electrode sizes were almost always standardized across patients. Considering the varying measurements, head sizes and shapes, we cannot guarantee that the current distribution is comparable between different patients across studies. One potential solution is HD-tDCS (Villamar et al., 2013; Karvigh et al., 2017) which can account for head shape and size variations, and perhaps lead to more comparable current distributions in tDCS. Most tDCS studies thus far are underpowered to show significance in categorical

outcomes, and effect sizes should be evaluated in larger RCTs, which are necessary to find optimal parameters for stimulation across different populations and disorders.

Importantly, few RCTs in this review were Class I. As a result, most recommendations are either Level B or Level C (probably or possibly effective), and in a number of conditions no recommendations could be given. These levels of recommendation should only be used when no better treatments exist, or when they have failed, in which case tDCS could be offered off-label as long as local regulatory policies are followed. Also, while we excluded single-session RCTs from our recommendations, we cannot guarantee that repeated-session tDCS changes were always due to cumulative as opposed to acute benefits as many studies did not measure changes immediately after the first stimulation session; however, some did take repeated measurements over time showing cumulative neuroplastic benefits. We consider the inclusion of single-session studies important to demonstrate the history and mechanisms of the intervention.

Despite the above limitations, we believe that our work has certain strengths, such as our team of experts, our comprehensive review of repeated- and single-session studies, our assessment of methodological bias and sensitivity analyses excluding low quality and smaller studies, and our easy to read tables showcasing the heterogeneity of parameters used in tDCS trial design. Furthermore, our secondary meta-analyses strengthen our claims for tDCS benefits in most disorders, e.g., neuropathic pain, Parkinson's disease (motor), epilepsy, depression, schizophrenia, chronic and subacute stroke (motor without robotics), and post-stroke aphasia. Additionally, the quantitative analyses also provide objective measures of heterogeneity and publication bias, although sometimes with very limited samples.

While it may impact outcomes, we have no evidence that this heterogeneity in tDCS trials outweighs that of surgical or behavioral trials, nor even drug trials considering pharmacokinetic and pharmacodynamic variabilities. Finally, there are many

recommendations but little consensus on how to investigate clinical heterogeneity (or "clinical diversity") in systematic reviews of RCTs, although we believe we covered many of the suggested methods, including using a team of clinical experts, careful covariate selection based on scientific rationales, and cautious interpretation of our findings (Gagnier et al., 2012; West et al., 2010).

Conclusions

According to this evidence-based review, we are able to recommend specific tDCS protocols for only some indications (e.g., MDD). These results were confirmed when studies with high risk of bias were excluded. Table 13 summarizes the recommendations on tDCS efficacy/safety according to clinical indication in 9 neurological and psychiatric disorders. A secondary meta-analysis provides even stronger evidence of tDCS benefits in multiple disorders, although sometimes with very limited samples. We summarize our results and synthesize them with the literature.

(Please insert Table 13 about here)

Statement of interest:

MB is affiliated with CUNY. CUNY has patents on brain stimulation with MB as inventor. The other authors report no conflicts of interest.

Funding

F.F. is supported by NIH R01: 1R01AT009491-01A1 and NIH R01 - 5R01HD082302-03

Author contributions

Felipe Fregni: study design, decisions on recommendations.

Mirret M. El-Hagrassy: study design, literature search, study selection, comprehensive review of all papers included for intellectual content, drafting and revision of the entire manuscript and all tables, guidance and revision of all quantitative analyses, decisions on recommendations, risk of bias assessment, literature review and synthesis.

Kevin Pacheco-Barrios: literature search, study selection, comprehensive review of papers included for intellectual content, drafting of tables and recommendations, quantitative analyses, revision of the entire manuscript and all tables, decisions on recommendations, risk of bias assessment.

Sandra Carvalho: literature search, study selection, drafting of tables and recommendations, revision of the entire manuscript and all tables, decisions on recommendations, risk of bias assessment.

Jorge Leite: literature search, study selection, drafting of tables and recommendations, revision of the entire manuscript and all tables, decisions on recommendations, risk of bias assessment.

Marcel Simis: study design, revision of the entire manuscript and all tables, decisions on recommendations.

Jerome Brunelin: study design, revision of the entire manuscript and all tables, decisions on recommendations.

Ester Miyuki Nakamura-Palacios: study design, revision of the entire manuscript and all tables, decisions on recommendations.

Paola Marangolo: study design, revision of the entire manuscript and all tables, decisions on recommendations.

Ganesan Venkatasubramanian: study design, revision of the entire manuscript and all tables, decisions on recommendations.

Daniel San-Juan: study design, revision of the entire manuscript and all tables, decisions on recommendations.

Wolnei Caumo: study design, revision of the entire manuscript and all tables, decisions on recommendations.

André R. Brunoni: study design, revision of the entire manuscript and all tables, decisions on recommendations.

Marom Bikson: study design, revision of the entire manuscript and all tables, decisions on recommendations.

Neuromodulation Center Working Group: literature search, study selection, risk of bias assessment, and drafting of tables.

References

Achacheluee ST, Rahnama L, Karimi N, Abdollahi I, Arslan SA, Jaberzadeh S (2018) The effect of unihemispheric concurrent dual-site transcranial direct current stimulation of primary motor and dorsolateral prefrontal cortices on motor function in patients with sub-acute stroke. Front Hum Neurosci 12.

Agarwal SM, Shivakumar V, Bose A, Subramaniam A, Nawani H, Chhabra H, V S, Kalmady JC, C J, Narayanaswamy, Venkatasubramanian G (2013) Transcranial Direct Current Stimulation in Schizophrenia. Clin Psychopharmacol Neurosci 11:118–125.

Alexander MP, Naeser MA, Palumbo C (1990) Broca's area aphasias: aphasia after lesions including the frontal operculum. Neurology 40:353–362.

Andrade SM, de Brito Aranha REL, de Oliveira EA, de Mendonça CTPL, Martins WKN, Alves NT, Fernández-Calvo B (2017) Transcranial direct current stimulation over the primary motor vs prefrontal cortex in refractory chronic migraine: A pilot randomized controlled trial. J Neurol Sci 378:225–232.

Anon (1950) Hebb, D. O. Organization of behavior. New York: Wiley, 1949, pp. 335. J Clin Psychol 6:307–307.

Anon (2017) Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.

Anon (n.d.) Humanitarian Device Exemption (HDE).

Aparício LVM, Guarienti F, Razza LB, Carvalho AF, Fregni F, Brunoni AR (2016) A Systematic Review on the Acceptability and Tolerability of Transcranial Direct Current Stimulation Treatment in Neuropsychiatry Trials. Brain Stimul 9:671–681.

Ardolino G, Bossi B, Barbieri S, Priori A (2005) Non-synaptic mechanisms underlie the after-effects of cathodal transcutaneous direct current stimulation of the human brain. J Physiol

568:653–663.

Arnsten AFT, Rubia K (2012) Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: disruptions in neurodevelopmental psychiatric disorders. J Am Acad Child Adolesc Psychiatry 51:356–367.

Artola A, Singer W (1993) Long-term depression of excitatory synaptic transmission and its relationship to long-term potentiation. Trends Neurosci 16:480–487.

Assanangkornchai S, Srisurapanont M (2007) The treatment of alcohol dependence. Curr Opin Psychiatry 20:222–227.

Assenza G, Campana C, Assenza F, Pellegrino G, Di Pino G, Fabrizio E, Fini R, Tombini M, Di Lazzaro V (2017) Cathodal transcranial direct current stimulation reduces seizure frequency in adults with drug-resistant temporal lobe epilepsy: A sham controlled study. Brain Stimul 10:333–335.

Attal N, Ayache SS, Ciampi De Andrade D, Mhalla A, Baudic S, Jazat F, Ahdab R, Neves DO, Sorel M, Lefaucheur J-P, Bouhassira D (2016) Repetitive transcranial magnetic stimulation and transcranial direct-current stimulation in neuropathic pain due to radiculopathy: a randomized sham-controlled comparative study. Pain 157:1224–1231.

Auvichayapat N, Rotenberg A, Gersner R, Ngodklang S, Tiamkao S, Tassaneeyakul W, Auvichayapat P (2013) Transcranial direct current stimulation for treatment of refractory childhood focal epilepsy. Brain Stimul 6:696–700.

Auvichayapat N, Sinsupan K, Tunkamnerdthai O, Auvichayapat P (2016) Transcranial Direct Current Stimulation for Treatment of Childhood Pharmacoresistant Lennox-Gastaut Syndrome: A Pilot Study. Front Neurol 7:66.

Bae S-H, Kim G-D, Kim K-Y (2014) Analgesic effect of transcranial direct current stimulation on central post-stroke pain. Tohoku J Exp Med 234:189–195.

Bai X, Guo Z, He L, Ren L, McClure MA, Mu Q (2019), Different Therapeutic Effects of

Transcranial Direct Current Stimulation on Upper and Lower Limb Recovery of Stroke Patients with Motor Dysfunction: A Meta-Analysis. Neural Plasticity 2019.

Bashir ZI, Alford S, Davies SN, Randall AD, Collingridge GL (1991) Long-term potentiation of NMDA receptor-mediated synaptic transmission in the hippocampus. Nature 349:156–158.

Basso A, Forbes M, Boller F (2013) Rehabilitation of aphasia. In: Handbook of clinical neurology, pp 325–334.

Bation R, Poulet E, Haesebaert F, Saoud M, Brunelin J (2016) Transcranial direct current stimulation in treatment-resistant obsessive-compulsive disorder: An open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry 65:153–157.

Batista EK, Klauss J, Fregni F, Nitsche MA, Nakamura-Palacios EM (2015) A Randomized Placebo-Controlled Trial of Targeted Prefrontal Cortex Modulation with Bilateral tDCS in Patients with Crack-Cocaine Dependence. Int J Neuropsychopharmacol 18:pyv066.

Beattie EC, Carroll RC, Yu X, Morishita W, Yasuda H, von Zastrow M, Malenka RC (2000) Regulation of AMPA receptor endocytosis by a signaling mechanism shared with LTD. Nat Neurosci 3:1291–1300.

Behler N, Leitner B, Mezger E, Weidinger E, Musil R, Blum B, Kirsch B, Wulf L, Löhrs L, Winter C, Padberg F, Palm U (2018) Cathodal tDCS over motor cortex does not improve tourette syndrome: Lessons learned from a case series. Front Behav Neurosci 12:1–7.

Bennabi D, Nicolier M, Monnin J, Tio G, Pazart L, Vandel P, Haffen E (2015) Pilot study of feasibility of the effect of treatment with tDCS in patients suffering from treatment-resistant depression treated with escitalopram. Clin Neurophysiol 126:1185–1189.

Benninger DH, Lomarev M, Lopez G, Wassermann EM, Li X, Considine E, Hallett M (2010) Transcranial direct current stimulation for the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 81:1105–1111.

Berlim MT, Van den Eynde F, Daskalakis ZJ (2013) Clinical utility of transcranial direct current stimulation (tDCS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials. J Psychiatr Res 47:1–7.

Bikson M et al. (2016) Safety of Transcranial Direct Current Stimulation: Evidence Based Update 2016. Brain Stimul 9:641–661.

Bliss T V, Gardner-Medwin AR (1973) Long-lasting potentiation of synaptic transmission in the dentate area of the unanaestetized rabbit following stimulation of the perforant path. J Physiol 232:357–374.

Blumberger DM, Tran LC, Fitzgerald PB, Hoy KE, Daskalakis ZJ (2012) A randomized double-blind sham-controlled study of transcranial direct current stimulation for treatment-resistant major depression. Front psychiatry 3:74.

Boggio PS, Ferrucci R, Rigonatti SP, Covre P, Nitsche M, Pascual-Leone A, Fregni F (2006) Effects of transcranial direct current stimulation on working memory in patients with Parkinson's disease. J Neurol Sci 249:31–38.

Boggio PS, Rigonatti SP, Ribeiro RB, Myczkowski ML, Nitsche MA, Pascual-Leone A, Fregni F (2008) A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression. Int J Neuropsychopharmacol 11:249–254.

Boggio PS, Amancio EJ, Correa CF, Cecilio S, Valasek C, Bajwa Z, Freedman SD, Pascual-Leone A, Edwards DJ, Fregni F (2009) Transcranial DC stimulation coupled with TENS for the treatment of chronic pain: a preliminary study. Clin J Pain 25:691–695.

Boon P, De Herdt V, Vonck K, Van Roost D (2007) Clinical experience with vagus nerve stimulation and deep brain stimulation in epilepsy. Acta Neurochir Suppl 97:273–280.

Bora E, Fornito A, Pantelis C, Yücel M (2012a) Gray matter abnormalities in Major Depressive Disorder: a meta-analysis of voxel based morphometry studies. J Affect Disord 138:9–18.

Bora E, Harrison BJ, Davey CG, Yücel M, Pantelis C (2012b) Meta-analysis of volumetric abnormalities in cortico-striatal-pallidal-thalamic circuits in major depressive disorder. Psychol Med 42:671–681.

Borckardt JJ, Reeves ST, Robinson SM, May JT, Epperson TI, Gunselman RJ, Schutte H Del, Demos HA, Madan A, Fredrich S, George MS (2013) Transcranial direct current stimulation (tDCS) reduces postsurgical opioid consumption in total knee arthroplasty (TKA). Clin J Pain 29:925–928.

Boros K, Poreisz C, Münchau A, Paulus W, Nitsche MA (2008) Premotor transcranial direct current stimulation (tDCS) affects primary motor excitability in humans. Eur J Neurosci 27:1292–1300.

Bose A, Shivakumar V, Agarwal SM, Kalmady S V., Shenoy S, Sreeraj VS, Narayanaswamy JC, Venkatasubramanian G (2018) Efficacy of fronto-temporal transcranial direct current stimulation for refractory auditory verbal hallucinations in schizophrenia: A randomized, double-blind, sham-controlled study. Schizophr Res 195:475–480.

Brainin M, Barnes M, Baron J-C, Gilhus NE, Hughes R, Selmaj K, Waldemar G, Guideline Standards Subcommittee of the EFNS Scientific Committee (2004) Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2004*. Eur J Neurol 11:577–581.

Brietzke AP, Rozisky JR, Dussan-Sarria JA, Deitos A, Laste G, Hoppe PFT, Muller S, Torres ILS, Alvares-da-Silva MR, de Amorim RFB, Fregni F, Caumo W (2016) Neuroplastic Effects of Transcranial Direct Current Stimulation on Painful Symptoms Reduction in Chronic Hepatitis C: A Phase II Randomized, Double Blind, Sham Controlled Trial. Front Neurosci 9.

Brodie MJ, Barry SJE, Bamagous GA, Norrie JD, Kwan P (2012) Patterns of treatment response in newly diagnosed epilepsy. Neurology 78:1548–1554.

Brunelin J, Mondino M, Gassab L, Haesebaert F, Gaha L, Suaud-Chagny M-F, Saoud M, Mechri A, Poulet E (2012) Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia. Am J Psychiatry 169:719–724.

Brunoni AR, Amadera J, Berbel B, Volz MS, Rizzerio BG, Fregni F (2011) A systematic review on reporting and assessment of adverse effects associated with transcranial direct current stimulation. Int J Neuropsychopharmacol 14:1133–1145.

Brunoni AR, Nitsche MA, Bolognini N, Bikson M, Wagner T, Merabet L, Edwards DJ, Valero-Cabre A, Rotenberg A, Pascual-Leone A, Ferrucci R, Priori A, Boggio PS, Fregni F (2012) Clinical research with transcranial direct current stimulation (tDCS): Challenges and future directions. Brain Stimul 5:175–195.

Brunoni AR, Valiengo L, Baccaro A, Zanão TA, de Oliveira JF, Goulart A, Boggio PS, Lotufo PA, Benseñor IM, Fregni F (2013) The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial. JAMA psychiatry 70:383–391.

Brunoni AR, Boggio PS, De Raedt R, Benseñor IM, Lotufo PA, Namur V, Valiengo LCL, Vanderhasselt M. (2014) Cognitive control therapy and transcranial direct current stimulation for depression: A randomized, double-blinded, controlled trial. J Affect Disord 162:43–49.

Brunoni AR, Moffa AH, Sampaio-Junior B, Borrione L, Moreno ML, Fernandes RA, Veronezi BP, Nogueira BS, Aparicio LVM, Razza LB, Chamorro R, Tort LC, Fraguas R, Lotufo PA, Gattaz WF, Fregni F, Benseñor IM (2017) Trial of Electrical Direct-Current Therapy versus Escitalopram for Depression. N Engl J Med 376:2523–2533.

Bucur M, Papagno C (2019), Are transcranial brain stimulation effects long-lasting in post-stroke aphasia? A comparative systematic review and meta-analysis on naming performance. Neuroscience & Biobehavioral Reviews.

Buhmann C, Huckhagel T, Engel K, Gulberti A, Hidding U, Poetter-Nerger M, Goerendt I, Ludewig P, Braass H, Choe C-U, Krajewski K, Oehlwein C, Mittmann K, Engel AK, Gerloff C, Westphal M, Köppen JA, Moll CKE, Hamel W (2017) Adverse events in deep brain stimulation: A retrospective long-term analysis of neurological, psychiatric and other occurrences. Toft M, ed. PLoS One 12:e0178984.

Burt T, Lisanby SH, Sackeim HA (2002) Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis. Int J Neuropsychopharmacol 5:73–103.

Carvalho S, Gonçalves ÓF, Soares JM, Sampaio A, Macedo F, Fregni F, Leite J (2015) Sustained Effects of a Neural-based Intervention in a Refractory Case of Tourette Syndrome. Brain Stimul 8:657–659.

Cha H-K, Ji S-G, Kim M-K, Chang J-S (2014) Effect of Transcranial Direct Current Stimulation of Function in Patients with Stroke. J Phys Ther Sci 26:363–365.

Chang C-C, Tzeng N-S, Chao C-Y, Yeh C-B, Chang H-A (2018) The Effects of Add-on Fronto-Temporal Transcranial Direct Current Stimulation (tDCS) on Auditory Verbal Hallucinations, Other Psychopathological Symptoms, and Insight in Schizophrenia: A Randomized, Double-Blind, Sham-Controlled Trial. Int J Neuropsychopharmacol 21:979–987.

Chang WH, Kim MS, Park E, Cho JW, Youn J, Kim YK, Kim Y-H (2017) Effect of Dual-Mode and Dual-Site Noninvasive Brain Stimulation on Freezing of Gait in Patients With Parkinson Disease. Arch Phys Med Rehabil 98:1283–1290.

Chen C-H, Ridler K, Suckling J, Williams S, Fu CHY, Merlo-Pich E, Bullmore E (2007) Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. Biol Psychiatry 62:407–414.

Chesney E, Goodwin GM, Fazel S (2014) Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry 13:153–160.

Chi KF, Korgaonkar M, Grieve SM (2015) Imaging predictors of remission to anti-depressant medications in major depressive disorder. J Affect Disord 186:134–144.

Choi Y-H, Jung S-J, Lee CH, Lee S-U (2014) Additional effects of transcranial direct-current stimulation and trigger-point injection for treatment of myofascial pain syndrome: a pilot study with randomized, single-blinded trial. J Altern Complement Med 20:698–704.

Cipollari S, Veniero D, Razzano C, Caltagirone C, Koch G, Marangolo P (2015) Combining TMS-EEG with transcranial direct current stimulation language treatment in aphasia. Expert Rev Neurother 15:833–845.

Costa-Ribeiro A, Maux A, Bosford T, Tenório Y, Marques D, Carneiro M, Nitsche MA, Filho AM, Monte-Silva K (2016) Dopamine-independent effects of combining transcranial direct current stimulation with cued gait training on cortical excitability and functional mobility in Parkinson's disease. J Rehabil Med 48:819–823.

Costa-Ribeiro A, Maux A, Bosford T, Aoki Y, Castro R, Baltar A, Shirahige L, Moura Filho A, Nitsche MA, Monte-Silva K (2017) Transcranial direct current stimulation associated with gait training in Parkinson's disease: A pilot randomized clinical trial. Dev Neurorehabil 20:121–128.

Cummings JL (1993) Frontal-subcortical circuits and human behavior. Arch Neurol 50:873–880.

D'Urso G, Brunoni AR, Anastasia A, Micillo M, de Bartolomeis A, Mantovani A (2016a) Polarity-dependent effects of transcranial direct current stimulation in obsessive-compulsive disorder. Neurocase 22:60–64.

D'Urso G, Brunoni AR, Mazzaferro MP, Anastasia A, de Bartolomeis A, Mantovani A (2016b) Transcranial direct current stimulation for obsessive-compulsive disorder: A randomized, controlled, partial crossover trial. Depress Anxiety 33:1132–1140.

da Silva MC, Conti CL, Klauss J, Alves LG, do Nascimento Cavalcante HM, Fregni F, Nitsche

MA, Nakamura-Palacios EM (2013) Behavioral effects of transcranial direct current stimulation (tDCS) induced dorsolateral prefrontal cortex plasticity in alcohol dependence. J Physiol Paris 107:493–502.

Dagan M, Herman T, Harrison R, Zhou J, Giladi N, Ruffini G, Manor B, Hausdorff JM (2018) Multitarget transcranial direct current stimulation for freezing of gait in Parkinson's disease. Mov Disord 33:642–646.

Daley DC (2013) Family and social aspects of substance use disorders and treatment. J Food Drug Anal 21:S73–S76.

Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39:889–909.

Davies CH, Starkey SJ, Pozza MF, Collingridge GL (1991) GABA autoreceptors regulate the induction of LTP. Nature 349:609–611.

de Wit SJ, de Vries FE, van der Werf YD, Cath DC, Heslenfeld DJ, Veltman EM, van Balkom AJLM, Veltman DJ, van den Heuvel OA (2012) Presupplementary motor area hyperactivity during response inhibition: a candidate endophenotype of obsessive-compulsive disorder. Am J Psychiatry 169:1100–1108.

DeLong MR, Wichmann T (2007) Circuits and circuit disorders of the basal ganglia. Arch Neurol 64:20–24.

den Uyl TE, Gladwin TE, Rinck M, Lindenmeyer J, Wiers RW (2017) A clinical trial with combined transcranial direct current stimulation and alcohol approach bias retraining. Addict Biol 22:1632–1640.

den Uyl TE, Gladwin TE, Lindenmeyer J, Wiers RW (2018) A Clinical Trial with Combined Transcranial Direct Current Stimulation and Attentional Bias Modification in Alcohol-Dependent Patients. Alcohol Clin Exp Res 42:1961–1969.

Di Sclafani V, Tolou-Shams M, Price LJ, Fein G (2002) Neuropsychological performance of

individuals dependent on crack-cocaine, or crack-cocaine and alcohol, at 6 weeks and 6 months of abstinence. Drug Alcohol Depend 66:161–171.

Dichter GS, Gibbs D, Smoski MJ (2015) A systematic review of relations between resting-state functional-MRI and treatment response in major depressive disorder. J Affect Disord 172:8–17.

Doruk D, Gray Z, Bravo GL, Pascual-Leone A, Fregni F (2014) Effects of tDCS on executive function in Parkinson's disease. Neurosci Lett 582:27–31.

Duchesne C, Gheysen F, Bore A, Albouy G, Nadeau A, Robillard ME, Bobeuf F, Lafontaine AL, Lungu O, Bherer L, Doyon J (2016) Influence of aerobic exercise training on the neural correlates of motor learning in Parkinson's disease individuals. NeuroImage Clin 12:559–569.

Duka T, Trick L, Nikolaou K, Gray MA, Kempton MJ, Williams H, Williams SCR, Critchley HD, Stephens DN (2011) Unique brain areas associated with abstinence control are damaged in multiply detoxified alcoholics. Biol Psychiatry 70:545–552.

Dworkin RH et al. (2008) Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations. J Pain 9:105–121.

Edwards DJ, Cortes M, Rykman-Peltz A, Chang J, Elder J, Thickbroom G, Mariman JJ, Gerber LM, Oromendia C, Krebs HI, Fregni F, Volpe BT, Pascual-Leone A (2019) Clinical improvement with intensive robot-assisted arm training in chronic stroke is unchanged by supplementary tDCS. Restor Neurol Neurosci 37:167–180.

Fagerlund AJ, Hansen OA, Aslaksen PM (2015) Transcranial direct current stimulation as a treatment for patients with fibromyalgia. Pain 156:62–71.

Feng Y, Zhang B, Zhang J, Yin Y (2019), Effects of Non- invasive Brain Stimulation on Headache Intensity and Frequency of Headache Attacks in Patients With Migraine: A Systematic Review and Meta- Analysis. Headache: The Journal of Head and Face Pain

59:1436-1447

Fernández-Lago H, Bello O, Mora-Cerdá F, Montero-Cámara J, Fernández-Del-Olmo MÁ (2017) Treadmill Walking Combined With Anodal Transcranial Direct Current Stimulation in Parkinson Disease: A Pilot Study of Kinematic and Neurophysiological Effects. Am J Phys Med Rehabil 96:801–808.

Fiori V, Cipollari S, Di Paola M, Razzano C, Caltagirone C, Marangolo P (2013) tDCS stimulation segregates words in the brain: evidence from aphasia. Front Hum Neurosci 7.

Fischer B, Blanken P, Da Silveira D, Gallassi A, Goldner EM, Rehm J, Tyndall M, Wood E (2015) Effectiveness of secondary prevention and treatment interventions for crack-cocaine abuse: a comprehensive narrative overview of English-language studies. Int J Drug Policy 26:352–363.

Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J, Forsgren L, French JA, Glynn M, Hesdorffer DC, Lee BI, Mathern GW, Moshé SL, Perucca E, Scheffer IE, Tomson T, Watanabe M, Wiebe S (2014) ILAE Official Report: A practical clinical definition of epilepsy. Epilepsia 55:475–482.

Fitzgerald PB, McQueen S, Daskalakis ZJ, Hoy KE (2014) A Negative Pilot Study of Daily Bimodal Transcranial Direct Current Stimulation in Schizophrenia. Brain Stimul 7:813–816.

Fleming MK, Rothwell JC, Sztriha L, Teo JT, Newham DJ (2017) The effect of transcranial direct current stimulation on motor sequence learning and upper limb function after stroke. Clin Neurophysiol 128:1389–1398.

Flöel A, Meinzer M, Kirstein R, Nijhof S, Deppe M, Knecht S, Breitenstein C (2011) Short-term anomia training and electrical brain stimulation. Stroke 42:2065–2067.

Földiák P (1990) Forming sparse representations by local anti-Hebbian learning. Biol Cybern 64:165–170.

Franzén-Dahlin A, Karlsson MR, Mejhert M, Laska A-C (2010) Quality of life in chronic disease: a comparison between patients with heart failure and patients with aphasia after stroke. J Clin Nurs 19:1855–1860.

Fregni F, Boggio PS, Lima MC, Ferreira MJL, Wagner T, Rigonatti SP, Castro AW, Souza DR, Riberto M, Freedman SD, Nitsche MA, Pascual-Leone A (2006a) A sham-controlled, phase II trial of transcranial direct current stimulation for the treatment of central pain in traumatic spinal cord injury. Pain 122:197–209.

Fregni F, Boggio PS, Nitsche MA, Marcolin MA, Rigonatti SP, Pascual-Leone A (2006b) Treatment of major depression with transcranial direct current stimulation. Bipolar Disord 8:203–204.

Fregni F, Boggio PS, Nitsche MA, Rigonatti SP, Pascual-Leone A (2006c) Cognitive effects of repeated sessions of transcranial direct current stimulation in patients with depression. Depress Anxiety 23:482–484.

Fregni F, Boggio PS, Santos MC, Lima M, Vieira AL, Rigonatti SP, Silva MTA, Barbosa ER, Nitsche MA, Pascual-Leone A (2006d) Noninvasive cortical stimulation with transcranial direct current stimulation in Parkinson's disease. Mov Disord 21:1693–1702.

Fregni F, Gimenes R, Valle AC, Ferreira MJL, Rocha RR, Natalle L, Bravo R, Rigonatti SP, Freedman SD, Nitsche MA, Pascual-Leone A, Boggio PS (2006e) A randomized, sham-controlled, proof of principle study of transcranial direct current stimulation for the treatment of pain in fibromyalgia. Arthritis Rheum 54:3988–3998.

Fregni F, Thome-Souza S, Nitsche MA, Freedman SD, Valente KD, Pascual-Leone A (2006f) A controlled clinical trial of cathodal DC polarization in patients with refractory epilepsy. Epilepsia 47:335–342.

Fregni F et al. (2015) Regulatory Considerations for the Clinical and Research Use of Transcranial Direct Current Stimulation (tDCS): review and recommendations from an

expert panel. Clin Res Regul Aff 32:22–35.

Fridriksson J, Rorden C, Elm J, Sen S, George MS, Bonilha L (2018) Transcranial Direct Current Stimulation vs Sham Stimulation to Treat Aphasia after Stroke: A Randomized Clinical Trial. JAMA Neurol 75:1470–1476.

Fu CHY, Steiner H, Costafreda SG (2013) Predictive neural biomarkers of clinical response in depression: a meta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies. Neurobiol Dis 52:75–83.

Fusco A, Assenza F, Iosa M, Izzo S, Altavilla R, Paolucci S, Vernieri F (2014) The Ineffective Role of Cathodal tDCS in Enhancing the Functional Motor Outcomes in Early Phase of Stroke Rehabilitation: An Experimental Trial. Biomed Res Int 2014:1–9.

Gagnier JJ, Moher D, Boon H, Beyene J, Bombardier C (2012), Investigating clinical heterogeneity in systematic reviews: a methodologic review of guidance in the literature. BMC medical research methodology 12:111.

Gelb DJ, Oliver E, Gilman S (1999) Diagnostic Criteria for Parkinson Disease. Arch Neurol 56:33.

Giacobbe V, Krebs HI, Volpe BT, Pascual-Leone A, Rykman A, Zeiarati G, Fregni F, Dipietro L, Thickbroom GW, Edwards DJ (2013) Transcranial direct current stimulation (tDCS) and robotic practice in chronic stroke: the dimension of timing. NeuroRehabilitation 33:49–56.

Glaser J, Reeves ST, Stoll WD, Epperson TI, Hilbert M, Madan A, George MS, Borckardt JJ (2016) Motor/prefrontal transcranial direct current stimulation (tDCS) following lumbar surgery reduces postoperative analgesia use. Spine (Phila Pa 1976) 41:835–839.

Goh ET, Morgan MY (2017) Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore. Aliment Pharmacol Ther 45:865–882.

Gonçalves ÓF, Carvalho S, Leite J, Pocinho F, Relvas J, Fregni F (2011) Obsessive

Compulsive Disorder as a functional interhemispheric imbalance at the thalamic level. Med Hypotheses 77:445–447.

Gonçalves ÓF, Sousa S, Maia L, Carvalho S, Leite J, Ganho A, Fernandes-Gonçalves A, Frank B, Pocinho F, Carracedo A, Sampaio A (2015) Inferior frontal gyrus white matter abnormalities in obsessive-compulsive disorder. Neuroreport 26:495–500.

Goodwill AM, Lum JAG, Hendy AM, Muthalib M, Johnson L, Albein-Urios N, Teo W-P (2017), Using non-invasive transcranial stimulation to improve motor and cognitive function in Parkinson's disease: a systematic review and meta-analysis. Scientific reports 7:1-11.

Gowda SM, Narayanaswamy JC, Hazari N, Bose A, Chhabra H, Balachander S, Bhaskarapillai B, Shivakumar V, Venkatasubramanian G, Reddy YCJ (2019) Efficacy of pre-supplementary motor area transcranial direct current stimulation for treatment resistant obsessive compulsive disorder: A randomized, double blinded, sham controlled trial. Brain Stimul 12:922–929.

Groves DA, Brown VJ (2005) Vagal nerve stimulation: a review of its applications and potential mechanisms that mediate its clinical effects. Neurosci Biobehav Rev 29:493–500.

Gruber D, Calmbach L, Kühn AA, Krause P, Kopp UA, Schneider G-H, Kupsch A (2019) Longterm outcome of cognition, affective state, and quality of life following subthalamic deep brain stimulation in Parkinson's disease. J Neural Transm 126:309–318.

Härtel-Petri R, Krampe-Scheidler A, Braunwarth W-D, Havemann-Reinecke U, Jeschke P, Looser W, Mühlig S, Schäfer I, Scherbaum N, Bothe L, Schaefer C, Hamdorf W (2017) Evidence-Based Guidelines for the Pharmacologic Management of Methamphetamine Dependence, Relapse Prevention, Chronic Methamphetamine-Related, and Comorbid Psychiatric Disorders in Post-Acute Settings. Pharmacopsychiatry 50:96–104.

Hatsukami DK, Fischman MW (1996) Crack cocaine and cocaine hydrochloride. Are the differences myth or reality? JAMA 276:1580–1588.

Healey A, Knapp M, Astin J, Gossop M, Marsden J, Stewart D, Lehmann P, Godfrey C (1998) Economic burden of drug dependency. Social costs incurred by drug users at intake to the National Treatment Outcome Research Study. Br J Psychiatry 173:160–165.

Hedden SL, Kennet J, Lipari R, Medley G, Tice P, P Copello EA, Kroutil LA (2016) Key Substance Use and Mental Health Indicators in the United States: Results from the 2015 National Survey on Drug Use and Health.

Hillis AE, Gold L, Kannan V, Cloutman L, Kleinman JT, Newhart M, Heidler-Gary J, Davis C, Aldrich E, Llinas R, Gottesman RF (2008) Site of the ischemic penumbra as a predictor of potential for recovery of functions. Neurology 71:184–189.

Hormes JM, Coffey SF, Drobes DJ, Saladin ME (2012) The Obsessive Compulsive Cocaine Use Scale: development and initial validation of a self-rated instrument for the quantification of thoughts about cocaine use. Drug Alcohol Depend 120:250–254.

Horvath JC, Najib U, Press D (2014) Transcranial Magnetic Stimulation (TMS) Clinical Applications: Therapeutics.

Hsu T-Y, Tseng L-Y, Yu J-X, Kuo W-J, Hung DL, Tzeng OJL, Walsh V, Muggleton NG, Juan C-H (2011) Modulating inhibitory control with direct current stimulation of the superior medial frontal cortex. Neuroimage 56:2249–2257.

Iruzubieta P, Crespo J, Fábrega E (2013) Long-term survival after liver transplantation for alcoholic liver disease. World J Gastroenterol 19:9198.

Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12.

Jardri R, Pouchet A, Pins D, Thomas P (2011) Cortical activations during auditory verbal

hallucinations in schizophrenia: a coordinate-based meta-analysis. Am J Psychiatry 168:73–81.

Jensen MP, Sherlin LH, Askew RL, Fregni F, Witkop G, Gianas A, Howe JD, Hakimian S (2013) Effects of non-pharmacological pain treatments on brain states. Clin Neurophysiol 124:2016–2024.

Jeon DW, Jung DU, Kim SJ, Shim JC, Moon JJ, Seo YS, Jung SS, Seo BJ, Kim JE, Oh M, Kim YN (2018) Adjunct transcranial direct current stimulation improves cognitive function in patients with schizophrenia: A double-blind 12-week study. Schizophr Res 197:378–385.

Kalu UG, Sexton CE, Loo CK, Ebmeier KP (2012) Transcranial direct current stimulation in the treatment of major depression: a meta-analysis. Psychol Med 42:1791–1800.

Kang N, Da Lee R, Lee JH, Hwang MH (2019), Functional Balance and Postural Control Improvements in Patients with Stroke after Non-Invasive Brain Stimulation: A Meta-Analysis. Archives of Physical Medicine and Rehabilitation.

Kang N, Summers JJ, Cauraugh JH (2016), Non-invasive brain stimulation improves paretic limb force production: a systematic review and meta-analysis. Brain stimulation 9:662-670.

Kantrowitz JT, Sehatpour P, Avissar M, Horga G, Gwak A, Hoptman MJ, Beggel O, Girgis RR, Vail B, Silipo G, Carlson M, Javitt DC (2019) Significant improvement in treatment resistant auditory verbal hallucinations after 5 days of double-blind, randomized, sham controlled, fronto-temporal, transcranial direct current stimulation (tDCS): A replication/extension study. Brain Stimul 12:981–991.

Karvigh SA, Motamedi M, Arzani M, Roshan JHN (2017) HD-tDCS in refractory lateral frontal lobe epilepsy patients. Seizure 47:74–80.

Kaski D, Allum JH, Bronstein AM, Dominguez RO (2014) Applying anodal tDCS during

tango dancing in a patient with Parkinson's disease. Neurosci Lett 568:39–43.

Kehagia AA, Barker RA, Robbins TW (2010) Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 9:1200–1213.

Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC (2014) The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol 29:63–76.

Keser Z, Dehgan MW, Shadravan S, Yozbatiran N, Maher LM, Francisco GE (2017) Combined Dextroamphetamine and Transcranial Direct Current Stimulation in Poststroke Aphasia. Am J Phys Med Rehabil 96:S141–S145.

Khedr EM, Omran EAH, Ismail NM, El-Hammady DH, Goma SH, Kotb H, Galal H, Osman AM, Farghaly HSM, Karim AA, Ahmed GA (2017a) Effects of transcranial direct current stimulation on pain, mood and serum endorphin level in the treatment of fibromyalgia: A double blinded, randomized clinical trial. Brain Stimul 10:893–901.

Khedr EM, Sharkawy ESA, Attia AMA, Ibrahim Osman NM, Sayed ZM (2017b) Role of transcranial direct current stimulation on reduction of postsurgical opioid consumption and pain in total knee arthroplasty: Double randomized clinical trial. Eur J Pain (United Kingdom) 21:1355–1365.

Kim YW, Shin I-S, Im Moon H, Lee SC, Yoon SY (2019), Effects of non-invasive brain stimulation on freezing of gait in parkinsonism: a systematic review with meta-analysis. Parkinsonism & related disorders 64:82-89.

Kim J, Iwata Y, Plitman E, Caravaggio F, Chung JK, Shah P, Blumberger DM, Pollock BG, et al. (2019), A meta-analysis of transcranial direct current stimulation for schizophrenia:"Is more better?". Journal of psychiatric research 110:117-126.

Kiran S (2012) What is the nature of poststroke language recovery and reorganization? ISRN

Neurol 2012:786872.

Klauss J, Penido Pinheiro LC, Silva Merlo BL, de Almeida Correia Santos G, Fregni F, Nitsche MA, Miyuki Nakamura-Palacios E (2014) A randomized controlled trial of targeted prefrontal cortex modulation with tDCS in patients with alcohol dependence. Int J Neuropsychopharmacol 17:1793–1803.

Klauss J, Anders QS, Felippe LV, Buback Ferreira LV, Cruz MA, Nitsche MA, Nakamura-Palacios EM (2018a) Lack of effects of extended sessions of transcranial direct current stimulation (tDCS) over dorsolateral prefrontal cortex on craving and relapses in crack-cocaine users. Front Pharmacol 9:1–11.

Klauss J, Anders QS, Felippe L V., Nitsche MA, Nakamura-Palacios EM (2018b) Multiple sessions of transcranial direct current stimulation (tDCS) reduced craving and relapses for alcohol use: A randomized placebo-controlled trial in alcohol use disorder. Front Pharmacol 9:1–11.

Koob GF, Volkow ND (2016) Neurobiology of addiction: a neurocircuitry analysis. The lancet Psychiatry 3:760–773.

Kreisler A, Godefroy O, Delmaire C, Debachy B, Leclercq M, Pruvo JP, Leys D (2000) The anatomy of aphasia revisited. Neurology 54:1117–1123.

Kubera KM, Barth A, Hirjak D, Thomann PA, Wolf RC (2015) Noninvasive brain stimulation for the treatment of auditory verbal hallucinations in schizophrenia: methods, effects and challenges. Front Syst Neurosci 9:131.

Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Hauser WA, Mathern G, Mosh?? SL, Perucca E, Wiebe S, French J (2010) Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51:1069–1077.

Kwon HJ, Lim WS, Lim MH, Lee SJ, Hyun JK, Chae J-H, Paik KC (2011) 1-Hz low frequency

repetitive transcranial magnetic stimulation in children with Tourette's syndrome. Neurosci Lett 492:1–4.

Kwon YH, Ko M-H, Ahn SH, Kim Y-H, Song JC, Lee C-H, Chang MC, Jang SH (2008) Primary motor cortex activation by transcranial direct current stimulation in the human brain. Neurosci Lett 435:56–59.

Lang N, Siebner HR, Ward NS, Lee L, Nitsche MA, Paulus W, Rothwell JC, Lemon RN, Frackowiak RS (2005) How does transcranial DC stimulation of the primary motor cortex alter regional neuronal activity in the human brain? Eur J Neurosci 22:495–504.

Lattari E, Costa SS, Campos C, de Oliveira AJ, Machado S, Maranhao Neto GA (2017) Can transcranial direct current stimulation on the dorsolateral prefrontal cortex improves balance and functional mobility in Parkinson's disease? Neurosci Lett 636:165–169.

Lazar RM, Minzer B, Antoniello D, Festa JR, Krakauer JW, Marshall RS (2010) Improvement in aphasia scores after stroke is well predicted by initial severity. Stroke 41:1485–1488.

Lee HK, Ahn SJ, Shin YM, Kang N, Cauraugh JH (2019), Does transcranial direct current stimulation improve functional locomotion in people with Parkinson's disease? A systematic review and meta-analysis. Journal of neuroengineering and rehabilitation 16:84.

Lefaucheur J-P et al. (2014a) Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol 125:2150–2206.

Lefaucheur J-P et al. (2014b) Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol 125:2150–2206.

Lefaucheur J-P et al. (2017) Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS). Clin Neurophysiol 128:56–92.

Lewis GN, Rice DA, Kluger M, McNair PJ (2018) Transcranial direct current stimulation for upper limb neuropathic pain: A double-blind randomized controlled trial. Eur J Pain

22:1312–1320.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700–b2700.

Lin J-H, Hsu M-J, Sheu C-F, Wu T-S, Lin R-T, Chen C-H, Hsieh C-L (2009) Psychometric comparisons of 4 measures for assessing upper-extremity function in people with stroke. Phys Ther 89:840–850.

Lindenberg R, Renga V, Zhu LL, Nair D, Schlaug G (2010) Bihemispheric brain stimulation facilitates motor recovery in chronic stroke patients. Neurology 75:2176–2184.

Lindenberg R, Zhu LL, Schlaug G (2012) Combined central and peripheral stimulation to facilitate motor recovery after stroke: the effect of number of sessions on outcome. Neurorehabil Neural Repair 26:479–483.

Lindenmayer JP, Kulsa MKC, Sultana T, Kaur A, Yang R, Ljuri I, Parker B, Khan A (2019) Transcranial direct-current stimulation in ultra-treatment-resistant schizophrenia. Brain Stimul 12:54–61.

Liu A, Bryant A, Jefferson A, Friedman D, Minhas P, Barnard S, Barr W, Thesen T, O'Connor M, Shafi M, Herman S, Devinsky O, Pascual-Leone A, Schachter S (2016) Exploring the efficacy of a 5-day course of transcranial direct current stimulation (TDCS) on depression and memory function in patients with well-controlled temporal lobe epilepsy. Epilepsy Behav 55:11–20.

Lloyd DM, Wittkopf PG, Arendsen LJ, Jones AKP (2020), Is transcranial direct current stimulation (tDCS) effective for the treatment of pain in fibromyalgia? A systematic review and meta-analysis. The Journal of Pain (In press).

Loo CK, Sachdev P, Martin D, Pigot M, Alonzo A, Malhi GS, Lagopoulos J, Mitchell P (2010)

A double-blind, sham-controlled trial of transcranial direct current stimulation for the treatment of depression. Int J Neuropsychopharmacol 13:61.

Loo CK, Alonzo A, Martin D, Mitchell PB, Galvez V, Sachdev P (2012) Transcranial direct current stimulation for depression: 3-week, randomised, sham-controlled trial. Br J Psychiatry 200:52–59.

Loo CK et al. (2018) International randomized-controlled trial of transcranial Direct Current Stimulation in depression. Brain Stimul 11:125–133.

Löscher W, Cole AJ, McLean MJ (2009) Commentary: physical approaches for the treatment of epilepsy: electrical and magnetic stimulation and cooling. Neurotherapeutics 6:258–262.

Lu C, Amundsen Huffmaster SL, Tuite PJ, MacKinnon CD (2018) The effects of anodal tDCS over the supplementary motor area on gait initiation in Parkinson's disease with freezing of gait: a pilot study. J Neurol 265:2023–2032.

Luedtke K, May A, Jürgens TP (2012) No Effect of a Single Session of Transcranial Direct Current Stimulation on Experimentally Induced Pain in Patients with Chronic Low Back Pain – An Exploratory Study Eldabe S, ed. PLoS One 7:e48857.

Luedtke K, Rushton A, Wright C, Jürgens T, Polzer A, Mueller G, May A (2015) Effectiveness of transcranial direct current stimulation preceding cognitive behavioural management for chronic low back pain: Sham controlled double blinded randomised controlled trial. BMJ 350:h1640–h1640.

M. El-Hagrassy M, Jones F, Rosa G, Fregni F (2018) CNS Non-invasive Brain Stimulation (Gilleran JP AS, ed)., Adult and. Springer International Publishing AG, part of Springer Nature 2018.

Madhavan S, Weber KA, Stinear JW (2011) Non-invasive brain stimulation enhances fine motor control of the hemiparetic ankle: Implications for rehabilitation. Exp Brain Res

209:9–17.

Malinow R, Malenka RC (2002) AMPA R ECEPTOR T RAFFICKING AND S YNAPTIC P LASTICITY. Annu Rev Neurosci 25:103–126.

Maller JJ, Thomson RHS, Rosenfeld J V., Anderson R, Daskalakis ZJ, Fitzgerald PB (2014) Occipital bending in depression. Brain 137:1830–1837.

Maltby N, Tolin DF, Worhunsky P, O'Keefe TM, Kiehl KA (2005) Dysfunctional action monitoring hyperactivates frontal-striatal circuits in obsessive-compulsive disorder: an event-related fMRI study. Neuroimage 24:495–503.

Manenti R, Brambilla M, Benussi A, Rosini S, Cobelli C, Ferrari C, Petesi M, Orizio I, Padovani A, Borroni B, Cotelli M (2016) Mild cognitive impairment in Parkinson's disease is improved by transcranial direct current stimulation combined with physical therapy. Mov Disord 31:715–724.

Manenti R, Cotelli MS, Cobelli C, Gobbi E, Brambilla M, Rusich D, Alberici A, Padovani A, Borroni B, Cotelli M (2018) Transcranial direct current stimulation combined with cognitive training for the treatment of Parkinson Disease: A randomized, placebo-controlled study. Brain Stimul 11:1251–1262.

Mantovani A, Lisanby SH, Pieraccini F, Ulivelli M, Castrogiovanni P, Rossi S (2006) Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette's syndrome (TS). Int J Neuropsychopharmacol 9:95–100.

Marangolo P, Fiori V, Calpagnano MA, Campana S, Razzano C, Caltagirone C, Marini A (2013a) tDCS over the left inferior frontal cortex improves speech production in aphasia. Front Hum Neurosci 7:1–10.

Marangolo P, Fiori V, Di Paola M, Cipollari S, Razzano C, Oliveri M, Caltagirone C (2013b) Differential involvement of the left frontal and temporal regions in verb naming: A tDCS

treatment study. Restor Neurol Neurosci 31:63–72.

Marangolo P, Fiori V, Campana S, Antonietta Calpagnano M, Razzano C, Caltagirone C, Marini A (2014) Something to talk about: Enhancement of linguistic cohesion through tdCS in chronic non fluent aphasia. Neuropsychologia 53:246–256.

Mariano TY, Burgess FW, Bowker M, Kirschner J, van't Wout-Frank M, Jones RN, Halladay CW, Stein M, Greenberg BD (2019) Transcranial Direct Current Stimulation for Affective Symptoms and Functioning in Chronic Low Back Pain: A Pilot Double-Blinded, Randomized, Placebo-Controlled Trial. Pain Med 20:1166–1177.

Marquez J, van Vliet P, McElduff P, Lagopoulos J, Parsons M (2015) Transcranial Direct Current Stimulation (tDCS): Does it Have Merit in Stroke Rehabilitation? A Systematic Review. Int J Stroke 10:306–316.

Marshall L, Mölle M, Hallschmid M, Born J (2004) Transcranial direct current stimulation during sleep improves declarative memory. J Neurosci 24:9985–9992.

Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, Jerabek PA (2000) Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 48:830–843.

Mayur P, Howari R, Byth K, Vannitamby R (2018) Concomitant Transcranial Direct Current Stimulation with Ultrabrief Electroconvulsive Therapy: A 2-Week Double-Blind Randomized Sham-Controlled Trial. J ECT 34:291–295.

Mazzoleni S, Tran V Do, Iardella L, Dario P, Posteraro F (2017) Randomized, sham-controlled trial based on transcranial direct current stimulation and wrist robot-assisted integrated treatment on subacute stroke patients: Intermediate results. In: 2017 International Conference on Rehabilitation Robotics (ICORR), pp 555–560. IEEE.

McGirr A, Berlim MT (2018), Clinical usefulness of therapeutic neuromodulation for major depression: a systematic meta-review of recent meta-analyses. Psychiatric Clinics 41:485-503.

McKay JR, Foltz C, Stephens RC, Leahy PJ, Crowley EM, Kissin W (2005) Predictors of alcohol and crack cocaine use outcomes over a 3-year follow-up in treatment seekers. J Subst Abuse Treat 28 Suppl 1:S73-82.

Meinzer M, Darkow R, Lindenberg R, Floel A (2016) Electrical stimulation of the motor cortex enhances treatment outcome in post-stroke aphasia. Brain 139:1152–1163.

Mendonca ME, Santana MB, Baptista AF, Datta A, Bikson M, Fregni F, Araujo CP (2011) Transcranial DC stimulation in fibromyalgia: optimized cortical target supported by high-resolution computational models. J Pain 12:610–617.

Mendonca ME, Simis M, Grecco LC, Battistella LR, Baptista AF, Fregni F (2016) Transcranial Direct Current Stimulation Combined with Aerobic Exercise to Optimize Analgesic Responses in Fibromyalgia: A Randomized Placebo-Controlled Clinical Trial. Front Hum Neurosci 10:68.

Miller PM, Book SW, Stewart SH (2011) Medical Treatment of Alcohol Dependence: A Systematic Review. Int J Psychiatry Med 42:227–266.

Moffa AH, Martin D, Alonzo A, Bennabi D, Blumberger DM, Benseñor IM, Daskalakis Z, Fregni F, et al. (2019), Efficacy and acceptability of transcranial direct current stimulation (tDCS) for major depressive disorder: An individual patient data meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry:109836.

Molina Rodríguez V, Montz Andrée R, Pérez Castejón MJ, Gutiérrez Labrador R, Ferre Navarrete F, Carreas Delgado JL, Rubia Vila FJ (1997) Cerebral perfusion correlates of negative symptomatology and parkinsonism in a sample of treatment-refractory schizophrenics: an exploratory 99mTc-HMPAO SPET study. Schizophr Res 25:11–20.

Mondino M, Brunelin J, Palm U, Brunoni AR, Poulet E, Fecteau S (2015a) Transcranial Direct Current Stimulation for the Treatment of Refractory Symptoms of Schizophrenia. Current Evidence and Future Directions. Curr Pharm Des 21:3373–3383.

Mondino M, Haesebaert F, Poulet E, Saoud M, Brunelin J (2015b) Efficacy of Cathodal Transcranial Direct Current Stimulation Over the Left Orbitofrontal Cortex in a Patient With Treatment-Resistant Obsessive-Compulsive Disorder. J ECT 31:271–272.

Mondino M, Poulet E, Suaud-Chagny M-F, Brunelin J (2016) Anodal tDCS targeting the left temporo-parietal junction disrupts verbal reality-monitoring. Neuropsychologia 89:478–484.

Monte-Silva K, Kuo M-F, Liebetanz D, Paulus W, Nitsche MA (2010) Shaping the optimal repetition interval for cathodal transcranial direct current stimulation (tDCS). J Neurophysiol 103:1735–1740.

Monte-Silva K, Kuo M-F, Hessenthaler S, Fresnoza S, Liebetanz D, Paulus W, Nitsche MA (2013) Induction of late LTP-like plasticity in the human motor cortex by repeated non-invasive brain stimulation. Brain Stimul 6:424–432.

Monti A, Cogiamanian F, Marceglia S, Ferrucci R, Mameli F, Mrakic-Sposta S, Vergari M, Zago S, Priori A (2008) Improved naming after transcranial direct current stimulation in aphasia. J Neurol Neurosurg Psychiatry 79:451–453.

Moreno-Duarte I, Morse LR, Alam M, Bikson M, Zafonte R, Fregni F (2014) Targeted therapies using electrical and magnetic neural stimulation for the treatment of chronic pain in spinal cord injury. Neuroimage 85:1003–1013.

Mortensen J, Figlewski K, Andersen H (2016) Combined transcranial direct current stimulation and home-based occupational therapy for upper limb motor impairment following intracerebral hemorrhage: a double-blind randomized controlled trial. Disabil Rehabil 38:637–643.

Moselhy HF, Georgiou G, Kahn A (2001) Frontal lobe changes in alcoholism: a review of the literature. Alcohol Alcohol 36:357–368.

Moura HF, Benzano D, Pechansky F, Kessler FHP (2014) Crack/cocaine users show more family problems than other substance users. Clinics (Sao Paulo) 69:497–499.

Mrakic-Sposta S, Marceglia S, Mameli F, Dilena R, Tadini L, Priori A (2008) Transcranial direct current stimulation in two patients with Tourette syndrome. Mov Disord 23:2259–2261.

Murray CJ, Lopez AD (1997) Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349:1436–1442.

Mutz J, Vipulananthan V, Carter B, Hurlemann R, Fu CHY, Young AH (2019), Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis. bmj 364:l1079.

Nachev P, Kennard C, Husain M (2008) Functional role of the supplementary and pre-supplementary motor areas. Nat Rev Neurosci 9:856–869.

Naeser MA, Helm-Estabrooks N, Haas G, Auerbach S, Srinivasan M (1987) Relationship between lesion extent in "Wernicke's area" on computed tomographic scan and predicting recovery of comprehension in Wernicke's aphasia. Arch Neurol 44:73–82.

Narayanaswamy JC, Jose D, Chhabra H, Agarwal SM, Shrinivasa B, Hegde A, Bose A, Kalmady S V, Venkatasubramanian G, Reddy YCJ (2015) Successful Application of Add-on Transcranial Direct Current Stimulation (tDCS) for Treatment of SSRI Resistant OCD. Brain Stimul 8:655–657.

Naro A, Milardi D, Russo M, Terranova C, Rizzo V, Cacciola A, Marino S, Calabro RS, Quartarone A (2016) Non-invasive Brain Stimulation, a Tool to Revert Maladaptive Plasticity in Neuropathic Pain. Front Hum Neurosci 10:376.

Navarro HJ, Doran CM, Shakeshaft AP (2011) Measuring costs of alcohol harm to others: a review of the literature. Drug Alcohol Depend 114:87–99.

Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR (2010) Estimation of the burden of active and life-time epilepsy: A meta-analytic approach. Epilepsia 51:883–890.

Niethammer M, Eidelberg D (2012) Metabolic brain networks in translational neurology: concepts and applications. Ann Neurol 72:635–647.

Nitsche MA, Paulus W (2001) Sustained excitability elevations induced by transcranial DC motor cortex stimulation in humans. Neurology 57:1899–1901.

Nitsche MA, Fricke K, Henschke U, Schlitterlau A, Liebetanz D, Lang N, Henning S, Tergau F, Paulus W (2003) Pharmacological modulation of cortical excitability shifts induced by transcranial direct current stimulation in humans. J Physiol 553:293–301.

Nord CL, Chamith Halahakoon D, Limbachya T, Charpentier C, Lally N, Walsh V, Leibowitz J, Pilling S, Roiser JP (2019) Neural predictors of treatment response to brain stimulation and psychological therapy in depression: a double-blind randomized controlled trial. Neuropsychopharmacology.

O'Brien AT, Bertolucci F, Torrealba- Acosta G, Huerta R, Fregni F, Thibaut A (2018), Non-invasive brain stimulation for fine motor improvement after stroke: a meta- analysis. European journal of neurology 25:1017-1026.

O'Connell NE, Wand BM, Marston L, Spencer S, Desouza LH (2014) Non-invasive brain stimulation techniques for chronic pain. Cochrane database Syst Rev:CD008208.

O'Connell NE, Marston L, Spencer S, DeSouza LH, Wand BM (2018) Non-invasive brain stimulation techniques for chronic pain. Cochrane Database Syst Rev.

O'Neill F, Sacco P, Bowden E, Asher R, Burnside G, Cox T, Nurmikko T (2018) Patient-delivered tDCS on chronic neuropathic pain in prior responders to TMS (A randomized controlled pilot study). J Pain Res 11:3117–3128.

Ovbiagele B, Nguyen-Huynh MN (2011) Stroke epidemiology: advancing our understanding of disease mechanism and therapy. Neurotherapeutics 8:319–329.

Palm U, Schiller C, Fintescu Z, Obermeier M, Keeser D, Reisinger E, Pogarell O, Nitsche MA, Möller H-J, Padberg F (2012) Transcranial direct current stimulation in treatment resistant depression: A randomized double-blind, placebo-controlled study. Brain Stimul 5:242–251.

Palm U, Keeser D, Hasan A, Kupka MJ, Blautzik J, Sarubin N, Kaymakanova F, Unger I, Falkai P, Meindl T, Ertl-Wagner B, Padberg F (2016) Prefrontal Transcranial Direct Current Stimulation for Treatment of Schizophrenia With Predominant Negative Symptoms: A Double-Blind, Sham-Controlled Proof-of-Concept Study. Schizophr Bull 42:1253–1261.

Palm U, Kirsch B, Leitner B, Popovic D, Padberg F (2017a) P017 Transcranial direct current stimulation (tDCS) for the treatment of depression during pregnancy: A pilot study. Clin Neurophysiol 128:e17–e18.

Palm U, Leitner B, Kirsch B, Behler N, Kumpf U, Wulf L, Padberg F, Hasan A (2017b) Prefrontal tDCS and sertraline in obsessive compulsive disorder: a case report and review of the literature. Neurocase 23:173–177.

Pestalozzi MI, Di Pietro M, Martins Gaytanidis C, Spierer L, Schnider A, Chouiter L, Colombo F, Annoni JM, Jost LB (2018) Effects of Prefrontal Transcranial Direct Current Stimulation on Lexical Access in Chronic Poststroke Aphasia. Neurorehabil Neural Repair 32:913–923.

Poreisz C, Boros K, Antal A, Paulus W (2007) Safety aspects of transcranial direct current stimulation concerning healthy subjects and patients. Brain Res Bull 72:208–214.

Pringsheim T, Jette N, Frolkis A, Steeves TDL (2014) The prevalence of Parkinson's disease: A systematic review and meta-analysis. Mov Disord 29:1583–1590.

Pulvermüller F (2018) Neural reuse of action perception circuits for language, concepts and communication. Prog Neurobiol 160:1–44.

Ray Chaudhuri K, Poewe W, Brooks D (2018) Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features. Mov Disord 33:909–919.

Ribeiro H, Sesterhenn RB, Souza A de, Souza AC de, Alves M, Machado JC, Burger NB, Torres IL da S, Stefani LC, Fregni F, Caumo W (2017) Preoperative transcranial direct current stimulation: Exploration of a novel strategy to enhance neuroplasticity before surgery to control postoperative pain. A randomized sham-controlled study. PLoS One 12:e0187013.

Riberto M (2011) Efficacy of Transcranial Direct Current Stimulation Coupled with a Multidisciplinary Rehabilitation Program for the Treatment of Fibromyalgia. Open Rheumatol J 5:45–50.

Rioult-Pedotti MS, Friedman D, Hess G, Donoghue JP (1998) Strengthening of horizontal cortical connections following skill learning. Nat Neurosci 1:230–234.

Rioult-Pedotti MS, Friedman D, Donoghue JP (2000) Learning-induced LTP in neocortex. Science 290:533–536.

Robinson TE, Berridge KC (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 18:247–291.

Rohde A, Worrall L, Le Dorze G (2013) Systematic review of the quality of clinical guidelines for aphasia in stroke management. J Eval Clin Pract 19:994–1003.

Rosso C, Perlbarg V, Valabregue R, Arbizu C, Ferrieux S, Alshawan B, Vargas P, Leger A, Zavanone C, Corvol JC, Meunier S, Lehéricy S, Samson Y (2014) Broca's area damage is necessary but not sufficient to induce after-effects of cathodal tDCS on the unaffected hemisphere in post-stroke aphasia. Brain Stimul 7:627–635.

Rosso C, Arbizu C, Dhennain C, Lamy J-C, Samson Y (2018), Repetitive sessions of tDCS to improve naming in post-stroke aphasia: Insights from an individual patient data (IPD) meta-analysis. Restorative neurology and neuroscience 36:107-116.

Rush AJ, Kraemer HC, Sackeim HA, Fava M, Trivedi MH, Frank E, Ninan PT, Thase ME, Gelenberg AJ, Kupfer DJ, Regier DA, Rosenbaum JF, Ray O, Schatzberg AF, ACNP Task Force (2006) Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder. Neuropsychopharmacology 31:1841–1853.

Saba G, Moukheiber A, Pelissolo A (2015) Transcranial Cortical Stimulation in the Treatment of Obsessive-Compulsive Disorders: Efficacy Studies. Curr Psychiatry Rep 17:36.

Sacher J, Neumann J, Fünfstück T, Soliman A, Villringer A, Schroeter ML (2012) Mapping the depressed brain: a meta-analysis of structural and functional alterations in major depressive disorder. J Affect Disord 140:142–148.

Sakrajai P, Janyacharoen T, Jensen MP, Sawanyawisuth K, Auvichayapat N, Tunkamnerdthai O, Keeratitanont K, Auvichayapat P (2014) Pain reduction in myofascial pain syndrome by anodal transcranial direct current stimulation combined with standard treatment a randomized controlled study. Clin J Pain 30:1076–1083.

Salanova V et al. (2015) Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy. Neurology 84:1017–1025.

Salazar A, de Sola H, Failde I, Moral-Munoz JA (2018) Measuring the Quality of Mobile Apps for the Management of Pain: Systematic Search and Evaluation Using the Mobile App Rating Scale. JMIR mHealth uHealth 6:e10718.

Salehinejad MA, Ghanavai E, Rostami R, Nejati V (2017) Cognitive control dysfunction in emotion dysregulation and psychopathology of major depression (MD): Evidence from transcranial brain stimulation of the dorsolateral prefrontal cortex (DLPFC). J Affect Disord 210:241–248.

Salomon JA et al. (2012) Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet (London, England) 380:2129–2143.

Sämann PG, Höhn D, Chechko N, Kloiber S, Lucae S, Ising M, Holsboer F, Czisch M (2013) Prediction of antidepressant treatment response from gray matter volume across diagnostic categories. Eur Neuropsychopharmacol 23:1503–1515.

San-Juan D, Morales-Quezada L, Orozco Garduño AJ, Alonso-Vanegas M, González-Aragón MF, Espinoza López DA, Vázquez Gregorio R, Anschel DJ, Fregni F (2015) Transcranial Direct Current Stimulation in Epilepsy. Brain Stimul 8:455–464.

San-Juan D, Espinoza López DA, Vázquez Gregorio R, Trenado C, Fernández-González Aragón M, Morales-Quezada L, Hernandez Ruiz A, Hernandez-González F, Alcaraz-Guzmán A, Anschel DJ, Fregni F (2017) Transcranial Direct Current Stimulation in Mesial Temporal Lobe Epilepsy and Hippocampal Sclerosis. Brain Stimul 10:28–35.

Sanfilipo M, Lafargue T, Rusinek H, Arena L, Loneragan C, Lautin A, Feiner D, Rotrosen J, Wolkin A (2000) Volumetric measure of the frontal and temporal lobe regions in schizophrenia: relationship to negative symptoms. Arch Gen Psychiatry 57:471–480.

Santangelo G, Vitale C, Picillo M, Moccia M, Cuoco S, Longo K, Pezzella D, di Grazia A, Erro R, Pellecchia MT, Amboni M, Trojano L, Barone P (2015) Mild Cognitive Impairment in newly diagnosed Parkinson's disease: A longitudinal prospective study. Parkinsonism Relat Disord 21:1219–1226.

Santisteban L, Térémetz M, Bleton J-P, Baron J-C, Maier MA, Lindberg PG (2016) Upper Limb Outcome Measures Used in Stroke Rehabilitation Studies: A Systematic Literature Review. PLoS One 11:e0154792.

Schabrun SM, Lamont RM, Brauer SG (2016) Transcranial Direct Current Stimulation to Enhance Dual-Task Gait Training in Parkinson's Disease: A Pilot RCT. Triche EW, ed.

PLoS One 11:e0158497.

Schambra HM, Bikson M, Wager TD, DosSantos MF, DaSilva AF (2014) It's All in Your Head: Reinforcing the Placebo Response With tDCS. Brain Stimul 7:623–624.

Schepers V, Ketelaar M, Visser-Meily A, Groot V, Twisk J, Lindeman E (2008) Functional recovery differs between ischaemic and haemorrhagic stroke patients. J Rehabil Med 40:487–489.

Segrave RA, Arnold S, Hoy K, Fitzgerald PB (2014) Concurrent cognitive control training augments the antidepressant efficacy of tDCS: a pilot study. Brain Stimul 7:325–331.

Shahbabaie A, Golesorkhi M, Zamanian B, Ebrahimpoor M, Keshvari F, Nejati V, Fregni F, Ekhtiari H (2014) State dependent effect of transcranial direct current stimulation (tDCS) on methamphetamine craving. Int J Neuropsychopharmacol 17:1591–1598.

Shine JM, Matar E, Ward PB, Frank MJ, Moustafa AA, Pearson M, Naismith SL, Lewis SJG (2013) Freezing of gait in Parkinson's disease is associated with functional decoupling between the cognitive control network and the basal ganglia. Brain 136:3671–3681.

Shiozawa P, Fregni F, Benseñor IM, Lotufo PA, Berlim MT, Daskalakis JZ, Cordeiro Q, Brunoni AR (2014) Transcranial direct current stimulation for major depression: an updated systematic review and meta-analysis. Int J Neuropsychopharmacol 17:1443–1452.

Shiozawa P, Gomes JS, Ducos DV, Akiba HT, Dias ÁM, Trevizol AP, Uchida RR, Orlov N, Cordeiro Q (2016) Effect of transcranial direct current stimulation (tDCS) over the prefrontal cortex combined with cognitive training for treating schizophrenia: a sham-controlled randomized clinical trial. Trends Psychiatry Psychother 38:175–177.

Siegal HA, Li L, Rapp RC (2002) Abstinence trajectories among treated crack cocaine users. Addict Behav 27:437–449.

Silva R de MF da, Brunoni AR, Miguel EC, Shavitt RG (2016) Transcranial direct current

stimulation for treatment-resistant obsessive-compulsive disorder: report on two cases and proposal for a randomized, sham-controlled trial. Sao Paulo Med J 134:446–450.

Smith RC, Boules S, Mattiuz S, Youssef M, Tobe RH, Sershen H, Lajtha A, Nolan K, et al. (2015), Effects of transcranial direct current stimulation (tDCS) on cognition, symptoms, and smoking in schizophrenia: a randomized controlled study. Schizophrenia research 168:260-266.

Soler MD, Kumru H, Pelayo R, Vidal J, Tormos JM, Fregni F, Navarro X, Pascual-Leone A (2010) Effectiveness of transcranial direct current stimulation and visual illusion on neuropathic pain in spinal cord injury. Brain 133:2565–2577.

Straudi S, Buja S, Baroni A, Pavarelli C, Pranovi G, Fregni F, Basaglia N (2018) The effects of transcranial direct current stimulation (tDCS) combined with group exercise treatment in subjects with chronic low back pain: a pilot randomized control trial. Clin Rehabil.

Suokas J, Suominen K, Lönnqvist J (2005) Chronic alcohol problems among suicide attempters--post-mortem findings of a 14-year follow-up. Nord J Psychiatry 59:45–50.

Swank C, Mehta J, Criminger C (2016) Transcranial direct current stimulation lessens dual task cost in people with Parkinson's disease. Neurosci Lett 626:1–5.

Tanaka S, Takeda K, Otaka Y, Kita K, Osu R, Honda M, Sadato N, Hanakawa T, Watanabe K (2011) Single session of transcranial direct current stimulation transiently increases knee extensor force in patients with hemiparetic stroke. Neurorehabil Neural Repair 25:565–569.

Tekturk P, Erdogan ET, Kurt A, Vanli-Yavuz EN, Ekizoglu E, Kocagoncu E, Kucuk Z, Aksu S, Bebek N, Yapici Z, Gurses C, Gokyigit A, Baykan B, Karamursel S (2016) The effect of transcranial direct current stimulation on seizure frequency of patients with mesial temporal lobe epilepsy with hippocampal sclerosis. Clin Neurol Neurosurg 149:27–32.

Theodore WH, Fisher RS (2004) Brain stimulation for epilepsy. Lancet Neurol 3:111–118.

Theodore WH, Spencer SS, Wiebe S, Langfitt JT, Ali A, Shafer PO, Berg AT, Vickrey BG (2006) Epilepsy in North America A Report Prepared under the Auspices of the Global Campaign against Epilepsy , the International Bureau for Epilepsy , the International League Against Epilepsy , and the World Health Organization. :1–23.

Theodore WH, Fisher R (2007) Brain stimulation for epilepsy. Acta Neurochir Suppl 97:261–272.

Thibaut A, Carvalho S, Morse LR, Zafonte R, Fregni F (2017) Delayed pain decrease following M1 tDCS in spinal cord injury: A randomized controlled clinical trial. Neurosci Lett 658:19–26.

Thomas GP, Jobst BC (2015) Critical review of the responsive neurostimulator system for epilepsy. Med Devices (Auckl) 8:405–411.

Thompson-Butel AG, Lin G, Shiner CT, McNulty PA (2015) Comparison of three tools to measure improvements in upper-limb function with poststroke therapy. Neurorehabil Neural Repair 29:341–348.

To WT, James E, Ost J, Hart J, De Ridder D, Vanneste S (2017) Differential effects of bifrontal and occipital nerve stimulation on pain and fatigue using transcranial direct current stimulation in fibromyalgia patients. J Neural Transm 124:799–808.

Triccas LT, Burridge JH, Hughes A, Verheyden G, Desikan M, Rothwell J (2015) A double-blinded randomised controlled trial exploring the effect of anodal transcranial direct current stimulation and uni-lateral robot therapy for the impaired upper limb in sub-acute and chronic stroke. NeuroRehabilitation 37:181–191.

Valentino F, Cosentino G, Brighina F, Pozzi NG, Sandrini G, Fierro B, Savettieri G, D'Amelio M, Pacchetti C (2014) Transcranial direct current stimulation for treatment of freezing of gait: a cross-over study. Mov Disord 29:1064–1069.

Verheyden G, Purdey J, Burnett M, Cole J, Ashburn A (2013) Immediate effect of transcranial

direct current stimulation on postural stability and functional mobility in Parkinson's disease. Mov Disord 28:2040–2041.

Vigod S, Dennis C-L, Daskalakis Z, Murphy K, Ray J, Oberlander T, Somerton S, Hussain-Shamsy N, Blumberger D (2014) Transcranial direct current stimulation (tDCS) for treatment of major depression during pregnancy: study protocol for a pilot randomized controlled trial. Trials 15:366.

Vigod SN, Murphy KE, Dennis CL, Oberlander TF, Ray JG, Daskalakis ZJ, Blumberger DM (2019) Transcranial direct current stimulation (tDCS) for depression in pregnancy: A pilot randomized controlled trial. Brain Stimul.

Villamar MF, Wivatvongvana P, Patumanond J, Bikson M, Truong DQ, Datta A, Fregni F (2013) Focal modulation of the primary motor cortex in fibromyalgia using 4×1-ring high-definition transcranial direct current stimulation (HD-tDCS): Immediate and delayed analgesic effects of cathodal and anodal stimulation. J Pain 14:371–383.

Vines BW, Cerruti C, Schlaug G (2008) Dual-hemisphere tDCS facilitates greater improvements for healthy subjects' non-dominant hand compared to uni-hemisphere stimulation. BMC Neurosci 9:103.

Vines BW, Norton AC, Schlaug G (2011) Non-Invasive Brain Stimulation Enhances the Effects of Melodic Intonation Therapy. Front Psychol 2.

Volpato C, Cavinato M, Piccione F, Garzon M, Meneghello F, Birbaumer N (2013a) Transcranial direct current stimulation (tDCS) of Broca's area in chronic aphasia: A controlled outcome study. Behav Brain Res 247:211–216.

Volpato C, Piccione F, Cavinato M, Duzzi D, Schiff S, Foscolo L, Venneri A (2013b) Modulation of affective symptoms and resting state activity by brain stimulation in a treatment-resistant case of obsessive–compulsive disorder. Neurocase 19:360–370.

Wang Z, Maia T V, Marsh R, Colibazzi T, Gerber A, Peterson BS (2011) The neural circuits

that generate tics in Tourette's syndrome. Am J Psychiatry 168:1326–1337.

Wesson DR, Havassy BE, Smith DE (1986) Theories of relapse and recovery and their implications for drug abuse treatment. NIDA Res Monogr 72:5–19.

West SL, Gartlehner G, Mansfield AJ, Poole C, Tant E, Lenfestey N, Lux LJ, Amoozegar J, et al. (2010), Comparative effectiveness review methods: clinical heterogeneity.

Wigström H, Gustafsson B (1983) Large long-lasting potentiation in the dentate gyrus in vitro during blockade of inhibition. Brain Res 275:153–158.

Witkiewitz K, Stein ER, Votaw VR, Wilson AD, Roos CR, Gallegos SJ, Clark VP, Claus ED (2019) Mindfulness-Based Relapse Prevention and Transcranial Direct Current Stimulation to Reduce Heavy Drinking: A Double-Blind Sham-Controlled Randomized Trial. Alcohol Clin Exp Res 43:1296–1307.

Wrigley PJ, Gustin SM, McIndoe LN, Chakiath RJ, Henderson LA, Siddall PJ (2013) Longstanding neuropathic pain after spinal cord injury is refractory to transcranial direct current stimulation: a randomized controlled trial. Pain 154:2178–2184.

Wu D, Qian L, Zorowitz RD, Zhang L, Qu Y, Yuan Y (2013) Effects on Decreasing Upper-Limb Poststroke Muscle Tone Using Transcranial Direct Current Stimulation: A Randomized Sham-Controlled Study. Arch Phys Med Rehabil 94:1–8.

Yang F, Fang X, Tang W, Hui L, Chen Y, Zhang C, Tian X (2019), Effects and potential mechanisms of transcranial direct current stimulation (tDCS) on auditory hallucinations: A meta-analysis. Psychiatry research 273:343-349.

Yao J, Drogos J, Veltink F, Anderson C, Concha Urday Zaa J, Hanson LI, Dewald JPA (2015) The effect of transcranial direct current stimulation on the expression of the flexor synergy in the paretic arm in chronic stroke is dependent on shoulder abduction loading. Front Hum Neurosci 9:1–7.

Yip AG, George MS, Tendler A, Roth Y, Zangen A, Carpenter LL (2017) 61% of unmedicated

treatment resistant depression patients who did not respond to acute TMS treatment responded after four weeks of twice weekly deep TMS in the Brainsway pivotal trial. Brain Stimul 10:847–849.

Yotnuengnit P, Bhidayasiri R, Donkhan R, Chaluaysrimuang J, Piravej K (2018) Effects of Transcranial Direct Current Stimulation Plus Physical Therapy on Gait in Patients With Parkinson Disease: A Randomized Controlled Trial. Am J Phys Med Rehabil 97:7–15.

You DS, Kim DY, Chun MH, Jung SE, Park SJ (2011) Cathodal transcranial direct current stimulation of the right Wernicke's area improves comprehension in subacute stroke patients. Brain Lang 119:1–5.

Yu H, Sternad D, Corcos DM, Vaillancourt DE (2007) Role of hyperactive cerebellum and motor cortex in Parkinson's disease. Neuroimage 35:222–233.

Zhao P, Yoo I, Lancey R, Varghese E (2019) Mobile applications for pain management: an app analysis for clinical usage. BMC Med Inform Decis Mak 19:106.

Ziemann U, Reis J, Schwenkreis P, Rosanova M, Strafella A, Badawy R, M??ller-Dahlhaus F (2015) TMS and drugs revisited 2014. Clin Neurophysiol 126:1847–1868.

Zimerman M, Heise KF, Cohen LG, Gerloff C (2012) Modulation of Training by Single-Session Transcranial Direct Current Stimulation to the Intact Motor Cortex Enhances Motor Skill Acquisition of the Paretic Hand. 43:2185–2191.

Zortea M, Ramalho L, Silveira Alves CFd, Braulio G, Lopes R, Torres ILS, Fregni F, Caumo W (2019), Transcranial Direct Current Stimulation to improve the dysfunction of descending pain-modulating system related to opioids in chronic noncancer pain: an integrative review of neurobiology and meta-analysis. Frontiers in neuroscience 13:1218.

Table 1- Evidence-based guidelines (Brainin et al., 2004; Lefaucheur et al., 2014b) (adapted from (Brainin et al., 2004))

Class I • Representative Population - n ⩾ 25 of patients receiving active treatment; • Data-supported, prospective, randomized, placebo-controlled clinical trials; • It should include all of these listed criteria: 1. Randomization concealment; 2. Clearly defined primary outcomes; 3. Clearly defined exclusion/inclusion criteria; 4. Adequate accounting for dropouts and crossovers with numbers sufficiently low to have minimal potential for bias; 5. Relevant baseline characteristics substantially equivalent among treatment groups or appropriate statistical adjustment for differences. ***Class II*** • Smaller sample size - $n < 25$; • Randomized, placebo-controlled trials **or** • Lacks at least one of the above-listed criteria (from 1 to 5). ***Class III*** • All other controlled trials ***Class IV*** • Uncontrolled studies; • Case series; • Case reports	***Level A -*** "***definitely effective or ineffective"*** • At least 2 convincing Class I studies **or** • One convincing Class I study and at least 2 consistent, convincing Class II studies. ***Level B - "probably effective or ineffective"*** • At least 2 convincing Class II studies **or** • One convincing Class II study and at least 2 consistent, convincing Class III studies. ***Level C - "possibly effective or ineffective"*** • One convincing Class II study **or** • At least 2 convincing Class III studies. ***No evidence*** • Absence of at least 2 convincing Class III studies with similar results on the same type of clinical features with similar stimulation method.

Pain

Author	Sample(n)	Anode	Cathode	Current density (A/m^2), duration	Number of sessions	Concomitant therapy/tasks	Results	Class
Neuropathic Pain								
Boggio et al. (2009)	8	C3/C4 on side opposite to maximal pain	Contralateral SO	0.571, 30 min	$1^{+aaT,asT,ssT}$	TENS (active/sham)	Positive (VAS)	**III**
Jensen et al. (2013)	30	C3/C4 on side opposite to maximal pain	Contralateral SO	0.571, 20 min	$1^{+as,h,m,n}$	No	Negative (NRS pain - current, least, worst, average)	**III**
Li et al. (2018)	12	C3	Contralateral SO	0.571, 20 min	1^{+as}	Breathing-controlled electrical stimulation (BreEStim) to median nerve on dominant side	Negative (VAS)	**III**
O'Neill et al. (2018)	21	Contralateral SO	C3/C4 on side opposite to pain	0.560, 20 min	5^{+acs}	No	Negative (NRS daily pain)	**III**
O'Neill et al. (2018)	21	C3/C4 on side opposite to pain	Contralateral SO	0.560, 20 min	5^{+acs}	No	Negative (NRS daily pain)	**III**
Wrigley et al. (2013)	10	C3/C4 based on dominant hemisphere	Contralateral SO	0.571, 20 min	5^{+as}	No	Negative (NPS)	**III**
Attal et a. (2016)	35	C3/C4 on side opposite to maximal pain	Contralateral SO	0.571, 30 min	3^{+as} (nested parallel trial – tDCS, rTMS)	No	Negative (BPI)	**III**
Fregni et al. (2006f)	17	C3/C4 on side opposite to maximal pain	Contralateral SO	0.571, 20 min	5	No	Positive (VAS)	**II**
Soler et al. (2010)	39	C3/C4 on side opposite to maximal pain	Contralateral SO	0.571, 20 min	10	Visual illusion/control illusion	Positive (combined group: NRS overall, continuous, paroxysmal; tDCS group: NRS paroxysmal)	**II**
Bae et al. (2014)	14	C3/C4 opposite to hemiplegic side	Contralateral SO	0.571, 20 min	9 (3/week x 3 weeks)	No	Positive (VAS)	**II**
Thibaut et al. (2017)/ Phase I	33	C3/C4 on side opposite to maximal pain	Contralateral SO	0.571, 20 min	5	No	Positive (VAS average, VAS least), Negative (VAS present, VAS worst)	**II**
Thibaut et al. (2017)/ Phase 2	9	C3/C4 on side opposite to maximal pain	Contralateral SO	0.571, 20 min	5	No	Positive (VAS average), Negative (VAS least, VAS present, VAS worst)	**II**
Lewis et al. (2018)	30	C3/C4 on side opposite to affected upper limb	Contralateral SO	0.286, 20 min	5	No	Negative (BPI, SF-MPQ2)	**II**
Recommendation: Anodal M1 tDCS is probably effective in reducing neuropathic pain (Level B)								
Fibromyalgia								
Villamar et al. (2013)	18	C3	Cz, F3, T7, P3	1.000, 20 min	1^{+acs}	No	Positive (VNS)	**III**
Mendonca et al. (2011)*	30	C3	Cervicothoracic	1. 250, 20 min	1	No	Negative (VNS)	**II**
Mendonca et al. (2011)*	30	Cervicothoracic	C3	1. 250, 20 min	1	No	Negative (VNS)	**II**
Mendonca et al. (2011)*	30	Right SO	Cervicothoracic	1. 250, 20 min	1	No	Positive (VNS)	**II**

Mendonca et al. (2011)*	30	Cervicothoracic	Right SO	1. 250, 20 min	1	No	Positive (VNS)	**II**
Fregni et al. (2006e)*	32	F3	Contralateral SO	0.571, 20 min	5	No	Negative (VAS)	**II**
To et al. (2017)*	42	Left occipital (nerve)	Right occipital (nerve)	0.429, 20 min	8 (2/week x 4 weeks)	No	Positive (NRS)	**II**
To et al. (2017)*	42	F3	F4	0.429, 20 min	8 (2/week x 4 weeks)	No	Positive (NRS)	**II**
Fregni et al. (2006e)*	32	C3	Contralateral SO	0.571, 20 min	5	No	Positive (VAS)	**II**
Riberto et al. (2011)	23	C3	Contralateral SO	0.571, 20 min	10 (1/week x 10 weeks)	Pain rehabilitation program	Positive (SF-36 pain), Negative (VAS)	**II**
Fagerlund et al. (2015)	48	C3	Contralateral SO	0.571, 20 min	5	No	Positive (NRS)	**II**
Mendonca et al. (2016)	45	C3	Contralateral SO	0.571, 20 min	5	Aerobic exercise	Positive (VNS)	**II**
Khedr et al. (2017)	36	C3	Contralateral arm	0.833, 20 min	10	No	Positive (VAS)	**II**
Recommendation: Anodal M1 tDCS is probably effective in reducing fibromyalgia pain (Level B); no recommendation for other montages								
Migraine								
Andrade et al. (2017)/Group C	13	F3	Contralateral SO	0.800, 20 min	12 (3/week x 4 weeks)	No	Positive (VAS)	**II**
Da silva et al. (2012)	13	C3/C4 on side opposite to maximal pain	Contralateral SO	0.571, 20 min	10 (every other day x 4 weeks)	No	Positive (VAS, migraine attack duration)	**II**
Andrade et al. (2017)/Group B	13	C3	Contralateral SO	0.800, 20 min	12 (3/week x 4 weeks)	No	Positive (VAS)	**II**
Recommendation: Anodal M1 tDCS is probably effective in reducing migraine pain (Level B)								
Myofascial Pain Syndrome (MPS)								
Choi et al. (2014)*	21	F3	Contralateral SO	0.571, 20 min	5	Trigger point injections	Negative (VAS)	**II**
Sakrajai et al. (2014)	31	C3/C4 on side opposite to maximal pain	Contralateral SO	0.286, 20 min	5	Standard MPS therapy	Positive (NRS)	**II**
Choi et al. (2014)*	21	C3/C4 on side opposite to maximal pain	Contralateral SO	0.571, 20 min	5	Trigger point injections	Negative (VAS)	**II**
No recommendation								
Postoperative acute pain after chronic pain-related surgery								
Dubois et al. (2013)*	59	F3	Above right ear	0.286, 20 min	1 (postoperative)	No	Negative (PCA use, VAS Dynamic pain)	**II**
Dubois et al. (2013)*	59	Above right ear	F3	0.286, 20 min	1 (postoperative)	No	Negative (PCA use, VAS Dynamic pain)	**II**
Borckardt et al. (2013)	39	C1h or C2h based on target knee	F4	1.250, 20 min	4 (2/day x 2 postoperative days)	No	Positive (PCA use), Negative (VAS)	**II**
Glaser et al. (2016)	27	Cz	F4	Unclear electrode size (2 mA), 20 min	4 (2/day x 2 postoperative days)	No	Positive (PCA use, NRS pain at its least), Negative (other pain measures)	**II**

Ribeiro et al. (2017)	40	C3	Contralateral SO	0.571, 20 min	4 (2/preoperative day x 2 days)	No	Positive (Analgesic use, VAS cumulative worst daily pain, VAS during rest), Negative (VAS worst pain when walking)	**II**
Khedr et al. (2017)	50	C1/C2 on side opposite to maximal knee pain	Ipsilateral arm	0.833, 20 min	2 (2/postoperative day)	No	Positive (PCA use, LANSS), Negative (VAS)	**I**
Recommendation: Postoperative anodal M1 tDCS is probably effective in reducing patient-controlled analgesia and pain (Level B)								
Low Back Pain								
Mariano et al. (2019)	21	Right mastoid	FC1	0.571, 20 min	10	No	Negative (DVPRS)	**II**
Straudi et al. (2018)	35	C3/C4 on side opposite to maximal pain, or dominant C3/C4 in case of central or bilateral pain	Contralateral SO	0.571, 20 min	5	Group exercise	Positive (VAS)	**II**
Luedtke et al. (2015)	122	C3	Contralateral SO	0.571, 20 min	5	CBT	Negative (VAS)	**I**
No recommendation								

Table 2: tDCS studies in chronic pain

*: multiple montages within different arms of the same study/experiment; +as - crossover with anodal/sham tDCS conditions; +aaT,asT,ssT - crossover with anodal tDCS/active TENS, anodal tDCS/sham TENS, sham tDCS/sham TENS conditions; +as,h,m,n - crossover with anodal/sham tDCS, hypnosis, meditation, neurofeedback conditions; +as (nested parallel trial – tDCS, rTMS) with active/active or sham/sham groups, crossover within those groups to 10Hz rTMS/anodal tDCS or sham rTMS/sham tDCS; +acs - crossover with anodal/cathodal/sham tDCS conditions.

Parkinson's Disease

Author	Sample (n)	Anode	Cathode	Current density (A/m²)	Number of sessions	Concomitant therapy/tasks	Results	Class
				Motor Function				
Fregni et al. (2006d)/Exp1a	9	C3	Contralateral SO	0.286, 20 min	1^{+as}	No	Positive (UPDRS III, simple RT), Negative (PPT)	**III**
Fregni et al. (2006d)/Exp1b	8	Contralateral SO	C3	0.286, 20 min	1^{+cs}	No	Negative (UPDRS III, simple RT, PPT)	**III**
Verheyden et al. (2013)	20	C3	Contralateral SO	Unclear electrode size (1 mA), 15 min	1^{+as}	Online motor assessments	Negative (10MWT, STS, FR, SS180 steps, SS180 seconds, TUG)	**III**
Kaski et al. (2014)	16	Anterior to Cz	Iz	0.500, 15 min	$1^{+as\ (nested\ parallel\ trial\ –\ PT/no\ PT)}$	Gait and balance training in PT group	Positive only in PT group (gait velocity, pull test, stride length, TUG, 6MWT)	**III**
Fernandez-Lago et al. (2017)	18	C1/C2 opposite to most affected side of body	Contralateral SO	0.571, 20 min	1^{+as}	Treadmill walking (with/without active/sham tDCS)	Negative (gait parameters: speed, stride length/frequency and coefficient of variation)	**III**
Lu et al. (2018)	10	Neuronavigated or anterior to Cz	SO	1.235, 10 min	1^{+as}	None	Negative with self-initiated gait (APA phase force amplitudes and CoP)	**III**
Dagan et al. (2018)*	20	Cz	AF4, FC1, CP1	1.5 mA maximal current at any electrode with maximal total injected current 4mA, 20 min	$1^{+as\ Cz\ F3,\ Cz}$	None	Negative (Modified FOG, TUG, gait speed)	**III**
Dagan et al. (2018)*	20	Cz and F3	AF4, FC1, FC5, CP1	1.5 mA maximal current at any electrode with maximal total injected current 4mA, 20 min	$1^{+as\ Cz\ F3,\ Cz}$	None	Positive (Modified FOG, TUG, gait speed)	**III**
Fregni et al. (2006d)/Exp1c*#	9	F3	Contralateral SO	0.286, 20 min	1^{+as}	No	Negative (UPDRS III, simple RT, PPT)	**III**
Swank et al. (2016)	10	F3	F4	0.571, 20 min	1^{+as}	No	Negative (single and dual task TUG)	**III**
Lattari et al. (2017)	17	F3	Contralateral SO	0.571, 20 min	1^{+as}	No	Positive (BBS, DGI, TUG)	**III**
Doruk et al. (2014)*	18	F4	Contralateral SO	0.571, 20 min	10	No	Negative (UPDRS III, simple RT, 4-CRT, PPT, finger tapping, walking time, buttoning-up, supination-pronation)	**II**
Doruk et al. (2014)*	18	F3	Contralateral SO	0.571, 20 min	10	No	Negative (UPDRS III, simple RT, 4-CRT, PPT, finger tapping, walking time, buttoning-up, supination-pronation)	**II**
Manenti et al. (2016)	20	Midway between F3-F7 or F4-F8 (opposite to most affected side of body)	Contralateral SO	0.571, 25 min	10	PT	Negative (UPDRS III, Hoehn-Yahr Stage, SST, FSST, SRT, TUG)	**II**
Chang et al. (2017)	32	F3	Contralateral SO	0.400, 20 min	5	10Hz rTMS at M1 of LL	Positive (TUG), Negative (FOG-Q, turning steps, turn time, UPDRS III)	**II**

Valentino et al. (2014)	10	C3/C4 of leg initiating after FOG episode	Contralateral SO	Unclear electrode size (2 mA), 20 min	5^{+as}	No	Positive (SWS, MDS-UPDRS total and part III, FOG-Q, Gait and Falls Questionnaire)	**III**
Benninger et al. (2010)	25	Anterior to Cz, alternating with SO	Two over mastoids	0.205, 20 min	8 (3 sessions/week x 2.5 weeks; alternating anode positions)	No	Positive (10MWT, bradykinesia, UPDRS bradykinesia), Negative (UPDRS total and III, serial RT)	**II**
Schabrun et al. (2016)	16	C3	Contralateral SO	0.571, 20 min	9 (3/week x 3 weeks)	Dual task gait training	Negative (Gait velocity during cognitive task, cadence, step length, double support time, TUG, bradykinesia, serial RT)	**II**
Costa-Ribeiro et al. (2016)	24	Anterior to Cz	SO contralateral to most affected side of body	0.571, 13 min	10 (3/week x 4 weeks)	Gait training with visual cues	Positive (TUG, ON and OFF), Negative (UL-MT)	**II**
Costa-Ribeiro et al. (2017)	22	Anterior to Cz	SO contralateral to most affected side of body	0.571, 13 min	10 (3/week x 4 weeks)	Gait training with visual cues	Negative (10MWT, TUG, cadence, stride length, UPDRS III affected side, UPDRS-Bradykinesia, UL-MT, BBS)	**II**
Yotnuengnit et al. (2018)	53	Cz	SO	0.571, 30 min	6 (3/week x 2 weeks)	PT	Negative (walking speed, step length, step width, cadence, UPDRS II and III)	**II**
Recommendation: Anodal motor/premotor/SMA tDCS is possibly effective for motor function in PD (Level C); anodal prefrontal tDCS is probably not effective for motor function in PD (Level B).								
Cognitive Function								
Boggio et al. (2006)/Exp1	9	F3	Contralateral SO	0.286, 20 min	1$^{+as\ F3,\ C3}$	No	Negative (working memory accuracy and RT)	**III**
Boggio et al. (2006)/Exp2	9	F3	Contralateral SO	0.571, 20 min	1$^{+as\ F3,\ C3}$	No	Positive (working memory accuracy), Negative (RT)	**III**
Boggio et al. (2006)/Exp1	9	C3	Contralateral SO	0.286, 20 min	1$^{+as\ F3,\ C3}$	No	Negative (working memory accuracy and RT)	**III**
Boggio et al. (2006)/Exp2	9	C3	Contralateral SO	0.571, 20 min	1$^{+as\ F3,\ C3}$	No	Negative (working memory accuracy and RT)	**III**
Dagan et al. (2018)*	20	Cz and F3	AF4, FC1, FC5, CP1	1.5 mA maximal current at any electrode with maximal total injected current 4mA, 20 min	1$^{+as\ Cz\ F3,\ Cz}$	None	Positive (Stroop)	**III**
Dagan et al. (2018)*	20	Cz	AF4, FC1, CP1	1.5 mA maximal current at any electrode with maximal total injected current 4mA, 20 min	1$^{+as\ Cz\ F3,\ Cz}$	None	Negative (Stroop)	**III**
Schabrun et al. (2016)	16	C3	Contralateral SO	0.571, 20 min	9 (3/week x 3 weeks)	Dual task gait training	Positive (TUG count, TUG words)	**II**
Doruk et al. (2014)*	18	F4	Contralateral SO	0.571, 20 min	10	No	Positive (TMT B maintenance of learning), Negative (other cognitive tests**)	**II**
Doruk et al. (2014)*	18	F3	Contralateral SO	0.571, 20 min	10	No	Positive (TMT B maintenance of learning), Negative (other cognitive tests**)	**II**
Manenti et al. (2016)	20	Midway between F3-F7 or F4-F8 (opposite to most affected side of body)	Contralateral SO	0.571, 25 min	10	PT	Positive (PD-CRS frontal-subcortical and total scales, semantic fluency), Negative (other cognitive assessments** on memory, attention, executive function, MMSE)	**II**

Chang et al. (2017)	32	F3	Contralateral SO	0.400, 20 min	5	10Hz rTMS at M1 of LL	Positive (TMT B), Negative (DS-forward, DS-backward, Montreal Cognitive Assessment-Korean)	**II**
Manenti et al. (2018)	22	F3	Right SO	0.571, 25 min	10	Computerized cognitive training	Positive (phonemic verbal fluency), Negative (other cognitive assessments** on global abilities, memory, language, attention and executive functions)	**II**

Recommendation: Anodal DLPFC tDCS is probably effective for cognitive function in PD (Level B)

Table 3: tDCS studies in Parkinson's disease targeting motor and cognitive functions

*: multiple montages within the same study/experiment; # this experiment was considered a control for M1 anodal tDCS in Experiment 1a and used the same subjects; **please see the papers for full lists of cognitive tests; +as: crossover - anodal/sham tDCS; +cs: crossover - cathodal/sham tDCS; +as (nested parallel trial – PT/no PT): tDCS with/without PT groups, crossover within those groups to anodal/sham tDCS; +as F3, C3: crossover – anodal/sham tDCS over left DLPFC and M1; +as Cz F3, Cz: crossover – anodal left M1 and left DLPFC (multi-target), anodal left M1, and "active" sham.

Chronic Stroke: Motor Function

Author	Sample (n)	Anode	Cathode	Current density (A/m²), duration	Number of sessions	Concomitant therapy/task	Results	Class
			Ipsilesional					
Fregni et al. (2005)	6	Ipsilesional C3/C4	Contralesional SO	0.286, 20 min	1^{+ics}	No	Positive (JTHFT)	**III**
Hummel et al. (2005)	6	Ipsilesional C3/C4	Contralesional SO	0.400, 20 min	1^{+is}	No	Positive (JTHFT)	**III**
Hummel et al. (2006)	11	Ipsilesional C3/C4	Contralesional SO	0.400, 20 min	1^{+is}	Simple reaction time, pinch force tasks	Positive (simple reaction time, pinch force)	**III**
Celnik et al. (2009)	9	Ipsilesional C3/C4	Contralesional SO	0.172, 20 min	$1^{+is,\ isPNS}$	Motor training (all groups), PNS of paretic hand (in active tDCS+PNS and sham tDCS+PNS groups)	Positive (finger motor sequence)	**III**
Giacobbe et al. (2013)	12	Ipsilesional C3/C4	Contralesional SO	Unclear electrode size (2mA), 20 min	1^{+is}	InMotion3 wrist robot movements	Positive for pre-training tDCS (movement smoothness), Negative for tDCS during (worse aim) and post-training (slower)	**III**
Mahmoudi et al. (2011)	10	Ipsilesional C3/C4	Contralesional SO	0.286, 20 min	1^{+iibcs}	No	Positive (JTHFT)	**III**
Mahmoudi et al. (2011)	10	Ipsilesional C3/C4	Contralesional deltoid	0.286, 20 min	1^{+iibcs}	No	Negative (JTHFT)	**III**
Stagg et al. (2012)/Exp1*	13**	Ipsilesional C3/C4	Contralesional SO	0.286, 20 min	1^{+ics}	Motor simple reaction time and grip force tasks	Positive (simple reaction time), Negative (grip force)	**III**
Stagg et al. (2012)/Exp2	11**	Ipsilesional C3/C4	Contralesional SO	0.286, 10 min	1^{+ics}	Motor simple and choice reaction time tasks	Positive (simple reaction time), Negative (choice reaction time)	**III**
Madhavan et al. (2011)	9	Ipsilesional $C1/C2^{LL}$	Contralesional SO	0.625, 15 min	$1^{+ia,ca,s}$	Tracking sinusoidal waveform using ankle movements	Positive (accuracy index)***	**III**
Tanaka et al. (2011)	8	Ipsilesional $C1/C2^{LL}$	Contralesional SO	0.571, 10 min	1^{+is}	Knee extension and hand grip tasks	Positive (maximum force of knee extension), Negative (maximum force of hand grip)	**III**
Au-Yeung et al. (2014)	10	Ipsilesional C3/C4	Contralesional SO	0.286, 20 min	1^{+ics}	No	Negative (Purdue pegboard unimanual test, pinch strength)	**III**
Yao et al. (2015)	9	Ipsilesional C3/C4	SO	0.500, 15 min	$1^{+ia,cc,ca,s}$	Reaching task (ACT3 Drobot)	Negative (reaching distance with shoulder abduction loads)	**III**
van Asseldonk and Boonstra (2016)	10	Ipsilesional $C1/C2^{LL}$	Contralesional SO	0.571, 10 min	1^{+ibs}	Treadmill Walking	Negative (paretic leg positive work, propulsion, step length, cycle time), Positive (positive work in nonparetic leg)	**III**
Marquez et al. (2017)	25	Ipsilesional C3/C4	Contralesional SO	0.286, 20 min	1^{+ics}	No	Negative (JTHFT, pinch force, grip force)	**III**
Fleming et al. (2017)[#]	24	Ipsilesional C3/C4	Contralesional SO	0.400, 20 min	1^{+icbs}	Motor sequence learning task	Positive (JTHFT)	**III**
Ojardias et al. (2018)	18	Ipsilesional M1 $C1/C2^{LL}$	Contralesional SO	0.800, 20 min	1^{+as}	None	Positive (6MWT), Negative (Wade test, step length/symmetry, balance measures)	**III**

				With Robotic Concomitant Therapy				
Danzl et al. (2013)	8	Ipsilesional C1/C2[LL]	SO	0.800, 20 min	12	Locomotor training with a robotic gait orthosis (LT-RGO)	Positive (FAC), Negative (10MWT, TUG, BBS)	**II**
Geroin et al. (2011)	30	Ipsilesional C1/C2[LL]	Contralesional SO	0.429, 7 min	10	Robot-assisted gait training (Gait Trainer GT1)	Negative（6minWT, 10MWT, spatiotemporal gait, FAC, MI leg）	**II**
Triccas et al. (2015)[#]	22	Ipsilesional C3/C4	Contralesional SO	0.286, 20 min	18 (about 2-3/week x 8 weeks)	Robot Therapy	Negative (FM UE, ARAT, MAL, robotic Hand Path Ratio)	**II**
Seo et al. (2017)	21	Ipsilesional C1/C2[LL]	Contralesional SO	0.571, 20 min	10	Robot-assisted gait training	Positive (FAC, 6MWT), Negative (10MWT, FM LE, BBS, MRC)	**II**
Edwards et al. (2019)	77	Ipsilesional C3/C4	Contralesional SO	0.571, 20 min	36 (3/week x 12 weeks)	Robot-assisted arm training	Negative (FM, WMFT)	**II**
				Without Robotic Concomitant Therapy				
Wu et al. (2013)[#]	90	Contralesional shoulder	Ipsilesional C3/C4	0.283, 20 min	20	Physical therapy	Positive (MAS elbow, MAS wrist, FM UE)	**I**
Boggio et al. (2007)/Exp1	4	Ipsilesional C3/C4	Contralesional SO	0.286, 20 min	4 (one per week x 4 weeks) [+ics]	No	Positive (JTHFT)	**III**
Cha et al. (2014)	20	Ipsilesional C3/C4	Contralesional SO	0.286, 20 min	20	Functional training (PT)	Positive (BBT, FM UE, FM LE)	**III**
Kasashima-Shindo et al. (2015)	18	Ipsilesional C3/C4	Contralesional SO	0.286, 10 min	10	BCI training + OT	Positive (FM UE)	**III**
Viana et al. (2014)	20	Ipsilesional C3/C4	Contralesional SO	0.571, 13 min	15	VR	Positive (MAS), Negative (FM UE, WMFT)	**II**
Mortensen et al. (2016)	15	Ipsilesional C3/C4	Contralesional SO	0.429, 20 min	5	Home-based OT	Positive (grip strength), Negative (JTHFT)	**II**
Rocha et al. (2016)	21	Ipsilesional C3/C4	SO	0.286, 13 min	12 (3/week x 4 weeks)	mCIMT	Positive (FM UE, FM total), Negative (MAL, handgrip strength)	**II**
Ilic et al. (2016)	26	Ipsilesional C3/C4	Contralesional SO	0.800, 20 min	10	OT/control	Positive (JTHFT), Negative (handgrip strength, FM UE)	**II**
Recommendation: Anodal tDCS of ipsilesional M1 is probably effective (Level B) for motor rehabilitation in chronic stroke								
Recommendation: Anodal tDCS of ipsilesional M1 to enhance robotic therapy is probably not effective (Level B) for motor rehabilitation in chronic stroke								
				Contralesional				
Fregni et al. (2005)	6	Ipsilesional SO	Contralesional C3/C4	0.286, 20 min	1[+ics]	No	Positive (JTHFT)	**III**
Mahmoudi et al. (2011)	10	Ipsilesional SO	Contralesional C3/C4	0.286, 20 min	1[+iicbs]	No	Positive (JTHFT)	**III**
Stagg et al. (2012)/Exp1*	13**	Ipsilesional SO	Contralesional C3/C4	0.286, 20 min	1[+ics]	Motor simple reaction time and grip force tasks	Positive (simple reaction time), Negative (grip force)	**III**
Stagg et al. (2012)/Exp2	11**	Ipsilesional SO	Contralesional C3/C4	0.286, 10 min	1[+ics]	Motor simple and choice reaction time tasks	Positive (simple reaction time), Negative (choice reaction time)	**III**
Zimerman et al. (2012)	12	Ipsilesional SO	Contralesional C3/C4	0.400, 20 min	1[+cs]	Motor Task	Positive (finger movement task)	**III**
Au-Yeung et al. (2014)	10	Ipsilesional SO	Contralesional C3/C4	0.286, 20 min	1[+ics]	No	Positive (Purdue pegboard unimanual test), Negative (pinch strength)	**III**
Yao et al. (2015)	9	SO	Contralesional C3/C4	0.500, 15 min	1[+ia,cc,ca,s]	Reaching task (ACT3D robot)	Negative (reaching distance with shoulder abduction loads)	**III**
Kwon et al. (2016)	20	Ipsilesional SO	Contralesional C3/C4	0.800, 20 min	1[+ca,cc,s/rTMS]	10Hz rTMS (ipsilesional C3/C4), sequential hand motor training	Positive (motor training, movement accuracy)	**III**

Marquez et al. (2017)	25	Ipsilesional SO	Contralesional C3/C4	0.286, 20 min	1^{+ics}	No	Negative (JTHF, pinch force, grip force)	**III**
Fleming et al. (2017)[#]	24	Ipsilesional SO	Contralesional C3/C4	0.400, 20 min	1^{+icbs}	Motor sequence learning task	Positive (JTHFT)	**III**
Boggio et al. (2007)/Exp1	4	Ipsilesional SO	Contralesional C3/C4	0.286, 20 min	4 (one per week x 4 weeks)$^{+ics}$	No	Positive (JTHFT)	**III**
Felice et al. (2016)	10	Ipsilesional SO	Contralesional C3/C4	0.400, 20 min	5^{+cbs}	No	Positive (MRC hand, elbow flexion, Ashworth score)	**III**
Nair et al. (2011)	14	Ipsilesional SO	Contralesional C3/C4	Unclear electrode size (1 mA intensity), 30 min	5	Occupational therapy	Positive (ROM, FM UE)	**II**
Rocha et al. (2016)	21	SO	Contralesional C3/C4	0.286, 9 min	12 (3/week x 4 weeks)	mCIMT	Negative (FM UE, FM total, MAL, handgrip strength)	**II**
Recommendation: Cathodal tDCS of contralesional M1 is probably effective (Level B) for motor rehabilitation in chronic stroke								
Bilateral								
Mahmoudi et al. (2011)	10	Ipsilesional C3/C4	Contralesional C3/C4	0.286, 20 min	1^{+iicbs}	No	Positive (JTHFT)	**III**
Lefebvre et al. (2013)	18	Ipsilesional C3/C4	Contralesional C3/C4	0.286, 30 min	1^{+bs}	Motor skill learning task	Positive (motor skill learning index, PPT, maximal hand grip force)	**III**
Lefebvre et al. (2014)	19	Ipsilesional C3/C4	Contralesional C3/C4	0.286, 20 min	1^{+bs}	Grip-lifts, PPT	Positive (precision grip measures, PPT)	**III**
O'Shea et al. (2014)/Exp2*	13	Ipsilesional C3/C4	Contralesional C3/C4	0.286, 20 min	1^{+icbs}	Motor reaction time and grip force tasks	Negative (reaction time)	**III**
van Asseldonk and Boonstra (2016)	10	Ipsilesional C1/C2^{LL}	Contralesional SO	0.571, 10 min	1^{+ibs}	Treadmill Walking	Negative (paretic leg positive work, propulsion,step length, cycle time), Positive (positive work in nonparetic leg)	**III**
Fleming et al. (2017)[#]	24	Ipsilesional C3/C4	Contralesional C3/C4	0.400, 20 min	1^{+icbs}	Motor sequence learning task	Negative (JTHFT)	**III**
Doost et al. (2019)	21	Ipsilesional C3/C4	Contralesional C3/C4	0.286, 30 min	1^{+bs}	Bimanual cooperative skill program (CIRCUIT)	Negative (bimanual speed/accuracy tradeoff, bimanual coordination factor, BBT)	**III**
Pavlova et al. (2017)	11	Ipsilesional and contralesional C3/C4 (bipolar anodal)	Contralesional SO	0.333, 20 min	40 (2/day x 4 weeks)	Visuo-motor power grip force-tracking task	Positive (FM UE shoulder-elbow subscore, ramp error), Negative (FM UE and other subscores, WMFT-FAS, WMFT-time, BBT, grip maximum voluntary contraction, other movement parameters)	**II**
Felice et al. (2016)	10	Ipsilesional C3/C4	Contralesional C3/C4	0.400, 20 min	5^{+cbs}	No	Positive (MRC hand, elbow flexion, Ashworth score)	**III**
Bolognini et al. (2011)	14	Ipsilesional C3/C4	Contralesional C3/C4	0.571, 40 min	10	CIMT	Positive (JTHFT, grip strength, FM UE)	**II**
Lindenberg et al. (2010)****	20	Ipsilesional C3/C4	Contralesional C3/C4	0.920, 30 min	5	PT + OT	Positive (FM UE, WMFT)	**II**
Lindenberg et al. (2012)****	10	Ipsilesional C3/C4	Contralesional C3/C4	0.920, 30 min	10 (2x5-day sessions separated by 2-29 days)	PT + OT	Positive (FM UE, WMFT)	**II**
Koh et al. (2017)	25	Ipsilesional C3/C4	Contralesional C3/C4	0.600, 30 min	24 (3/week x 8 weeks)	Sensory modulation on both hands + passive	Negative (FM UE, MAS, ARAT)	**II**

						repetitive wrist/finger movements + cutaneous anesthesia of both upper extremities		
Beaulieu et al. (2018)	14	Ipsilesional C3/C4	Contralesional C3/C4	0.571, 20 min	12 (3/week x 4 weeks)	Progressive resistance training program	Negative (FM, WMFT, BBT, grip strength, MAS)	**II**
Salazar et al. (2019)	30	Ipsilesional C3/C4	Contralesional C3/C4	0.800, 30 min	10	Functional electrical stimulation	Positive (movement cycle time, mean reaching phase velocity, handgrip force), Negative (FM UL, other motor measures)	**II**

Recommendation: Bilateral tDCS of M1 is probably effective (Level B) for motor rehabilitation in chronic stroke

Table 4: tDCS studies in chronic stroke motor function

*Stagg et al., 2012 had included the same sample with ipsilesional, contralesional and sham tDCS conditions (pilot study) to which the sample in O'Shea et al., 2014, was later compared in a bilateral tDCS montage; ** 2 participants dropped out between Stagg et al., 2012 Experiments 1 and 2; ***positive results for ipsilesional motor anodal with contralesional SO cathodal tDCS condition, negative for contralesional motor anodal with ipsilesional SO cathodal condition; ****4/10 subjects in Lindenberg et al., 2012, were from Lindenberg el al., 2010; # paper had a large or unclear mix of subacute and chronic stroke patients and was included in both subacute and chronic stroke tables; LL– Target was the motor cortex corresponding to the left or right lower limbs, placed mesial to the upper limbs/just lateral to the sagittal plane, roughly corresponding with C1/C2 in the 10/10 International EEG system; +is – crossover with ipsilesional anodal and sham tDCS conditions; +ics – crossover with ispilesional anodal, contralesional cathodal and sham tDCS conditions (note – for Boggio et al., 2007/Experiment 1, each condition lasted for 4 weeks, so the experiment lasted 16 weeks); +is, isPNS – crossover with ispilesional anodal and sham tDCS conditions, and peripheral nerve stimulation; +iibcs – crossover with ipsilesional anodal (cathode over contralesional SO or deltoid), contralesional cathodal, bilateral, and sham tDCS conditions; + icbs – crossover with ipsilesional anodal, contralesional cathodal, bilateral and sham tDCS conditions; +ia,ca,s – crossover with ipsilesional anodal, contralesional anodal and sham tDCS conditions; +cs – crossover with contralesional cathodal and sham tDCS conditions; +bs – crossover with bilateral and sham tDCS conditions; +ia,cc,ca,s – crossover with ipsilesional anodal, contralesional cathodal, contralesional anodal and sham tDCS conditions (note – contralesional anode was no different than sham while contralesional cathode significantly worsened reaching distance at high load); +ca,cc,s/rTMS – crossover with 5 conditions for dual-mode bihemispheric stimulation: contralesional cathodal tDCS or contralesional anodal tDCS plus online ipsilesional 10 Hz rTMS (Conditions 1 and 2 respectively), contralesional cathodal tDCS or contralesional anodal tDCS followed by ipsilesional 10 Hz rTMS (Conditions 3 and 4), and contralesional sham tDCS plus online ipsilesional 10 Hz rTMS (Condition 5) – Condition 3 had significantly improved movement time compared to all other conditions.

Subacute Stroke: Motor Function

Author	Sample (n)	Anode	Cathode	Current density (A/m²)	Number of sessions	Concomitant therapy or motor tasks	Results	Class
				Ipsilesional				
Sohn et al. (2013)	11	Ipsilesional C1/C2[LL]	Contralesional SO	0.800, 10 min	1[+is]	No	Positive (isometric peak torque for knee extensor, stability indices)	**III**
Fusco et al. (2013)	9	Ipsilesional C3/C4	Contralesional SO	0.429, 15 min	1[+icbs]	No	Positive (9HPT), Negative (pinch force, grip force)	**III**
Fusco et al. (2014b)	16	Ipsilesional C3/C4	Contralesional SO	0.429, 15 min	1[+is]	Upper limb rehabilitation	Positive (9HPT), Negative (pinch and grip force)	**III**
Fleming et al. (2017)[#]	24	Ipsilesional C3/C4	Contralesional SO	0.400, 20 min	1[+icbs]	Motor sequence learning task	Positive (JTHFT)	**III**
Achachelue et al. (2018) – A	15	Ipsilesional C3/C4 and F3/F4	Contralesional SO	0.16 per electrode x2 electrodes at each site, 20 min	1[+asCF,C]	None	Positive (RT, 9HPT), Negative (FM)	**III**
Achachelue et al. (2018) – B	15	Ipsilesional C3/C4	Contralesional SO	0.16 (one electrode), 20 min	1[+asCF,C]	None	Negative (RT, 9HPT, FM)	**III**
				With Robotic concomitant therapy				
Triccas et al. (2015)[#]	22	Ipsilesional C3/C4	Contralesional SO	0.286, 20 min	18 (about 2-3/week x 8 weeks)	Robot Therapy	Negative (FM UE, ARAT, MAL, robotic Hand Path Ratio)	**II**
Mazzoleni et al. (2017)	24	Ipsilesional C3/C4	Contralesional SO	0.571, 20 min	30	Wrist robot-assisted training	Negative (FM UE, FM wrist, MI, BBT, MAS wrist, kinematic parameters)	**II**
Mazzoleni et al. (2019)	39	Ipsilesional C3/C4	Contralesional SO	0.571, 20 min	30	Wrist robot-assisted rehabilitation (InMotion WRIST)	Negative (FM UE, FM wrist, FM LE, MAS wrist, MI, BBT, wrist kinematic parameters)	**II**
Hesse et al. (2011)	96	Ipsilesional C3/C4	Contralesional SO	0.571, 20 min	30	Robot-assisted arm training (Bi-Manu Track)	Negative (FM UE, BBT, MRC, MAS)	**I**
				Without Robotic concomitant therapy				
Manji et al. (2018)	30	3.5 cm anterior to Cz	Inion	0.400, 20 min	5[+is]	BWSTT	Positive (10MWT, TUG), Negative (FM LL, TCT, POMA)	**III**
Koo et al. (2018)	24	Ipsilesional CP3/CP4	Contralesional SO	0.400, 20 min	10	None	Negative (MFT, MBC, FAC)	**II**
Wu et al. (2013)[#]	90	Contralesional shoulder	Ipsilesional C3/C4	0.283, 20 min	20	Physical therapy	Positive (MAS elbow, MAS wrist, FM UE)	**I**
Kim et al. (2010)	18	Ipsilesional C3/C4	Contralesional SO	0.800, 20 min	10	OT	Negative (FM UE)	**II**
Rossi et al. (2013)	50	Ipsilesional C3/C4	Contralesional SO	0.571, 20 min	5	No	Negative (FM UE, NIHSS)	**II**
Khedr et al. (2013)	40	Ipsilesional C3/C4	Contralesional SO	0.571, 25 min	6	Conventional rehabilitation therapy	Positive (OMCASS), Negative (NIHSS, MAC)	**II**
Sattler et al. (2015)	20	Ipsilesional C3/C4	Contralesional SO	0.343, 13 min	5	rPNS, conventional rehabilitation therapy	Positive (JTHFT), Negative (FM UE, hand grip, 9HPT, hand tapping test)	**II**
Figlewski et al. (2017)	44	Ipsilesional C3/C4	Contralesional SO	0.429, 30 min	10	CIMIT	Positive (WMFT FAS), Negative (WMFT time, grip strength, arm strength)	**II**
Andrade et al. (2017)	60	Ipsilesional C3/C4	Contralesional SO	0.571, 20 min	10	PT	Positive (falls, FSST, OSI, FES-I, BBS, 6MWT, STS)	**II**

Recommendation: Anodal tDCS of ipsilesional M1 is probably effective (Level B) for motor rehabilitation in subacute stroke
Recommendation: Anodal tDCS of ipsilesional M1 to enhance robotic therapy is definitely not effective (Level A) for motor rehabilitation in subacute stroke

				Contralesional				
Fusco et al. (2013)	9	Ipsilesional SO	Contralesional C3/C4	0.429, 15 min	1[+icbs]	No	Positive (9HPT, pinch force), Negative (grip force)	**III**
Fleming et al. (2017)[#]	24	Ipsilesional SO	Contralesional C3/C4	0.400, 20 min	1[+icbs]	Motor sequence learning task	Positive (JTHFT)	**III**
				With Robotic concomitant therapy				
Hesse et al. (2011)	96	Ipsilesional SO	Contralesional C3/C4	0.571, 20 min	30	Robot-assisted arm training (Bi-Manu Track)	Negative (FM UE, BBT, MRC, MAS)	**I**
				Without Robotic concomitant therapy				
Kim et al. (2010)	18	Ipsilesional SO	Contralesional C3/C4	0.800, 20 min	10	OT	Positive (FM UE)	**II**
Khedr et al. (2013)	40	Ipsilesional SO	Contralesional C3/C4	0.571, 25 min	6	Conventional therapy	Positive (OMCASS), Negative (NIHSS, MAC)	**II**
Lee and Chun (2014)	59	Ipsilesional SO	Contralesional C3/C4	0.800, 20 min	15	OT but no VR (Group A) or VR (Group C)	Positive (MFT and FM UE in Group C), Negative (MAS, MMT, BBT)	**II**
Fusco et al. (2014a)	11	Extracephalic (above right shoulder)	Contralesional C3/C4	0.429, 10 min	10	Traditional rehabilitation	Negative (CNS, 9HPT, pinch force, grasp force, FM UE, TUG, 6MWT, 10MWT, FAC)	**II**
Andrade et al. (2017)	60	Ipsilesional SO	Contralesional C3/C4	0.571, 20 min	10	PT	Positive (falls, FSST, OSI, FES-I, BBS, 6MWT, STS)	**II**
Rabadi et al. (2017)	16	Ipsilesional SO	Contralesional C3/C4	0.286, 30 min	10	OT	Negative (ARAT)	**II**
Recommendation: Cathodal tDCS of contralesional M1 is probably effective (Level B) for motor rehabilitation in subacute stroke								
Recommendation: Cathodal tDCS of contralesional M1 to enhance robotic therapy is probably not effective (Level B) for motor rehabilitation in subacute stroke								
				Bilateral				
Fusco et al. (2013)	9	Ipsilesional C3/C4	Contralesional C3/C4	0.429, 15 min	1[+icbs]	No	Positive (9HPT), Negative (pinch force, grip force)	**III**
Fleming et al. (2017)[#]	24	Ipsilesional C3/C4	Contralesional C3/C4	0.400, 20 min	1[+icbs]	Motor sequence learning task	Negative (JTHFT)	**III**
Klomjai et al. (2018)	19	Ipsilesional C3/C4	Contralesional C3/C4	0.571, 20 min	1[+bs]	PT	Positive (FTSST), Negative (TUG, knee extensor MVC)	**III**
Wang et al. (2014)	9	Ipsilesional C3/C4	Contralesional C3/C4	0.286, 20 min	1	Methylphenidate	Positive (PPT)	**II**
Oveisgharan et al. (2017)	20	Ipsilesional C3/C4*, then F3	Contralesional C3/C4, then right SO	1.250, 30 min (C3/C4) then 60 min (F3)	10	No	Positive (FM UE, ARAT)	**II**
Saeys et al. (2015)	31	Ipsilesional C3/C4	Contralesional C3/C4	0.429, 20 min	16 (4/week x4 weeks)[+bs]	PT + OT	Positive (Tinetti test total, RMA leg-trunk), Negative (TIS, Tinetti test and other RMA subscores)	**III**
Di Lazzaro et al. (2014)/Exp1	14	Ipsilesional C3/C4	Contralesional C3/C4	0.571, 40 min	5	Standardized PT	Negative (ARAT, 9HPT, hand grip, NIHSS)	**II**
Di Lazzaro et al. (2014)/Exp2	20	Ipsilesional C3/C4	Contralesional C3/C4	0.571, 40 min	5	CIMT	Negative (ARAT, 9HPT, hand grip, NIHSS)	**II**
Andrade et al. (2017)	60	Ipsilesional C3/C4	Contralesional C3/C4	0.571, 20 min	10	PT	Positive (falls, FSST, OSI, FES-I, BBS, 6MWT, STS)	**II**
Recommendation: Bilateral tDCS of M1 is possibly effective (Level C) for motor rehabilitation in subacute stroke								

Table 5: tDCS studies in subacute stroke motor function

* M1 tDCS was active in all while left DLPFC tDCS was active/sham; # paper had a large or unclear mix of subacute and chronic stroke patients and was included in both subacute and chronic stroke tables; +is – crossover with ipsilesional anodal and sham tDCS conditions; +icbs – crossover with ipsilesional anodal, contralesional cathodal, bilateral and sham tDCS conditions; +asCF,C - crossover with ipsilesional anodal/sham M1 and DLPFC or M1 alone tDCS conditions; +bs – crossover with bilateral and sham tDCS conditions; LL– Target was the motor cortex corresponding to the left or right lower limbs, placed mesial to the upper limbs/just lateral to the sagittal plane, roughly corresponding with C1/C2 in the 10/10 International EEG system

Chronic Stroke: Aphasia

Author	Sample (n) (aphasia type)	Anode	Cathode	Current density (A/m²), duration	Number of sessions	Concomitant therapy/task	Results	Class
			Anodal					
Monti et al. (2008)/Exp1	4 (nonfluent - Broca's, global)	Left frontotemporal area	Right shoulder	0.571, 10 min	$1^{+as,cs}$	No	Negative (picture naming accuracy, RT)	**III**
Pestalozzi et al. (2018)	14 (4 nonfluent, 10 fluent – Broca, global, anomic, conduction)	F3	Right SO	0.400, 20 min	1^{+as}	Picture naming, phonemic (verbal) fluency, repetition, Flanker tasks	Positive (verbal fluency, RT of picture naming very high frequency words), Negative (picture naming, repetition)	**III**
Baker et al. (2010)	10 (4 nonfluent, 6 fluent)	Left frontal area	Right shoulder	0.400, 20 min	5^{+as}	Computerized anomia treatment (online picture-word matching task)	Positive (naming accuracy for treated nouns and untreated nouns)	**III**
Fridriksson et al. (2011)	8 (fluent)	Left posterior cortex	Contralesional SO	0.400, 20 min	5^{+as}	Computerized anomia treatment (word-picture matching task)	Positive (RT during correct naming of trained nouns), Negative (for untrained nouns)	**III**
Vines et al. (2011)	6 (nonfluent)	Right posterior inferior frontal gyrus	Contralesional SO	0.736, 20 min	3^{+as}	Melodic intonation therapy	Positive (verbal fluency)	**III**
Marangolo et al. (2011)	3 (nonfluent apraxia of speech)	Left inferior frontal gyrus (Broca's area)	Contralesional SO	0.286, 20 min	5^{+as}	Language training (repetition tasks)	Positive (articulated response accuracy, various transfer of treatment effects)	**III**
Fiori et al. (2013)	7 (nonfluent)	Left frontal (Broca's) area	Contralesional SO	0.286, 20 min	5^{+aFaTs}	Language training (noun and verb training, separated by a month)	Positive (naming accuracy for verbs)	**III**
Marangolo et al. (2013b)	12 (nonfluent)	Left inferior frontal (Broca's) area	Contralesional SO	0.286, 20 min	10^{+aFaTs}	Conversational therapy (discourse skills)	Positive (production of correct Content Units, verbs, sentences, treatment generalization)	**III**
Marangolo et al. (2013a)	7 (nonfluent)	Left frontal (Broca's) area	Contralesional SO	0.286, 20 min	5^{+aFaTs}	Language training (verb naming)	Positive (verb naming accuracy)	**III**
Volpato et al. (2013a)	8 (6 fluent, 2 nonfluent)	Left inferior frontal (Broca's) area	Contralesional SO	0.571, 20 min	10^{+as}	No*	Negative (object and action naming)	**III**
Marangolo et al. (2014a)	8 (nonfluent)	Left inferior frontal (Broca's) area	Contralesional SO	0.286, 20 min	10^{+aFaTs}	Conversational therapy	Positive (number of endophoric references, treatment generalization)	**III**
Vestito et al. (2014)	3 (2 nonfluent, 1 fluent anomic)	Left inferior frontal area	Contralesional SO	0.600, 20 min	10^{+as}	Naming training	Positive (picture naming)	**III**
Campana et al. (2015)	20 (nonfluent)	Left inferior frontal gyrus	Contralesional SO	0.571, 20 min	10^{+as}	Conversational therapy	Positive (picture description, noun and verb naming)	**III**
Cipollari et al. (2015)	6 (nonfluent)	Right inferior frontal gyrus (F8)	Left SO	0.571, 20 min	15^{+as}	Melodic intonation therapy	Positive (improved words and sentences repetition)	**III**
Floel et al. (2011)	12 (nonfluent and fluent)	Right temporoparietal cortex	Contralesional SO	Unclear electrode size (1mA), 20 min	3^{+acs}	Computerized anomia training	Positive (picture naming accuracy for trained objects)	**III**

Fiori et al. (2011)/Exp2	3 (nonfluent)	Left Wernicke's area	Contralesional SO	0.286, 20 min	5^{+as}	Language training (anomic treatment paradigm - lists of different words)	Positive (picture naming accuracy, decreased vocal RT)	**III**
Fiori et al. (2013)	7 (nonfluent)	Left temporal (Wernicke's) area	Contralesional SO	0.286, 20 min	5^{+aFaTs}	Language training (noun and verb training, separated by a month)	Positive (naming accuracy for nouns)	**III**
Marangolo et al. (2013b)	12 (nonfluent)	Left posterior superior temporal (Wernicke's) area	Contralesional SO	0.286, 20 min	10^{+aFaTs}	Conversational therapy (discourse skills)	Negative (production of correct Content Units, verbs, sentences, treatment generalization)	**III**
Marangolo et al. (2013a)	7 (nonfluent)	Left temporal (Wernicke's) area	Contralesional SO	0.286, 20 min	5^{+aFaTs}	Language training (verb naming)	Positive (noun naming accuracy)	**III**
Marangolo et al. (2014b)	8 (nonfluent)	Left posterior superior temporal (Wernicke's) area	Contralesional SO	0.286, 20 min	10^{+aFaTs}	Conversational therapy	Negative (number of endophoric references, treatment generalization)	**III**
You et al. (2011)	21 (nonfluent global)	Left superior temporal gyrus	Contralesional SO	0.571, 30 min	10	Conventional speech and language therapy	Negative (auditory verbal comprehension, spontaneous speech, repetition, naming)	**II**
Meinzer et al. (2016)	26 (nonfluent and fluent – Broca's, global, amnestic Wernicke's)	C3	Contralesional SO	0.286, 20 min	16 (2/day x 8 days)	Computer-assisted naming treatment	Positive (naming trained items maintenance, transfer to untrained items, functional communication)	**II**
Fridikson et al. (2018)	74 (nonfluent and fluent)	Temporal lobe region with highest naming activation on fMRI	Right SO	0.400, 20 min	15	Speech therapy (computerized behavioral treatment of anomia)	Positive for non-futility (Naming 80 trained items)	**I**
Recommendation: Anodal tDCS of Broca's area, its homologue, or Wernicke's area is possibly effective (Level C) in chronic post-stroke aphasia rehabilitation								
Cathodal								
Monti et al. (2008)/Exp1	4 (nonfluent - Broca's, global)	Contralesional (right) shoulder	Ipsilesional (left) frontotemporal	0.571, 10 min	$1^{+as,cs}$	No	Positive (picture naming accuracy), Negative (RT)	**III**
Monti et al. (2008)/Exp2	8 (nonfluent – Broca's, global)	Contralesional (right) shoulder	Occipital	0.571, 10 min	1^{+cs}	No	Negative (picture naming accuracy, RT)	**III**
Rosso et al. (2014)	25 (nonfluent)	Left SO	Right inferior cortex	0.286, 15 min	1^{+cs}	No	Positive for group with Broca's area lesions and correlating with integrity of arcuate fasciculus (picture naming accuracy), Negative for group with no Broca's area lesions (picture naming accuracy)	**III**
Floel et al. (2011)	12 (9 nonfluent, 3 fluent)	Contralesional SO	Right temporoparietal cortex	Unclear electrode size (1mA), 20 min	3^{+acs}	Computerized anomia training	Positive (picture naming accuracy for trained objects)	**III**
Fiori B et al. (2019) – 1**	10 (nonfluent)	Ring (4 electrodes around cathode at radius of 3.5 cm)	F6 (Broca's homologue)	Unclear electrode size (1 mA), 20 min	5^{+cs}	Verb retrieval task	Negative (verb recovery)	**III**

Fiori et al. (2019) - 2**	10 (nonfluent)	Ring (4 electrodes around cathode at radius of 3.5 cm)	F6 (Broca's homologue)	Unclear electrode size (2 mA), 20 min	5^{+cs}	Verb retrieval task	Positive (verb recovery)	**III**
Kang et al. (2011)	10 (8 nonfluent, 2 fluent)	Ipsilesional SO	Right inferior frontal (Broca's homologue) area	0.800, 20 min	5^{+cs}	Conventional word retrieval training	Positive (picture naming accuracy), Negative (reaction times, cued responses)	**III**
You et al. (2011)	21 (nonfluent - global)	Ipsilesional SO	Right superior temporal gyrus	0.571, 30 min	10	Conventional speech and language therapy	Positive (auditory verbal comprehension), Negative (spontaneous speech, repetition, naming)	**II**
Silva et al. (2018)	14 (nonfluent)	Left SO	Right Broca's area homologue (F8)	Unclear electrode size (2mA), 20 min	5	No	Positive (Boston test mean time for correct responses with strategy), Negative (number of hits with/without strategies, mean time of hits)	**II**
Recommendation: Cathodal right frontotemporal tDCS is possibly effective (Level C) in chronic post-stroke aphasia rehabilitation								
			Bilateral					
Santos et al. (2017)	13 (fluent and nonfluent)	Left inferior frontal (Broca's) area	Right inferior frontal (Broca's homologue) area	0.200 (anode), 0.571 (cathode), 20 min	1^{+bs}	No	Negative (picture naming/strategy, response time/strategy, total response time)	**III**
Marangolo et al. (2013c)	8 (nonfluent)	Left inferior frontal gyrus	Contralesional inferior frontal gyrus	0.571, 20 min	10^{+bs}	Language therapy (for speech apraxia)	Positive (accuracy data for syllables, words, sentences; vocal reaction times data for words, sentences)	**III**
Marangolo et al. (2014b)	7 (nonfluent)	Left inferior frontal gyrus	Contralesional inferior frontal gyrus	0.571, 20 min	10^{+bs}	Speech therapy	Positive (correct picture description and verb and noun naming)	**III**
Marangolo et al. (2016)	9 (nonfluent)	Left inferior frontal gyrus	Contralesional inferior frontal gyrus	0.571,20 min	10^{+bs}	Language therapy (for speech apraxia)	Positive (accuracy data for syllables, words, sentences; vocal reaction times data for words, sentences)	**III**
Recommendation: Bilateral tDCS with anodal stimulation of Broca's area and cathodal stimulation of its homologue is possibly effective (Level C) in chronic post-stroke aphasia rehabilitation								

Table 6: tDCS studies in chronic post-stroke aphasia

* participants were undergoing inpatient rehabilitation including speech therapy but logopedic training was intentionally separated by 90 min from tDCS to avoid its physiologic effects; **2 separate groups of participants were crossed over to either 2 mA or 1 mA of cathodal tDCS vs. sham; +as,cs – two groups of 4 participants each, and within each group participants were crossed over to anodal and sham or cathodal and sham tDCS conditions – note that all 8 participants were in Experiment 2 months later; +as – crossover with anodal and sham tDCS conditions; +cs – crossover with cathodal and sham tDCS conditions; +acs – crossover with anodal, cathodal and sham tDCS conditions; +bs – crossover with bilateral and sham tDCS conditions; +aFaTs – crossover with anodal frontal, anodal temporal and sham conditions

Epilepsy

Author	Sample (n)	Anode	Cathode	Current density (A/m²)	Number of sessions	Concomitant therapy/tasks	Results	Class
Assenza et al. (2017)	10	Contralateral homologue	Epileptic focus	0.286, 20 min	1+cs	No	Positive (seizure frequency decreased)	**III**
Fregni et al. (2006c)	19	Silent area	Epileptic focus	0.286, 20 min	1	No	Negative (seizure frequency not increased or decreased)	**II**
Auvichayapat et al. (2013)	36	Contralateral shoulder	Epileptic focus	0.286, 20 min	1	No	Positive (seizure frequency decreased)	**II**
Tekturk et al. (2016)	12	Contralateral SO	Epileptic focus – HS side (T7 or T8)	0.571**, 30 min	3+cs	No	Positive (seizure frequency decreased)	**III**
Liu et al. (2016)	33	F3	Contralateral SO	0.571, 20 min	5	No	Negative (seizure frequency not increased or decreased)	**II**
Auvichayapat et al. (2016)	22	Right shoulder	C3	0.571, 30 min	5	No	Positive (seizure frequency decreased)	**II**
San-Juan et al. (2017)*	28	Contralateral (silent) SO	Epileptic focus	0.571, 30 min	3	No	Positive (seizure frequency decreased)	**II**
San-Juan et al. (2017)*	28	Contralateral (silent) SO	Epileptic focus	0.571, 30 min	5	No	Positive (seizure frequency decreased)	**II**

Recommendation: Cathodal tDCS is probably safe (no increase in seizures) and effective (decrease in seizures) in epilepsy (Level B)

Table 7: tDCS studies in epilepsy

*one trial with 3 arms (3 sessions, 5 sessions and sham); ** modulated tDCS peak sinusoidal direct current, 12 Hz frequency; +cs: crossover study with cathodal and sham conditions

Major Depressive Disorder

Author	Sample (n)	Anode	Cathode	Current density (A/m²)	Number of sessions	Concomitant therapy	Results	Class
				Depressive symptoms				
Boggio et al. (2008a)*	40	Occipital (2 cm above Iz)	Right SO	0.286, 20 min	10	No	Negative (HDRS, BDI)	**II**
Nord et al. (2019)	39	F3	Extracephalic (ipsilateral deltoid)	0.286, 20 min	7-8 sessions (one per week x 7-8 weeks)	n-back working memory task, CBT	Negative (HDRS)	**II**
Vigod et al. (2019)	17 (pregnant)	F3	F4	0.571, 30 min	15	No	Positive (MADRS remission 4 weeks postpartum), Negative (MADRS immediately post-treatment and 12 weeks postpartum)	**II**
Blumberger et al. (2012)	24	F3	F4	0.571, 20 min	15	No	Negative (HDRS, MADRS, BDI-II)	**II**
Brunoni et al. (2014)	40	F3	F4	0.800, 30 min	10	CCT	Negative (HDRS, BDI)	**II**
Salehinejad et al. (2017)	24	F3	F4	0.571, 30 min	10	No	Positive (BDI, HDRS)	**II**
Mayur et al. (2018)	16	F3	F4	0.800, 30 min	10	Ultrabrief Electroconvulsive Therapy (right unilateral)	Negative (MADRS)	**II**
Brunoni et al. (2013)	120	F3	F4	0.800, 30 min	12 (10 daily sessions, then one session every 2 weeks x 4 weeks)	Sertraline/placebo	Positive (MADRS)	**I**
Brunoni et al. (2017)	245	F3	F4	0.571, 30 min	22 (5/week x 3 weeks, then once per week x7 weeks)	Escitalopram/placebo	Positive to placebo (HDRS, MADRS), Negative to placebo (BDI), Not	**I**

							significant for noninferiority to escitalopram (HDRS)	
Loo et al. (2010)	40	pF3	F8	0.286, 20 min	10 (on alternate days; sessions 1-5 active/sham, sessions 6-10 all active)	No	Negative (HDRS, MADRS, CGI, BDI)	**II**
Segrave et al. (2014)	27	F3	F8	0.571, 24 min	5	CCT/sham CCT	Positive (MADRS, BDI-II)	**II**
Loo et al. (2012)	64	pF3	F8	0.571, 20 min	15	No	Positive (MADRS), Negative (IDS, QIDS-C, CGI)	**I**
Loo et al. (2018)	120	F3	F8	0.714, 30 min	20	No	Negative (MADRS, CGI)	**I**
Palm et al. (2012)	22	F3	Contralateral SO	0.286 and 0.571, 20 min	10^{+as}	No	Negative (HDRS, BDI, CGI)	**III**
Fregni et al. (2006b)	10	F3	Contralateral SO	0.286, 20 min	5 (on alternate days)	No	Positive (HDRS, BDI)	**II**
Fregni et al. (2006a)	18	F3	Contralateral SO	0.286, 20 min	5 (on alternate days)	No	Positive (HDRS)	**II**
Boggio et al. (2008a)*	40	F3	Contralateral SO	0.286, 20 min	10	No	Positive (HDRS, BDI)	**II**
Bennabi et al. (2014)	24	F3	Contralateral SO	0.571, 30 min	10 (twice a day x 1 week)	Escitalopram	Negative (HDRS, MADRS)	**II**
Recommendation: Anodal left DLPFC tDCS is definitely effective (Level A) for treatment of depression in MDD								

Table 8: tDCS studies in Major Depressive Disorder

* *multiple montages in one study; +as: crossover study with anodal and sham conditions*

Obsessive Compulsive Disorder (OCD) and Tourette Syndrome

Author	Sample(n)	Anode	Cathode	Current density (A/m²)	Number of sessions	Concomitant therapy	Results	Class
				OCD				
Volpato et al. (2013b)	1	Posterior neck-base	F3	0.571, 20 min	10[+cs,rTMSas]	No	Negative (YBOCS)	**IV**
Mondino et al. (2015a)	1	Above O2	Left SO	0.571, 20 min	10 (2/day x 1 week)	No	Positive (YBOCS)	**IV**
Bation et al. (2016)	8	Right cerebellum	Left SO	0.571, 20 min	10 (2/day x 1 week)	No	Positive (YBOCS, OCD VAS)	**IV**
Palm et al. (2017)	1	F3	F4	0.571, 30 min	20 (2/day x 2 weeks)	Sertraline	Positive (YBOCS total, obsessions and compulsions subscales)	**IV**
D'Urso et al. (2016)*	12	Anterior to Cz	Right deltoid	0.800, 20 min	10 (10/phase x 2 phases)[+ac]	No	Negative (YBOCS)	**III**
D'Urso et al. (2016)*	12	Right deltoid	Anterior to Cz	0.800, 20 min	10 (10/phase x 2 phases)[+ac]	No	Positive (YBOCS)	**III**
D'Urso et al. (2016)**	1	Anterior to Cz	Right deltoid	0.800, 20 min	10	No	Negative (YBOCS)	**IV**
D'Urso et al. (2016)**	1	Right deltoid	Anterior to Cz	0.800, 20 min	10	No	Negative (YBOCS)	**IV**
Da Silva et al. (2016)	2	Left deltoid	Bilateral SMA	0.800, 30 min	20	No	Positive (YBOCS)	**IV**
Narayanaswamy et al. (2015)	2	Fz	Right SO	0.571, 20 min	20 (2/day x 2 weeks)	No	Positive (YBOCS)	**IV**
Gowda et al. (2019)	25	Fz	Right SO	0.571, 20 min	10 (2/day x 1 week)	No	Positive (YBOCS total, compulsion and insight subscores)	**II**
Recommendation: Anodal pre-SMA tDCS is possibly effective (Level C) in improving OCD symptoms								
				Tourette Syndrome				
Mrakic-Sposta et al. (2008)	2	Right deltoid	Left motor-premotor areas	0.952, 15 min	5[+cs]	No	Positive (YGTSS)	**IV**
Carvalho et al. (2015)	1	Right deltoid	Bilateral pre-SMAs	0.570, 30 min	10	No	Positive (tic severity, YGTSS)	**IV**
Behler et al. (2018)	3	Extracephalic (left and right sternocleidmastoid muscles)	C3 and C4 (longitudinally to cover pre-SMAs)	0.571, 30 min	10 (2/day x 1 week)	No	YGTSS Positive in 1/3, Negative in 2/3; tic severity Positive in 1/3, Negative in 2/3, tic frequency worse in 3/3	**IV**
No recommendation								

Table 9: tDCS studies in Obsessive-Compulsive Disorder and Tourette Syndrome

[*] *multiple montages in one study; ** multiple montages in another study; +cs,rTMSas: crossover with cathodal and sham conditions of tDCS, and active and sham conditions of rTMS; +ac: crossover study with anodal and cathodal tDCS condition; +cs crossover with cathodal and sham tDCS conditions*

Schizophrenia (and schizoaffective disorder)

Author	Sample (n)	Anode*	Cathode	Current density (A/m^2), session duration	Number of sessions	Concomitant therapy	Results**	Class
Auditory Hallucinations / Negative and Positive Symptoms								
Brunelin et al. (2012)	30	Midway between F3-FP1	Midway between T7-P3	0.571, 20 min	10 (2/day x 1 week)	No	Improvement (AHRS, PANSS total and negative), No improvement (PANSS positive)	**II**
Mondino et al. (2015b)	28	Midway between F3-FP1	Midway between T7-P3	0.571, 20 min	10 (2/day x 1 week)	No	Improvement (AVH frequency, covert/overt speech misattribution)	**II**
Mondino et al. (2016)	23	Midway between F3-FP1	Midway between T7-P3	0.571, 20 min	10 (2/day x 1 week)	No	Improvement (AHRS)	**II**
Chang et al. (2018)	60	Midway between F3-FP1	Midway between T7-P3	0.571, 20 min	10 (2/day x 1 week)	No	No improvement (AHRS, PANSS total and subscores)	**II**
Kantrowitz et al. (2018)	89	Midway between F3-FP1	Midway between T7-P3	0.515, 20 min	10 (2/day x 1 week)	No	Improvement (AHRS***, AHRS Loudness, PANSS Hallucinatory behavior), No improvement (other AHRS items, PANSS total and subscores)	**II**
Bose et al. (2018)	25	Midway between F3-FP1	Midway between T7-P3	0.571, 20 min	10 (2/day x 1 week)	No	Improvement (AHRS)	**II**
Lindenmayer et al. (2019)	28	Midway between F3-FP1	Midway between T7-P3	0.571, 20 min	40 (2/day x 4 weeks)	No	Improvement (AHRS and Frequency, Number of Voices and Length of AH subscores, PANSS total), No improvement (other AHRS and PANSS subscores, PANSS Hallucinatory behavior)	**II**
Shiozawa et al. (2016)	9	F3	F4	0.571, 20 min	10 (2/day x 1 week)	Cognitive training	No improvement (PANSS)	**II**
Jeon et al. (2018)	39	F3	F4	0.800, 30 min	10	No	No improvement (PANSS total and subscores, CGI positive and negative symptoms)	**II**
Fitzgerald et al. (2014)****	11	F3	Midway between T7-P3	0.571, 20 min	15	No	No improvement (PANSS, SANS)	**II**
Fitzgerald et al. (2014)****	13	F3 and F4	Midway between T7-P3 and T8-P4	0.571, 20 min	15	No	No improvement (PANSS, SANS)	**II**
Palm et al. (2016)	20	F3	Contralateral SO	0.571, 20min	10	No	Improvement (SANS, PANSS total and negative)	**II**
Recommendation: Anodal left prefrontal with cathodal left temporoparietal tDCS is probably effective (Level B) for reducing auditory hallucinations in schizophrenia								

Table 10: tDCS studies in schizophrenia (and schizoaffective disorder)
*FP1 is the left SO region; **to avoid confusion with positive/negative symptoms in schizophrenia, we used the terminology "Improvement" for studies showing significant improvement compared to sham, and "No improvement" for nonsignificant changes; ***AHRS showed improvement only when chlorpromazine equivalents (which had correlated significantly with higher baseline AHRS and PANSS Hallucinations scores) was added as a covariate; **** in the same paper; +a1,a2,s: crossover anodal 1 mA, anodal 2 mA, sham; note, F3-FP1 targeted left prefrontal regions, T7-P3 targeted left temporoparietal regions.

Addiction

Author	Sample (n)	Anode	Cathode	Current density (A/m^2), duration	Number of sessions	Concomitant therapy/task	Results	Class
				Alcohol – craving or relapses				
Boggio et al. (2008b)	13	F3	F4	0.571, 20 min	$1^{+F3a,F4a,s}$	No	Positive (AUQ)	**III**
Boggio et al. (2008b)	13	F4	F3	0.571, 20 min	$1^{+F3a,F4a,s}$	No	Positive (AUQ)	**III**
den Uyl et al. (2015)	41	F3	Contralateral SO	0.286, 10 min	1	No	Positive (AAAQ)	**II**
den Uyl et al. (2015)	41	Crossing of F7, Cz, Fz, T7*	Contralateral SO	0.286, 10 min	1	No	Negative (AAAQ)	**II**
Wietschorke et al. (2016)	30	F4	F3	0.286, 20 min	1	No	Positive (VAS desire to drink), Negative (VAS other subscales)	**II**
Witkiewitz et al. (2019)	84	F10*	Left upper arm	1.33, 30 min	8 (one per week x 8 weeks)	Mindfulness-based relapse prevention	Negative (DDD, PHDD, PACS)	**II**
da Silva et al. (2013)	13	F3	Right supra-deltoid area	0.571, 20 min	5 (one per week x 5 weeks)	No	Positive (OCDS), Negative (AUQ, relapse)	**II**
Den Uyl et al. (2017)	91	F3	F4	0.571, 20 min	4	Cognitive bias modification/control	Negative (PACS, relapse)	**II**
Den Uyl et al. (2019)	83	F3	F4	0.571, 20 min	4	ABM/control ABM	Negative (PACS, ABM, IAAA, relapse)	**II**
Klauss et al. (2014)	33	F4	F3	0.571, 13 min	10 (2/day x 1 week)	No	Positive (relapse), Negative (OCDS)	**II**
Klauss et al. (2018)	45	F4	F3	0.571, 20 min	10 (on alternate days including weekends x 3 weeks)	No	Positive (OCDS, relapse)	**II**
Recommendation: Right DLPFC anodal with left DLPFC cathodal tDCS is probably effective in decreasing relapses or craving in alcohol addiction (Level B)								
				Crack-Cocaine				
Batista et al. (2015)	36	F4	F3	0.571, 20 min	5 (on alternate days)	No	Positive (OCDS)	**II**
Klauss et al. (2018)	33	F4	F3	0.571, 20 min	10 (on alternate days including weekends x 3 weeks)	No	Negative (OCDS, relapses)	**II**
No recommendation								
				Methamphetamine				
Shahbabaie et al. (2014)	30	F4	Contralateral SO	0.571, 20 min	1^{+as}	CICT	Positive (VAS craving), Negative (CICT)	**III**
No recommendation								

Table 11: tDCS studies in addiction (craving and relapses for alcohol, crack-cocaine, methamphetamine).

*Authors of those papers were targeting the left inferior frontal gyrus (crossing of F7, Cz, Fz, T7) and right inferior frontal gyrus (F10); +as: crossover active and sham tDCS; +F3a,F4a,s = crossover bilateral tDCS with DLPFC anode/cathode (F3/F4), DLPFC anode/cathode (F4/F3), and sham tDCS.

Condition		Jadad score (SD)	% of low risk of bias (≥3 points)	Mean Jadad on excluding studies with score <3	SD of Jadad on excluding studies with score <3	Studies that have Jadad score of <3	Does removing studies with Jadad <3 change recommendation?
Pain	Neuropathic Pain	4.40 (0.70)	100	4.38	0.70	None	N/A
	Fibromyalgia	5.00 (0.41)	100	4.83	0.00	None	N/A
	Migraine	4.50 (0.71)	100	4.50	0.71	None	N/A
	Myofascial Pain Syndrome	3.50 (2.12)	50	5.00	2.12	Choi et al. 2014	No
	Postoperative acute pain	4.25 (0.96)	100	4.25	0.96	None	N/A
	Low Back Pain	4.67 (0.58)	100	4.67	0.58	None	N/A
Parkinson's Disease	Motor function	4.50 (0.73)	100	4.44	0.73	None	N/A
	Cognitive function	4.60 (0.55)	100	4.60	0.55	None	N/A
Chronic Stroke	Motor Function	4.32 (0.72)	100.00	4.45	0.72	None	N/A
	Aphasia	3.90 (0.62)	100.00	4.53	0.62	None	N/A
Subacute Stroke	Motor Function	4.45 (0.76)	100.00	3.95	0.76	None	N/A
Epilepsy	Seizure frequency	4.00 (0.00)	100.00	3.75	0.00	None	N/A
Major Depressive Disorder	Depression	4.53 (0.74)	100.00	4.53	0.74	None	N/A
Obsessive Compulsive Disorder (OCD) and Tourette syndrome	Obsessive Compulsive Disorder	1.56 (1.67)	25.00	3.67	1.67	Mondino 2015, Narayanaswamy 2015, Bation 2016, Silva 2016, Palm 2017	No
	Tourette syndrome	1.67 (1.15)	33.33	3.00	1.15	Carvalho 2015, Behler 2018	No
Schizophrenia	Auditory Hallucinations	4.00 (0.77)	90.91	4.20	0.77	Fitzgerald 2014	No
Addiction	Alcohol	4.33 (1.21)	83.33	4.80	1.21	da Silva 2013	No
	Crack/Cocaine	5.00 (-)	50	5.00	0.00	None	N/A

Table 12: Risk of bias assessment for each condition (studies with repeated tDCS sessions). Jadad scores are presented as mean and standard deviation (SD).

Condition		Recommendation	Pooled Effect sizes *
Pain	Neuropathic Pain	*Anodal M1 tDCS probably effective in reducing neuropathic pain (Level B)*	*-0.29 (-0.60, 0.02)*
	Fibromyalgia	*Anodal M1 tDCS is probably effective in reducing fibromyalgia pain (Level B)*	*-0.62 (-1.23, -0.01)*
	Migraine	*Anodal M1 tDCS is probably effective in reducing migraine pain (Level B)*	*-0.41 (-1.40, 0.59)*
	Myofascial Pain Syndrome (MPS)	*No recommendation*	*Not estimable*
	Postoperative acute pain	*Postoperative anodal M1 tDCS is probably effective in reducing patient-controlled analgesia and pain (Level B)*	*-0.70 (-1.09, -0.30)*
	Low Back Pain	*No recommendation*	*Not estimable*
Parkinson´s Disease	Motor function	*Anodal motor/premotor/SMA tDCS is possibly effective for motor function in PD (Level C); anodal prefrontal tDCS is probably not effective for motor function in PD (Level B)*	*-0.38 (-0.68, -0.09)*
	Cognitive function	*Anodal DLPFC tDCS is probably effective for cognitive function in PD (Level B)*	*-0.33 (-1.02, 0.35)*
Chronic Stroke	Motor Function	*Anodal tDCS of ipsilesional M1 is probably effective for motor rehabilitation in chronic stroke (Level B)*	*0.52 (-0.04, 1.09)*
		Anodal tDCS of ipsilesional M1 to enhance robotic therapy is probably not effective for motor rehabilitation in chronic stroke (Level B)	*0.23 (-0.31, 0.77)*
		Cathodal tDCS of contralesional M1 is probably effective for motor rehabilitation in chronic stroke (Level B)	*0.44 (-.18, 1.06)*
		Bilateral tDCS of M1 is probably effective for motor rehabilitation in chronic stroke (Level B)	*0.44 (0.10, 0.79)*
	Aphasia	*Anodal tDCS of Broca's area, its homologue, or Wernicke's area is possibly effective in chronic post-stroke aphasia rehabilitation (Level C)*	*Broca's Area: 0.65 (0.29, 1.01)*
		Cathodal right frontotemporal tDCS is possibly effective in chronic post-stroke aphasia rehabilitation (Level C)	*Not estimable*
		Bilateral tDCS with anodal stimulation of Broca's area and cathodal stimulation of its homologue is possibly effective in chronic post-stroke aphasia rehabilitation (Level C)	*Not estimable*
Subacute Stroke	Motor Function	*Anodal tDCS of ipsilesional M1 is probably effective for motor rehabilitation in subacute stroke (Level B)*	*0.44 (-0.03, 0.91)*
		Anodal tDCS of ipsilesional M1 to enhance robotic therapy is definitely not effective for motor rehabilitation in subacute stroke (Level A)	*0.01 (-0.33, 0.34)*
		Cathodal tDCS of contralesional M1 is probably effective for motor rehabilitation in subacute stroke (Level B)	*0.47 (0.10, 0.84)*
		Cathodal tDCS of contralesional M1 to enhance robotic therapy is probably not effective for motor rehabilitation in subacute stroke (Level B)	*Not estimable*
		Bilateral tDCS of M1 is possibly effective for motor rehabilitation in subacute stroke (Level C)	*0.39 (-0.07, 0.86)*
Epilepsy	Seizure frequency	*Cathodal tDCS is probably safe (no increase in seizures) and effective (decrease in seizures) in epilepsy (Level B)*	*-0.70 (-1.38, -0.02)*
Major Depressive Disorder	Depression	*Anodal left DLPFC tDCS is definitely effective for treatment of depression in MDD (Level A)*	*-0.36 (-0.66, -0.06)*

OCD and Tourette syndrome	Obsessive Compulsive Disorder	*Anodal pre-SMA tDCS is possibly effective in improving OCD symptoms (Level C)*	*-0.61 (-1.87, 0.64)*
	Tourette syndrome	*No recommendation*	*Not estimable*
Schizophrenia	Auditory Hallucinations and Positive/negative symptoms	*Anodal left prefrontal with cathodal left temporoparietal tDCS is probably effective for reducing auditory hallucinations in schizophrenia (Level B)*	*-0.47 (-0.72, -0.22)*
Addiction	Alcohol – craving or relapses	*Right DLPFC anodal with left DLPFC cathodal tDCS is probably effective in decreasing relapses or craving in alcohol addiction (Level B)*	*0.21 (-0.08, 0.49)*
	Crack-Cocaine	*No recommendation*	*Not estimable*
	Methamphetamine	*No recommendation*	*Not estimable*

Table 13: Summary of the recommendations on tDCS efficacy according to clinical indications * Effect sizes are based on a smaller number of studies due to data availability.